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Abstract 
Multiple sclerosis (MS) is a chronic inflammatory and degenerative condition of 
the Central Nervous System. Focal demyelinating lesions are its neuropathological 
hallmark, but widespread abnormalities found in otherwise “normal-appearing” 
tissue are better associated with disability outcomes. HMGB1 is a promiscuous 
sensor of cellular stress, acting as a link between sterile damage and innate 
immune mechanisms, with its extra-nuclear release producing diverse outcomes.  
We report novel findings of significantly increased HMGB1 expression throughout 
the brain tissue of MS vs. non-MS patients, particularly in macrophages/microglia 
and oligodendrocytes (OGD). In addition, cerebrospinal fluid HMGB1 levels were 
increased in early-stage MS patients compared to non-inflammatory control 
patients. HMGB1 stimulation in-vitro upregulates expression of its receptors in an 
OGD cell line, potentially propagating chronic inflammation. Expression of the 
Leucine Rich Repeat and Ig-domain-containing molecules, AMIGO-3 and LINGO-1 
is also significantly increased by HMGB1 stimulation in-vitro. These molecules 
demonstrate particularly intense immunoreactivity in human brain tissue taken 
at biopsy, at an early disease stage. Thus, exogenous HMGB1 may influence 
neurodegenerative processes via AMIGO-3 and LINGO-1 and blocking their 
function could have therapeutic value. Increased expression of HMGB1 in OGD, 
however, may highlight endogenous neuroprotective mechanisms in response to 
an unknown trigger. 
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1.  
General Introduction 
 
 
 
 
 
 
 
 2 
 
1.1 Clinical aspects of MS 
1.1.1 History of MS 
 
“17 October 1827. 
“To my surprise (in Venice) I one day found a torpor or indistinctness of feeling 
about the Temple of my left Eye. At Florence I began to suffer from a confusion of 
sight. About the 6th November the malady increased to the extent of my seeing all 
objects double. Each eye had its separate visions. Dr. Kissock supposed bile to be 
the cause: I was twice blooded from the temple by leeches; — purges were 
administered; One Vomit, and I twice lost blood from the arm.. The malady in my 
Eyes abated, I again saw all objects naturally in their single state. I was able to go 
out and walk..”  
Excerpt from the diaries of Augustus D’Este (1794-1848), illegitimate grandson of 
King George III. (Landtblom et al. 2010) 
 
This description of relapses affecting the brainstem over weeks, followed by 
remission, is the earliest detailed description of MS– related symptoms recorded. 
It remains as informative for us now as it was likely to have been when presented 
to the physicians of the time, although our therapeutic armamentarium has 
certainly evolved over time. His detailed diaries describing the condition 
commenced in 1822; 16 years before the original depiction of neuropathological 
changes in the spinal cord occurring in MS by Scottish pathologist Robert Carswell 
(Carswell 1838). Others subsequently reported either clinical or pathological 
findings (Compston 1988), but it was Jean Martin Charcot who drew all of this 
information together using the clinicopathological findings in a single female 
 3 
 
patient, in the seminal publication ‘Histologie de la sclérose en plaques’ (Charcot 
1868). The clinical observations he described were particularly prescient, 
including a formal description of cognitive changes which we now believe are 
related to cortical changes in MS. Following this, clinical cases were reported by 
Eugene Devic (1858-1930), Josef Balo (1895-1979), Paulo Ferdinand Schilder 
(1886-1940) and Otto Marburg (1874-1948) which describe distinct but related 
conditions to MS.  Oligodendrocytes- always difficult to stain for- were the last glial 
cell to be discovered using a new staining method created by the Spanish 
pathologist, Pio del Rio Hortega in 1921. In 1935, the first experiments in 
experimental allergic encephalitis (EAE) were carried out (Rivers & Schwentker 
1935) and oligoclonal bands in the spinal fluid were discovered by Elvin Kabat in 
1942 (Kabat et al. 1942). This confirmed the link between MS and the immune 
system and by the 1960s, ACTH was used to manage symptomatic relapses 
(MILLER et al. 1961). MRI was first used in the early 1980s, rapidly proving itself 
to be an invaluable biomarker for use in clinical trials and in 1993, the trials results 
for first injected disease-modifying drug, Betaferon were published (The IFNB 
Multiple Sclerosis Study Group 1993). Of all the neurological diseases, disease 
modification has been particularly successful in the management of MS, and has 
been aggressively pursued since these early studies. They are discussed in more 
detail in section 1.1.4 of this chapter. 
1.1.2 Epidemiology 
The mean age of onset is approximately 30 years with 70% of patients manifesting 
symptoms between ages of 20 and 40. Disease onset is rare before the age of 10 
and after 60 years, forming a unimodal, age-specific onset curve. Between 80 and 
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100,000 patients in the UK have been diagnosed with MS, with approximately 
2,500 people newly diagnosed each year. The distribution is not geographically 
uniform- the greatest incidence tends to be at the extremes of latitude in both 
northern and southern hemispheres. For example, the prevalence rate in England 
and Wales is approximately 100 per 100,000, whilst the northern areas of 
Scotland have a prevalence approaching 200 per 100 000. This strong latitudinal 
variation has been postulated to be due to sunlight, local microbial flora or even 
direct infection by specific viruses, though none have been directly proven 
(Hassan-Smith & Douglas 2011). 
Women were previously thought to be two to three times more likely to develop 
MS than men. Despite extensive research, the reason for this difference was 
unclear, beyond the standard observations that women are generally more 
susceptible to autoimmune conditions, and that this predisposition may therefore 
be hormonally related. Several studies have suggested that oral contraceptive 
(OCP) use leads to a milder disease course (Gava et al. 2014; Sena et al. 2012). 
However, more recently, epidemiological data from a prospectively collected 
cohort failed to demonstrate sexual dimorphism. The authors stated that this 
difference could be ascribed to the method of data acquisition, and hence the 
female bias was likely to be untrue (Tintore, Brain 2015).  
1.1.3 Risk factors for developing MS 
Genetic: Genetic influences on MS are clearly seen in twin studies, where the 
concordance rate for MS in monozygotic twins is as high as 30%, as compared to 
1% for dizygotic twins. The risk of developing MS in first-degree relatives is about 
1 in 40, which is 20 times higher than in the general population. For second degree 
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relatives, the risk falls to around 1 in 100- still approximately 10 times higher than 
the background rate. Genetically unrelated family members living in the same 
environment however, exhibit the same risk as the background population (Ebers 
et al. 2004; Dyment et al. 2004; Sadovnick et al. 1996).  However, the converse is 
also true, as 70% of monozygotic twins are discordant for MS. This suggests that 
the genetic susceptibility of MS patients likely follows a polygenic heritability 
pattern. The best described genetic association through extensive genome-side 
association studies, is with the HLA haplotype DR2 (HLA-DRB1*1501). Despite a 
clear association, the relative risk of an individual HLA-DR2-positive individual 
developing MS remains low, and it remains impossible to accurately assess this on 
the basis of genetic susceptibility alone (Oksenberg et al. 2008; Sawcer et al. 
2014).  
Environmental: Studies investigating links between environmental factors and 
MS are difficult to interpret, particularly as migration studies have highlighted 
that movement of individuals from a high-risk to a low-risk areas prior to puberty 
confers a degree of protection from developing the disease, and vice versa (Dean 
& Elian 1997). This suggests that the timing of exposure to environmental factors 
may be critical in determining subsequent risk - the so-called ‘age-of-vulnerability’ 
hypothesis. Reproducible evidence links Epstein-Barr virus (EBV) exposure, 
smoking and vitamin D levels to the development of MS and are the best 
established environmental risk factors at present. With respect to EBV, this 
demonstrates the only consistent association of MS with an infectious trigger. 
More than 99% of MS patients are EBV-seropositive, but interpretation is 
complicated by high background rate of infection in the general population which 
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can reach 95%. There is also dispute over the potential pathogenic mechanism 
involved in the association of EBV with MS, although immortalisation of 
autoreactive B cells and molecular mimicry with the CNS as the autoimmune 
target have been suggested as possible mechanisms (Levin et al. 2005). Recent 
studies have shown that smoking roughly doubles the risk of developing MS, 
although possible mechanisms are not clear (Hernán et al. 2001) (Hedström et al. 
2009) (Pittas et al. 2009). 
 Lower serum levels of vitamin D have been associated with increased risk of MS 
and correlate with disability and brain atrophy in MS (Weinstock-Guttman et al. 
2011). It is thought to exert immunomodulatory effects by influencing the number 
and/or activity of regulatory T lymphocytes. In this context, the previously 
described latitudinal gradient observed in MS natural history studies is thought to 
be a consequence of lower serum Vitamin D levels further away from the equator. 
However, a direct causal relationship is difficult to infer (Douglas et al, 2014).  
1.1.4  Clinical presentation 
Approximately 85% of patients present with a subacute neurological event, 
lasting over 24 hours and without evidence of fever, infection or encephalopathy. 
The symptoms peak in severity within 2-3 weeks and are followed by resolution 
over subsequent weeks. The first event is usually noted in young adults (aged 20–
45 years old) and is termed a clinically isolated syndrome (CIS). One large study 
found that 46% of patients with CIS presented with long-tract symptoms and 
signs, 21% with optic neuritis, 10% with a brainstem syndrome and 23% with 
multifocal abnormalities (Confavreux et al. 2000). Once there is a second 
neurological event, patients fulfil the criteria for relapsing-remitting MS (RRMS), 
 7 
 
hence the term dissemination of relapses in time. In contrast to RRMS, a 
proportion of patients never experience true relapses or remissions, but instead 
become gradually disabled over time, and are the ‘primary-progressive MS’ 
(PPMS) cohort. They commonly present with progressive limb spasticity and 
weakness and constitute 10-15% of the MS population (Rice et al. 2013).  
Over time, typically 10-15 years, the majority of patients with RRMS find their 
relapses become less marked or even cease. Instead they note a progressive 
increase in their disability, usually with worsening gait or mobility due either to 
predominant ataxia or spasticity.  These patients are termed as having entered the 
secondary progressive phase of MS (SPMS). It remains unclear whether early 
therapeutic intervention to minimise relapses in early disease truly slows or 
prevents the development of secondary progression (Filippini et al. 2013). 
1.1.5  Diagnosis of CDMS 
MS remains a clinical diagnosis following demonstration of typical signs and 
symptoms, and exclusion of MS-mimics.. Supporting ancillary MRI evidence is 
particularly useful as it is now possible to make a diagnosis of MS after one clinical 
event using the 2010 McDonald criteria (Polman et al. 2011). MRI changes are 
characterised by high signal white matter lesions on FLAIR/T2-weighted 
sequences, in regions typical for MS (periventricular, juxtacortical or posterior 
fossa). The most recent criteria do not typically require CSF analysis or 
neurophysiology (eg VEPs) to make the diagnosis. Basic CSF parameters are 
usually normal – with protein and glucose levels within the normal range. Some 
patients may exhibit a lymphocytic pleocytosis, but CSF cell counts are often 
normal. More strikingly, over 90% of MS patients will be positive for oligoclonal 
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bands (OCB) and are discussed further in chapter 5. CSF-specific OCBs are 
occasionally present in other neurological conditions, including syphilis and Lyme 
disease although the clinical picture would usually distinguish these conditions 
from MS. 
1.1.6  Treatment 
The aim of therapy in MS is either to treat related symptoms or modify the long-
term outcome of disease (disease modifying treatments-DMT).  
Symptom management: acute relapses are usually managed with high-dose 
methylprednisolone, reducing the duration of clinical symptoms, but there is no 
impact on long-term recovery (Hickman 2003). Actively managing chronic 
symptoms such as neuropathic pain, urge incontinence, fatigue, sexual 
dysfunction and spasticity-related symptoms, are optimally managed with multi-
disciplinary input. 
Disease modification- DMT: The injectable interferons (‘Rebif’, ‘Betaferon’ and 
‘Avonex’) and glatiramer acetate (Copaxone) were introduced in the 1990s and 
are ‘first- line’ treatments in patients presenting with two or more relapses in the 
preceding two years, all reducing relapse rates by about 30%.  
More recently, natalizumab (Tysabri), a monoclonal antibody to the vascular 
cellular adhesion molecule α4β1 was shown to reduce relapse rate by 68%, a more 
significant disease-modifying effect than first-line DMT (Polman et al. 2006). 
Other infused monoclonals also show efficacy in both clinical (relapse reduction) 
and paraclinical (e.g. MRI) outcomes. Alemtuzumab targets the CD52 antigen on 
lymphocytes/monocytes resulting in their profound depletion. Monoclonal 
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therapies targeting B-cells also demonstrate remarkable efficacy in 
clinical/paraclinical endpoints, such as Rituximab and the humanised 
Ocrelizumab which bind different epitopes of CD20. Daclizumab, another 
humanized monoclonal, antagonises CD25 and also appears to significantly 
reduce relapse rates. 
The next generation of drugs are notable for their oral route of administration, 
with comparable efficacy. In addition, drugs such as dimethylfumarate potentially 
demonstrate novel, neuroprotective mechanisms of action by enhancing levels of 
nuclear erythroid-2 related factor 2 (Nrf-2) levels. This acts as a transcription 
factor for antioxidant response element targeting genes responsible for cellular 
repair with resultant reduction in neuro-axonal damage.  
Uncertainty remains regarding the correlation between brain MRI parameters 
(e.g. number/volume of T2 (T2LL) or contrast enhancing lesions) and annual 
relapse rates (RR), with underlying disease progression and accumulation of 
disability. The apparent protection of DMTs against developing disability as stated 
in many clinical trials (Trojano et al. 2009; Goodin et al. 2012) may be influenced 
by relapse-related disability as the low rate of relapsing patients evolving annually 
into progressive MS is unlikely to be reflected in the short duration of most clinical 
trials (Hauser et al. 2013). When controlling for factors such as age, the benefit of 
DMTs appear to be lost on disability measures for example (Greenberg et al. 2013; 
Shirani et al. 2012). Recently, a direct correlation was shown between T2LL and 
relapse-rate (RR) in a pooled analysis of multiple RCTs, and combining T2LL and 
atrophy measures showed the strongest correlation with disability outcomes (De 
Stefano et al, 2013). Despite this, it remains unclear whether DMTs truly slow 
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disability accrual/death, although better outcome measures such brain atrophy 
have potential in refining our understanding. It is critically important to be clear 
on true clinical efficacy with the newer generation of MS drugs in particular, as 
they appear to have greater therapeutic potency but an increased risk of serious 
side effects, such as the development of Progressive Multifocal 
Leukoencephalopathy (PML) with natalizumab therapy (Bloomgren et al. 2012). 
In the end, the real interest lies in the long-term outcome data-comprising both 
efficacy and safety- of patients treated at the earliest stage with aggressive 
immunotherapy. 
Regardless of the debate however, most neurologists would agree that current 
immunomodulatory therapy has revolutionized the management of relapsing MS 
patients (Evangelou 2012).  
1.1.7  Prognosis 
Although it is known that a diagnosis of MS will impact on overall life-expectancy 
(Scalfari et al. 2013), patients will generally live for 40 years or more following the 
diagnosis of the condition. Outcome data in treatment- naive CIS patients has been 
generated through a number of clinical trials (Beck et al. 1993), (Jacobs et al. 2000) 
(Comi et al. 2001). The probability of conversion to CDMS was 16.7%, 38% and 
45% respectively in these trials although a more definite answer requires longer 
follow-up (Fisniku et al. 2008a). Prognostic markers are summarised in table 1.1, 
although younger age of onset, female sex and non-Caucasian ethnicity (Mowry et 
al. 2009) also influence prognosis. 
Good Prognosis Poor prognosis 
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Table 1.1. Clinical features influencing prognosis of patients presenting with CIS.  
 
The presence of 10 or more lesions on baseline MRI-brain set patients at high risk 
of developing CDMS, although the relationship with subsequent disability at 20 
years is not clear-cut (Fisniku et al. 2008b). CSF indices which help predict 
conversion include OCB positivity (Tintore et al. 2008), levels of CXCL13 
(Brettschneider et al. 2010)  and free-light chain (FLC) (Villar et al. 2012).  
1.2  Pathological changes in MS  
 1.2.1  Macroscopic pathology 
Externally, the meninges and brain surface appear relatively normal although 
mild cortical atrophy with widened sulci may be noted. Circumscribed, hardened 
light-grey areas may be seen on the unfixed surface, over the medulla, pons, 
corpus callosum, optic nerves and chiasm and distributed randomly on the surface 
of the spinal cord (Prineas, J; in Cook, S (Ed) 2001). Coronal slices of fixed brain 
demonstrate scattered plaques, often straddling subependymal veins through the 
lining of the lateral and fourth ventricles. Plaques containing multiple foamy 
macrophages display a characteristic ‘chalky white’ appearance. They are usually 
ellipsoidal in shape when viewed in three dimensions, measuring between 1 and 
15mm in diameter. They can occur anywhere in the central nervous system (CNS) 
(BROWNELL & HUGHES 1962), although there is a predilection for regions 
Optic neuritis ‘Multifocal’ CIS 
Isolated sensory symptoms Efferent (motor/cerebellar) systems affected 
Long interval to second relapse High relapse rate in first 5 years  
No evidence of disability at 5y Substantial disability after 5 years 
Normal MRI-brain Abnormal MRI with heavy lesion load 
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described above in addition to subpial and juxtacortical regions, with extension 
into the grey matter.  
1.2.2  Microscopic pathology and staging of MS plaques 
Once plaques are identified in post-mortem cases, the brain is then cut into blocks 
and those containing plaques can be sectioned for further microscopic analysis. 
They can be classified based on criteria as demonstrated in table 1.2: 
Classification CD68+ cells Myelin: 
MBP+/ PLP+     
Lesion border  
Early active 
Extensive; around and within 
lesion Yes Diffuse 
Late active Some; around and within lesion Yes Diffuse 
Chronic active Around the lesion No Diffuse to sharp 
Chronic Virtually absent No Sharp 
Remyelinated Absent Yes - 
 
Table 1.2 Classification of MS plaques based on ICDNS criteria. CD68+ denotes 
activated macrophages/ microglia expressing CD68 on the cell surface. MBP: myelin 
basic protein; PLP: proteolipid protein; LFB: luxol-fast blue 
 
Active plaques: Foamy macrophages containing myelin fragments are evident, and 
the lesion is characterised by progressive myelin destruction, variable 
perivascular inflammatory infiltrate comprising T-lymphocytes predominantly, 
reactive astrocytosis, and activation of microglial cells. Axons are often swollen 
and non-linear indicating damage with occasional demonstration of spheroids 
which represent neurodegenerative axonal retraction bulbs, (Trapp et al. 1998).  
Chronic active plaques: Over time, plaques grow centrifugally and the centre of the 
lesion demonstrates increasing hypocellularity, with myelin stripped and cleared 
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by lipophages. Activated leucocytes at the lesion border can be seen although 
foamy macrophages filled with neutral lipids, but negative for MBP/LFB, can 
remain in tissue for months (Prineas, J; in Cook, S (Ed) 2001)). In addition, there 
are non-specific reactive astrocytic changes, increased number of microglia and 
lymphocytes and plasma cells in surrounding perivascular spaces.  
Chronic plaques:  Most MS plaques will become inactive with no evidence of recent 
demyelination/ active inflammation but an intense astroglial reaction, leading to 
the hardened, fibrillary plaques described by Charcot.   
Remyelinated (‘shadow plaques’): Varying degrees of remyelination occur in MS 
and, in specific areas such as the cortical grey matter, it appears to be fairly 
efficient in both animal models (Merkler et al. 2006) and human tissue (Albert et 
al. 2007). Despite this, failure of remyelination is a prominent feature in MS. 
1.2.3  Immunopathogenesis 
Traditionally, the CNS was viewed as an immune-privileged site due to the lack of 
a conventional lymphatic system and the fact that the blood brain barrier (BBB) 
and the blood-CSF barrier (BCSFB) appear impenetrable to cellular migration 
under resting conditions (Engelhardt 2008).  However, it is now accepted that the 
CNS is also subject to immune surveillance, with continuous immune cell-
mediated interactions behind both the BBB and the BCSFB (Wraith & Nicholson 
2012).  As stated earlier, both the BBB and BCSFB pose significant physical 
limitations to access and attention has thus turned to leucocyte entry via the 
choroid plexus for example (Engelhardt et al. 2001; Coisne et al. 2013). The 
immune mechanisms leading to demyelination and axonal injury in autoimmune 
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and virally-mediated animal models of inflammatory demyelinating diseases are 
extraordinarily complex. The innate and adaptive components of the immune 
system are both key mediators of damage, although may also serve protective 
functions (Bogie et al. 2014a; Schwartz & Raposo 2014). I will discuss salient 
aspects of both adaptive and innate immunity below. 
Innate immunity 
Tissue injury is mainly effected via activated macrophages which produce a 
plethora of toxic substances (Hendriks et al. 2005; Yamasaki et al. 2014; Bogie et 
al. 2014b), including lipolytic and proteolytic enzymes, reactive oxygen and 
nitrogen species’ and excitotoxins. These cells can be activated in MS lesions by 
cytokines produced by activated T-lymphocytes, thereby initiating characteristic 
inflammatory, demyelinating processes. However, some studies have reported 
profound macrophage activation on a background of fairly mild T-cell infiltration, 
which may be limited to the perivascular space (Michael H Barnett & Prineas 
2004; Marik et al. 1997). Thus, other mechanisms of activation may also be 
important in the pathological process. Stimulation of macrophages through innate 
immune mechanisms, e.g. toll like receptors (TLRs), is sufficient to induce 
demyelinating lesions (Felts et al. 2005). Of note, many endogenous ligands for 
TLRs may be present within multiple sclerosis lesions, one of which is HMGB1 
(Andersson et al. 2008). 
 
 
Adaptive immunity 
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The basic observation of inflammatory demyelination with associated or 
subsequent axonal degeneration is classically induced by MHC Class II restricted 
T-cells. It is thought that genetically susceptible individuals exposed to viral or 
other microbial infections trigger a CNS-specific cell-mediated immune response. 
Autoreactive T-cells (including both Th1 and Th17 phenotypes) are thought to be 
primed in the periphery, possibly via molecular mimicry to myelin proteins or by 
direct exposure to cognate antigen from draining lymph nodes e.g. cervical (see 
Chapter 5; section 5.1). Following access of these cells into the CNS and along with 
antibodies and complement, this can lead to selective destruction of myelinating 
oligodendrocytes and axons. Cytokines facilitate leucocyte extravasation and 
trigger inflammatory lesion development by upregulating chemokines, adhesion 
molecules and inducing MHC-Class II expression on endothelial and glial cells. 
Increased MHC-II expression on local and infiltrating cells, e.g. microglia and 
macrophages, allows interaction with the T-cell receptor and activation of the T-
cell. Immune tolerance is normally maintained by mechanisms such as regulatory 
or suppressor cells, or clonal deletion of autoreactive T-cells. 
Further focused tissue injury can be induced by MHC Class I cytotoxic T- cells 
(Cabarrocas et al. 2003; Huseby et al. 2001). These cells are primed to directly 
attack CNS-resident, antigen- laden target cells expressing MHC Class I molecules. 
Due to their ability to produce mediators such as matrix metalloproteases, 
granzymes and other elements that are capable of stromal destruction, these cells 
are able to traverse and invade the parenchyma.  
Highly targeted tissue destruction is also induced by specific antibodies produced 
by B-cells, which recognize antigen or exact epitope expressed on the membrane 
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of target cells in the CNS (Linington et al. 1988). These antibodies still require a T-
cell mediated pro-inflammatory environment, in order to open up the blood brain 
barrier and facilitate antibody access to the target tissue. Locally, effector 
mechanisms such as activated macrophages or complement, finally destroy the 
antibody- opsonized CNS targets (Lassmann 2008). In addition to their direct 
effects on lesional pathology, B-cells have also been implicated in chronic CNS 
inflammation, where soluble factors released from ectopic B-cell follicles in the 
meninges have been suggested as drivers of inflammation in later stages of the 
disease (Aloisi et al. 2010) (Magliozzi et al. 2007a). 
1.2.4  Putative pathological subtypes in MS 
In theory, the final common pathway for tissue injury in MS can be instigated by 
multiple immune mechanisms. An important aspect of MS research is to define 
which of these immune mechanisms are most relevant topathology and whether 
their relative contribution changes at different stages of the disease. The seminal 
publication by Lucchinetti et al (Lucchinetti et al. 2000) revealed four distinct 
patterns of acute MS lesions, obtained from patients who had died from a 
fulminant attack of MS leading to rapid death or else cerebral biopsy of patients 
presenting in a similar fashion. Pattern I lesions demonstrate perivascular T-cells 
and macrophages with preservation of oligodendrocytes but with no evidence of 
complement activation. Pattern II is similar to pattern I, but signs of complement 
system activation can also be seen. Pattern III lesions are more diffuse with 
inflammation, oligodendrocyte apoptosis and microglial activation. Pattern 
IV lesions demonstrate sharp borders and oligodendrocyte apoptosis, with a rim 
of normal appearing white matter and little evidence of active inflammation. The 
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presence of four lesional subtypes restricted to specific patients suggested 
therapeutic management could be individualised to their particular subtype; for 
example, pattern II lesions would be particularly amenable to plasmapharesis.  
However, using similar early stage lesional tissue, Prineas et al disputed these 
findings, claiming that all of the patterns described above could be seen within the 
same patient. They concluded that these changes represented pathological 
evolution over time rather than distinct mechanisms unique to individuals per se 
(Michael H Barnett & Prineas 2004). Although they postulated a primary defect of 
oligodendrocytes (OGD) initiating MS pathogenesis, as OGD loss in ‘pre-active’ 
lesions preceded immune cell infiltration, it is not possible to extrapolate these 
observations universally. More recently, Lucchinetti et al have added further 
follow-up data to the biopsy series, demonstrating that those patients with 
specific pathological patterns in the initial study retained this pattern until re-
biopsy or death, when their tissue was re-examined (Metz et al. 2014).  
1.2.5  Metabolic insufficiency and axonal damage 
Tissue damage following the release of oxygen and nitric oxide free-radicals also 
trigger mitochondrial dysfunction, and metabolic failure has been shown to play 
an important part in MS lesions (Witte et al. 2014). Neuropathological reports 
have suggested that in some highly aggressive pathological phenotypes, the 
pattern of tissue injury and demyelination demonstrate a hypoxia-like pattern of 
damage (Trapp & Stys 2009). Similar to classical hypoxic lesions seen in stroke, 
small calibre axons and neurons are disproportionately affected in MS lesions 
(Evangelou 2001). In addition, microarray studies have demonstrated widespread 
increased expression of hypoxia inducible factor 1α (Zeis et al. 2008), suggesting 
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that energy failure in the brain may also contribute to tissue damage in the 
progressive stage of the disease.  
Given the significant metabolic demands placed upon axons in normal functioning, 
operating in the context of demyelination renders them particularly vulnerable to 
bioenergetic insufficiency. Depolarisation in this state leads to accumulation of 
Na+ ions within the cytoplasm and metabolic processes are further compromised 
as ATP produced by mitochondria is required to clear these ions from the 
axoplasm. Inefficiency of this process can lead to classical ‘conduction block’ in 
demyelinated axons. Upregulation and redistribution of sodium channels along 
the axonal length restores conduction, but normal metabolic efficiency 
accompanying saltatory conduction is lost, further compounding the energy 
imbalance (Craner et al. 2004). Neuroprotective strategies have thus attempted to 
use Na+channel blockers, and recent clinical trials have reported both negative 
(Kapoor et al. 2010) and positive (Arun et al. 2013) outcomes, as discussed in 
chapter 6, section 6.6.6.1  
1.2.6  ‘Normal-appearing’ brain tissue (NABT) in MS 
The data presented above delineate the hallmarks of MS-related neuropathology; 
namely, inflammatory demyelinating lesions. However, recent work has 
suggested that MS is not, in fact, a collection of discrete lesions, but instead these 
represent the ‘tip of the iceberg’, appearing against a background of highly 
abnormal tissue (Chard & Miller 2009; Filippi & Rocca 2005).  The key question 
then becomes; are the focal lesions discussed above the primary pathology 
leading to subsequent global changes or is there an underlying, diffuse 
pathological process from which lesions then arise? There need to be clear 
 19 
 
definitions of ‘normal-appearing brain tissue’ (NABT), to determine whether 
these changes represent (i) entirely normal material adjacent to peri-lesional 
tissue only (ii) a diffuse intermediate between normal tissue and MS lesions, or 
(iii) whether normal tissue is surrounded by more extensive areas of abnormality 
which are not picked by conventional MRI or indeed histopathological techniques. 
Novel MRI biomarkers 
 Increasingly sensitive MRI metrics derived from diffusion tensor (DT) and 
magnetisation transfer (MT) MRI have led the way in delineating pathological 
changes in NABT since the early 1990s (Feinstein et al. 1992), and have suggested 
that diffuse changes occur earlier in the disease course. In addition, the 
biochemical features of these changes can be further examined by proton MR 
spectroscopy, with an important recent study demonstrating that related metrics 
can be used to predict disability evolution (Llufriu et al. 2014). These techniques 
reflect diffuse axonal damage with consequent closer correlation with longer-
term clinical outcomes, such as disability, than white matter lesions (Filippi et al. 
1999; Werring et al. 1999; Filippi et al. 2001; Traboulsee et al. 2003). They also 
showed less of an association with short-term outcomes such as relapses (Gallo et 
al. 2005). Vrenken et al found that MTR changes occur predominantly in the peri-
lesional white matter, although changes in NAWM were thought to represent 
subtle demyelination and axonal damage, as well as oedema, widening of the 
extracellular space, slow BBB leakage and leakage of fibrinogen into the 
parenchyma with microplaque formation (Vrenken et al. 2006).  MTR indices in 
NAWM using a 7Tesla machine, was examined in relapsing MS patients (Mistry et 
al. 2014). The authors found that cortical lesions in this cohort were connected to 
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the remote NAWM in the same way as white matter lesions (WML) are, and that 
they were implicated in the generation of remote axonal damage underpinning 
diffuse NAWM change. 
 Neuropathological changes  
 Neuropathologists have always been aware that much of the so-called NABT is 
not normal at all, characterised by subtle and widespread abnormalities including 
diffuse astrocytic hyperplasia, perivascular cellular infiltration, patchy edema and 
variable axonal damage (Allen & McKeown 1979; Bjartmar et al. 2001; Barkhof 
2002). 
An important study by Kutzelnigg, and colleagues used a large collection of post-
mortem tissue from patients with various MS subtypes (n=52) compared to 
controls (n=30) and found that new,focally active WML were most commonly 
observed in patients with acute and relapsing MS, whilst diffuse injury and cortical 
demyelination were characteristic of progressive MS, either primary or secondary 
(Kutzelnigg et al. 2005). NABT changes were described as “diffuse axonal injury 
with profound microglial activation..on the background of a global inflammatory 
response in the whole brain and meninges..”. There was a weak correlation 
between focal WML load and both diffuse white matter injury and cortical lesions. 
They concluded that MS commences as a focal inflammatory disease, but over time 
diffuse inflammation accumulates globally, with associated axonal injury in the 
NAWM and subsequent cortical demyelination.  
As described above, meningeal ectopic B-cell follicle-like structures may be 
driving chronic inflammation within a sealed BBB, down from the pial surface 
through both the grey matter and white matter beneath, leading to globally diffuse 
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abnormalities in the chronic phase of the disease (Serafini et al. 2004). However 
in an influential paper, Bo et al reported that there was no evidence of 
inflammation in cortical demyelinating lesions in a series of autopsy specimens 
from patients with progressive disease (Bo et al. 2003). They concluded that this 
provided evidence of primary neurodegeneration in MS, leading to the remote 
axonal dysfunction in the NAWM as alluded to in many of the MRI studies above. 
More recently however, Lucchinetti and colleagues demonstrated florid 
inflammatory cortical demyelination in, once again, an extensive series of brain 
biopsies from patients with tumefactive MS at very early disease stages 
(Lucchinetti et al. 2011a). They reported T- and B-cell perivenular infiltrates, 
lipid-filled macrophages, and neuronal pyknosis indicating neuronal death. They 
concluded their findings supported an ‘outside-in’ model of demyelination- 
commencing in the subarachnoid space and cortex and subsequently extending 
into the white matter. If this is true, one would speculate that cortical damage is 
likely to ensue around cortical lesions and into the normal-appearing grey and 
white matter, and the authors report this to be related to cytokine diffusion. Whilst 
the evidence is certainly compelling, there are a number of caveats to these 
findings, not least the fact that tumefactive MS samples often represent outliers, 
which could be associated with a higher incidence of meningeal inflammation and 
cortical disease due to mass effect and extensive breach of the BBB. In addition, 
distal axonal damage either from WML or the NABT may also contribute to the 
neurodegenerative changes observed, resulting in local glial activation and 
release of inflammatory mediators.  
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Other work has suggested that NABT changes are not directly influenced by 
adaptive immune responses. In close proximity to actively demyelinating lesions, 
microglial cells appear to be related to axonal pathology (Singh et al. 2013; Moll et 
al. 2011), underscoring the relevance of active inflammation and its effects on 
axonal damage (Trapp et al. 1998). However, clusters of activated microglia- 
characterised by upregulation of MHC-II molecules on their surface, are often 
found in the absence of overt demyelination, significant leukocyte infiltration, or 
obvious blood-brain barrier breakdown. They have been variably termed ‘pre-
active lesions’ (De Groot et al. 2001), ‘newly-forming lesions’ (M H Barnett & 
Prineas 2004) or ‘microglial nodules’ (Moll et al. 2011). These nodules have also 
been suggested to reflect the early stages of pattern III lesions as described earlier, 
and essentially reflect pre-conditioned tissue which may precede the formation of 
a frankly demyelinating lesion (Marik et al. 1997). Evidence of their close 
association with oligodendroglial abnormalities such as apoptosis has also been 
reported (M H Barnett & Prineas 2004). Surprisingly, few studies have gone on to 
probe the molecular abnormalities underpinning these pathological observations, 
however.  
Whilst investigating the MS patient antibody response to a wide variety of myelin-
associated proteins, Van Noort et al discovered profound serum reactivity to 
Alpha B-crystallin, a small heat-shock protein (Van Noort et al. 2010), finding that 
it accumulates exclusively in stressed oligodendrocytes in the context of 
microglial nodules. They further demonstrated that a highly purified preparation 
of this molecule induced cultured microglia to produce immunoregulatory 
cytokines and chemokines, and more recently, a variety of antiviral factors (Bsibsi 
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et al. 2013a). The authors concluded that the oligodendroglial accumulation of the 
protein was the initiating factor, given its ability to activate microglia. The cue for 
this remains speculative, and the authors purported that OGD stress may result 
from inflammation itself, although intrathecal antibodies targeting OGD in 
addition to oxidative radicals, mitochondrial dysfunction and other neuroaxonal 
disturbances were also potential mechanisms of stress. Thus, they stated that the 
apparently protective, innate immune responses to Alpha B-crystallin 
accumulation might be in a precarious balance with the intensely damaging 
aspects of adaptive responses in MS, broadly in agreement with other NABT 
studies (Zeis et al. 2008). 
It is important to continue the search for reliable markers of NABT changes. Thus, 
when considering outcome measures following treatment of patients in the 
relapsing phase of the disease, parameters assessing diffuse damage should also 
be taken into account in order to obtain an accurate a measure as possible of 
dynamic changes in the whole of the MS brain.   
1.2.7  Oligodendrocytes  
As described, OGD activity in NABT is of interest due to this purported balance 
between neuroprotection and damage. Macroglial cells in the CNS comprise 
astrocytes, ependymal cells, radial glia and OGD. Like all macroglial cells, OGD 
originate from tightly restricted periventricular germinal areas of the ectoderm, 
and are the last cell type to be generated in the CNS. Myelination increases 
exponentially in the first year of life but is not complete until 20-25 years of age. 
The myelin sheath is 80% lipid:20% protein and one oligodendrocyte can extend 
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its myelinating processes to ensheath 50 axons, wrapping around 1μm of myelin 
around each axon.  
The function of myelin in the subcortical white matter is primarily to increase 
impulse speed, as saltatory propagation of action potentials occurs at the nodes of 
Ranvier in between OGD. Velocity increases linearly with axon diameter, with the 
insulating thickness proportional to the diameter of the fiber inside. In contrast, 
satellite oligodendrocytes are considered to be a part of the grey matter and are 
functionally distinct. They are characteristically positioned in apposition with 
neurons and thought to regulate their surrounding extracellular compartment 
(Ludwin 1984) (Lee et al. 2012).  
1.2.7.1 Mechanisms of oligodendrocyte injury in the CNS 
The profound metabolic demands placed upon OGD, largely due to the 
maintenance of multiple myelin sheaths, render them particularly vulnerable to 
damage in the CNS. CD4+ and CD8+ T-lymphocytes are activated following 
presentation of antigen by MHC molecules, generally expressed on macrophages/ 
microglia. Expression of MHC molecules in the CNS under physiological conditions 
is generally not detectable (Redwine et al. 2001), although OGD can express MHC 
I upon stimulation with pro-inflammatory cytokines such as IFNγ (Massa et al. 
1993). However, whilst clonal expansion of CD8 T-cells is evident, the antigenic 
specificity of the expanded clones resulting in cell-mediated lysis remains 
unknown (Babbe et al. 2000). In addition, MHC class II expression on OGD could 
not be demonstrated in MS lesions, although are readily evident on macrophages/ 
microglia and astrocytes (Lee & Raine 1989). Thus, damage may result from toxic 
mediators secreted by a variety of cells (Berger et al. 1997) (Williams et al. 2007). 
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Figure 1.1 summarises the different cell types implicated in MS-related pathology 
and how they contribute to OGD damage and dysfunction.  
 
 
Figure 1.1. Cells mediating oligodendrocyte injury in the course of MS. Many cell types can 
injure oligodendrocytes. CD4+ Th1 cells can induce damage through mediators such as IL-2, IFN-
g and LT, whereas damage resulting from Th17 T cells involves IL-17 itself as well as IL-6 and TNF-
a. CD8+ T cells can cause direct injury by MHC class I-restricted cell lysis. B cell-mediated damage 
to oligodendrocytes can occur following antibody secretion and opsonization. Macrophages are a 
key cell type inducing oligodendrocyte damage by TNF-a,, ROS/RNS, FasL and other mechanisms. 
Finally, astrocytes were also shown to be harmful to oligodendrocytes by mechanisms involving 
TNF-a, LT, and RNS. Adapted from (Zeis & Schaeren-Wiemers 2008) 
1.2.7.2 OGD as potential immune modulators 
Recent work has suggested that oligodendrocytes are not just passive targets of 
inflammatory injury, but are in fact active participants of the neuroimmune 
networks involved in MS-related pathology (Zeis & Schaeren-Wiemers 2008). As 
discussed in chapters 3 and 4, the widespread changes in non-lesional brain tissue 
described in this thesis are increasingly recognised in MS generally (Zeis et al. 
2008; Graumann et al. 2003). Zeis and Graumann et al found that upregulation of 
genes such as CXCL10, CCL3 and CCL5 as well as STAT-6 signalling pathways could 
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be seen in NAWM. Subsequent protein work using IHC also showed that these 
changes were particularly notable in OGD. In addition, M2-polarised microglia/ 
macrophages- thought to promote repair, versus the pro-inflammatory profile of 
M1-macrophages, drive differentiation of OGD precursors to aid remyelination 
(Miron et al. 2013).  
This suggests that OGD are not simply victims of the immune-mediated processes 
occurring in MS, but instead appear to demonstrate a protective phenotype, 
acutely sensitive to inflammatory and metabolic challenges.  
1.3 HMGB1 as a novel marker in MS  
The high-mobility group (HMG) family of proteins, HMGB1 (previously HMG1), 
HMGB2 and HMGB3, were named due to their high electrophoretic mobility on 
SDS-PAGE gels. Their expression occurs mainly during development, and this 
thesis relates solely to HMGB1. Its unique properties linking sterile inflammation 
and damage as discussed below make it an ideal target to further develop our 
molecular understanding of pathological changes occurring in MS. 
1.3.1  Structure and expression of HMGB1 
HMGB1 is encoded on chromosome 13q12-13 and is composed of two DNA-
binding domains- the HMG boxes –A and –B, and a C-terminal chain of aspartic and 
glutamic acids (figure 1.2).  
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Figure 1.2 Structure of the HMGB1 protein. (a) HMGB1 is a 29-kDa non-histone protein 
of 216 amino acids. It is arranged in three domains made up by two positively charged 
DNA-binding structures (A and B box), and a negatively charged C-terminal acidic tail 
composed exclusively of 30 glutamic and aspartic acids. The latter is required for its 
transcriptional activity within the nucleus. There are two positively charged nuclear-
localization signals, including amino-acid sequence segments 28–44 for NLS1 and 179–
185 for NLS2. Amino acids 150–183 in the C-terminus of HMGB1 are responsible for RAGE 
binding. In addition, the cytokine activity of HMGB1 is located within the B box, and it can 
be antagonized by a truncated A box domain, although the latter’s function is still not 
clearly defined. The cysteine in position 106 in the B box is required for HMGB1 to activate 
cytokine release, as shown by selective mutation. 
 
Despite a molecular weight of 25kDa, it is detected at a position of 30kDa upon 
electrophoresis, probably due to its abundance of positively charged amino acids. 
It is highly conserved evolutionarily and abundantly expressed in most eukaryotic 
cells at approximately 106 molecules/ cell and has a vital role in nuclear 
homeostasis. 
1.3.2 Nuclear role of HMGB1  
HMGB1 was originally described by Johns and colleagues as a family member of 
the non-histone proteins (Goodwin et al. 1973) and its expression was accordingly 
thought to be restricted to the nucleus. Here, it binds to the minor groove of DNA 
(Yu & Spring 1977) and a strip of hydrophobic amino acids bulging from its inner 
surface interpolates between the bases, resulting in uncoiling and bending of DNA. 
The resultant local distortion of its helical structure enables distant molecules to 
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associate and form multiprotein complexes, which can have important biological 
functions. These include increased binding affinity of several transcription factors, 
including a uniquely important interaction with p53 (Jayaraman et al. 1998), and 
the RAG1 protein- responsible for V(D)J recombination (Bustin 1999).  
However, knock- out mouse studies underscore the critically important role that 
HMGB1 plays in normal cellular physiology. Phenotypically, the mice are small and 
extremely lean (fat is virtually absent) with ruffled fur and long hind paws, but 
they die with 24 hours after birth due to a combination of hypoglycaemia, 
metabolic failure and defects in transcriptional control (Calogero et al. 1999) 
1.3.3  Rediscovery of HMGB1 and its extranuclear function 
Many nuclear proteins have been found to have extranuclear function, and the role 
of secreted HMGB1 was discovered serendipitously years after its initial 
discovery. Its multifunctional role was described in two important papers 
published at a similar time, but each following disparate lines of enquiry. 
HMGB1 is expressed on the plasma membrane to facilitate neurite outgrowth 
Interest in its role outside the nucleus was first raised following neuroscientific 
findings by Heikke Rauvala and colleagues who discovered a 30kDa protein, 'p30', 
secreted by neurons and which significantly enhanced neurite outgrowth 
(Rauvala & Pihlaskari 1987). Further characterisation of this molecule by the 
same group the following year showed that it was expressed on the membrane at 
the leading edge of developing neurones, and that a heparin-like structure was 
needed for the binding of p30 to advance neurite outgrowth through the 
surrounding ECM (Rauvala et al. 1988). The authors then added an addendum in 
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proof at the end of this paper, that subsequent review had shown sequence 
homology to HMG-1 as it was then known. They observed that,”'..the adhesive and 
heparin-binding properties of this protein as well as its localisation in the 
extracellular and cytoplasmic compartments strongly suggest that extranuclear 
mechanisms should be considered as the basis of the role of p30 in cell growth”.  
 HMGB1 is secreted by activated macrophages and is important in innate 
immunity  
During the same period but in an entirely different context, Wang et al reported 
that HMGB1 was critically important in innate immune mechanisms and identified 
it as an important pro-inflammatory mediator released by macrophages upon 
exposure to LPS, TNF and IL-1 (Wang 1999). They described its role as a delayed 
mediator of sepsis-related lethality in mice and that its attentuation, using 
polyclonal anti-HMGB1 antibodies, confirmed its functional relevance by 
improving mortality outcomes in mice. Serum ultrafiltration and subsequent SDS-
PAGE analysis of patients with septicaemia also revealed higher HMGB1 levels in 
patients vs. healthy controls, and highest levels in those who died. They pointed 
out that whilst low levels of extracellular HMGB1 may be protective, akin to TNF 
and IL-1 (Leal et al. 2013; Chertoff et al. 2011), the delayed release in response to 
these prototypically early cytokines, produced high levels which were pathogenic. 
Unlike the brief, monophasic appearance of early cytokines, its late-onset kinetics 
and subsequent persistence highlighted its critically important role in 
propagating chronic inflammation as a damage-associated molecular pattern 
(DAMP). In addition, its potential as a biomarker for disease severity and blockade 
as a therapeutic intervention was also raised.  
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These two papers provided greater appreciation of its extra-nuclear function and 
thus demanded deeper understanding of (i) stimuli for release from the nucleus, 
(ii) mechanisms enabling release (iii) potential receptors and (iv) putative 
downstream signalling pathways to produce its pleiotropic actions. These will be 
discussed in more detail in the following sections. 
1.3.4  Stimuli for release of nuclear HMGB1 
Previously, it was thought that HMGB1 release from the nucleus occurred via two 
major pathways, either passively or actively. Whilst this is still accepted, our 
understanding of the mechanisms directing nuclear release have been greatly 
refined. In particular, it has become apparent that both post-translational and, 
critically, redox modifications direct the fate of HMGB1 molecules leaving the 
nucleus. As described earlier, myeloid cells secrete HMGB1 in response to a wide 
variety of stimuli including PAMPs such as LPS and endogenously derived 
inflammatory mediators such as TNF and IL-1. In addition, HMGB1 is actively 
released from a variety of other cells including myeloid dendritic cells (Ingrid E 
Dumitriu et al. 2005), natural killer cells (Semino et al. 2005), platelets 
(Rouhiainen et al. 2000), endothelial cells- where they significantly upregulate 
expression of VCAM/ ICAM (Fiuza et al. 2003), pituicytes (Wang et al. 1999), 
neurones and astrocytes (Hayakawa, Miyamoto, et al. 2012).  
1.3.4.1  Microbial exposure  
Although initial work focussed on its role in LPS-mediated responses, one of the 
most important roles of HMGB proteins have been their function as universal 
sensors of nucleic acids secondary to viral invasion, as DNA and RNA potently 
activate innate and adaptive immune responses. Interestingly, it also has a key 
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role in facilitating and potentiating viral infection within the nucleus (Moisy et al. 
2012). HMGB1 directly stimulates enhanceosome formation by Epstein-Barr viral 
activators such as Rta and ZEBRA on their target gene, BHFL-1, by simply bending 
the DNA. This allows either nonspecific bowing of the helix to create a DNA 
conformation favourable for Rta binding to this region or by facilitating the 
binding of specific proteins such as ZEBRA (Mitsouras et al. 2002). The 
significance of this in MS patients has not yet been explored. 
However, it is also important in viral clearance as it binds to multiple TLRs and other PRRs 
either at the membrane or in the cytosol, to activate innate and adaptive immune 
responses (Yanai et al. 2009). Stimulation of these receptors results in induction of type-
I interferons (IFNs), proinflammatory cytokines, chemokines and inflammasome 
formation, resulting in secretion of IL-1β. Following various stimuli mimicking different 
types of viral insult, HMGB1 was shown to bind to all nucleic acids examined, thus acting 
as a master-sensor following nucleic acid exposure and orchestrating the subsequent 
specific responses via its downstream signalling pathways, as shown in figure 1.3. 
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Figure 1.3. Schematic view of the hierarchy in the nucleic-acid-mediated activation 
of immune responses. All immunogenic nucleic acids bind HMGBs (promiscuous 
sensing), which is required for subsequent recognition by specific pattern recognition 
receptors (discriminative sensing) to activate the innate immune responses. Adapted 
from Yanai et al (2009). 
 
The authors concluded that HMGBs serve an evolutionarily conserved role, able 
to sense invading particles prior to development of more discriminatory PRR for 
subsequent innate immune responses. Thus, the binding of nucleic acids to HMGBs 
enables a more efficient and targeted response of the appropriate PRR. IHC 
analysis suggested that HMGB1 was already present in the cytosol, as HMGBs were 
found to bind to some PRRs on the endosomal membrane and then released into 
the cytosol following membrane fusion. Lu et al went on to investigate 
mechanisms underlying release and found post-translational modifications were 
critically important; discussed  below (Lu et al. 2012). 
1.3.4.2 Necrosis 
HMGB1 is a prototypic DAMP, signalling early tissue injury and necrosis 
exemplifies many aspects of HMGB1-related pathology. Simply put, it is clear that 
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the presence of a nuclear protein in the extracellular space implies cellular 
damage and various groups have demonstrated that HMGB1 can indeed leak 
passively following necrotic cell death (Degryse et al. 2001) and that its 
subsequent presence extracellularly was proinflammatory (Scaffidi et al. 2002). 
In this context, HMGB1 does not appear to be post-translationally modified (Lu et 
al. 2012) as release is almost instantaneous, and its extracellular presence 
initiates a cascade of inflammatory events predominantly via NFkB signalling as 
described below. 
1.3.4.3 Inflammasome activation and pyroptosis 
Pyroptosis describes programmed, necrotic cell death induced by caspase-1 and 
stimulates HMGB1 release by PKR (double-stranded RNA dependent protein 
kinase R)/ inflammasome activation.  
HMGB1 secretion is markedly increased from macrophages upon exposure of to a 
variety inflammasome agonists, including polyinosinic:polycytidylic acid- a viral 
mimic, live E. Coli and DAMPs such as ATP (Lu et al. 2012). Genetic or 
pharmacological inhibition of inflammasome generation was associated with 
decreased HMGB1 expression in stimulated cell supernatants.  This paper was 
critically important as it identified that HMGB1 released was hyperacetylated at 
the NLSs as already known, but also that its movement from the nucleus was 
under direct influence of PKR and inflammasome activation, to carry out further 
innate immune sensing functions (Yanai et al. 2009). 
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1.3.4.4 Apoptosis 
Apoptosis describes programmed cell death and it was previously thought that 
HMGB1 was not released from apoptotic cells (Scaffidi et al. 2002). However, 
recent work has demonstrated that exposure to apoptotic bodies does induce 
monocytes to secrete HMGB1 in large quantities (Kazama et al. 2008). Curiously, 
however, it was found to be immunologically inert by failing to stimulate TNF 
release from neighbouring macrophages. Detailed analyses revealed the presence 
of a disulfide bond between cysteines 23 and 46. In addition, caspase cleavage and 
resultant ROS in apoptotic mitochondria go on to oxidise a specific cysteine at 
position 106 in the pro-inflammatory B-box domain of the HMGB1 molecule, 
suppressing its otherwise pro-inflammatory effect. Experimentally blocking the 
oxidation step at cysteine-106 reversed this non-inflammatory effect. This was a 
pivotal finding as it contributed to the explanation of why apoptosis was an 
immunologically tolerising event, and that HMGB1 was critical in mediating this 
(Kazama et al. 2008). 
1.3.4.5 Autophagy  
HMGB1 is critically important in autophagy (Tang et al. 2010) and this may have 
unique relevance to chronic CNS diseases given the inherently non-regenerative 
environment here (Frake et al. 2015) (Nixon 2013). A comparison of autophagic 
vs.apoptotic processes is shown in figure 1.4.   
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Neurons have uniquely large cytoplasmic expanses in their dendrites and axons, 
and so face distinct bioenergetic challenges in the disposal of dysfunctional 
proteins/cellular waste over time, particularly given their post-mitotic status. The 
specific protein involved is less relevant, as all aggregates are processed along a 
common pathway, implicated in many neurological diseases (figure 1.5). 
Figure 1.4. Morphological features of autophagic, apoptotic and pyroptic cells. (a) 
Normal, (b) autophagic, (c) apoptotic and (d) pyroptotic cells. Necrosis also stimulates 
autophagy by catabolising constituent molecules. Thus, vacuolation of the cytoplasm is 
observed in both autophagic cells (b) and in cells stimulated to undergo programmed 
necrosis (d). Conversely, ATP levels are preserved in normal (a) and apoptotic cells (c) 
consistent with fewer cytoplasmic phagosomes. Scale bar=1 μm. Adapted from (Edinger 
& Thompson 2004) 
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Figure 1.5. Timeline for neurodegeneration associated with protein misfolding. The 
CNS is subject to multiple insults, and these can activate resident glial cells which produce 
both protective (eg BDNF, VEGF) and toxic (NO, IL-6, TNFα) factors. If the latter 
predominates, the sustained cell stress leads to protein misfolding. Ubiquitination of 
these aberrant proteins and removal by the ubiquitin proteasome pathway (UPP) 
contains the damage and promotes cell survival. However, prolongation of this process 
places increased metabolic demands on the cell and eventually ATP levels decline 
secondary to mitochondrial dysfunction, leading to aggregation of ubiquitinated proteins. 
Autophagy enables cells to remove these aggregates from the cytosol, but a tipping point 
between pro-survival and pro-death pathways ultimately leads to neurodegeneration in 
some cells. Accordingly, autophagic clearance has been examined in Alzheimer’s disease 
(Nixon et al. 2005; Salminen et al. 2013; W. Li et al. 2013), amyotrophic lateral sclerosis 
(Chen et al. 2012), Huntington’s disease (Martinez-Vicente et al. 2010) and Parkinson’s 
disease (Winslow et al. 2010), with defects arising at different stages of the pathway. 
Adapted from (Huang & Figueiredo-Pereira 2010) 
 37 
 
Reactive oxygen species (ROS) are key stimuli inducing cellular autophagy, 
primarily generated via the mitochondrial electron transport chain and liberated 
by stimuli such as hypoxia, nutrient starvation and mitochondrial toxicity.  
 
HMGB1 is an important regulator of autophagy, and its cytoplasmic translocation 
is stimulated directly by ROS (Tang et al. 2010). Inhibition of HMGB1 cytoplasmic 
translocation (using ethyl pyruvate) limited starvation-induced autophagy. 
Furthermore, they identified specific, intramolecular changes in HMGB1 critical 
for binding to Beclin1, displacing Bcl-2 to avert apoptosis and sustain autophagy. 
A summary of HMGB1’s role in autophagy is shown in figure 1.6. 
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Figure 1.6. HMGB1-mediated autophagy pathways in response to stress. ROS are 
either a primary cause for damage/death via oxidative stress or a secondary signal to 
recruit and activate inﬂammatory cells. By inducing autophagy and releasing DAMPs such 
as HMGB1, cells are able to maintain homeostasis and promote survival. Pleiotropic 
mechanisms of HMGB1 in autophagy induction are illustrated; nuclear HMGB1 modulates 
the expression of heat shock protein beta-1 (HSPB1/Hsp27). Phosphorylated 
Hsp27/HSPB1 modulates the actin cytoskeleton, followed by mitophagy and/or 
autophagy promotion. Cytoplasmic HMGB1 with C23-C45 binding and displacing Beclin-
1 from Bcl2/Bclxl, sustains autophagosome formation. Extracellular HMGB1 also triggers 
autophagy via interaction with the receptor glycation end product (RAGE), which initiates 
Beclin 1–PI3KC3 complex formation and inhibition of the mTOR pathway. Adapted from 
(Hou et al. 2013). 
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1.3.5   Mechanism of release 
HMGB1 is secreted as a leaderless protein without an N-terminal signal peptide, 
akin to IL-1b and other DAMPs. It subsequently undergoes non-conventional 
lysosome-mediated exocytosis through the cytosol and into the extracellular 
space. Ultimately, the degree of stress that the cell is subjected to dictates the 
particular role that HMGB1 will adopt, related to its post-translational 
modifications as detailed in figure 1.6 and 1.7. 
1.3.6 Post-translational modifications of HMGB1 and effects upon signalling 
pathways 
Epigenetic modification: As discused earlier and shown in figure 1.1, acetylation 
is an important cue enabling HMGB1 to exit the nucleus  (Sterner et al. 1979) 
(Bonaldi et al. 2003). The cues initiating acetylation remain poorly understood, 
but may involve modulation of histone deacetylases (Fu et al. 2004). Since then, 
methylation in neutrophils (Ito et al. 2007), phosphorylation (Oh et al. 2009) and 
redox-sensitive modifications (see below) have all been described.  
Redox modification: HMGB1 is an excellent example of how one molecule can 
mediate a myriad of different cellular events, simply by redox modification of 
critical amino acids. In essence, increasing oxidative cellular stress results in a 
progressively pro-inflamatory phenotype and function as seen in figure 1.7. It is 
worth highlighting that different redox forms of the molecule can be found within 
the same subcellular compartment, indicating considerable functional plasticity. 
(Venereau et al. 2012).  
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Figure. 1.7 The pathways of HMGB1 secretion or release in response to different 
degree of oxidative stress. Under resting conditions, HMGB1 is located primarily within 
the nucleus, protecting DNA structure and acting as a regulator of transcription. 
Modification of the amino-acid cysteine at key positions (23, 45 and 106) of the molecule 
determine subsequent HMGB1 function upon release. In its resting state within the 
nucleus, all of the cysteine residues are in their reduced form (Venereau et al. 2012). Upon 
mild metabolic stress, acetylated HMGB1 is released in a reduced form but with mutation 
of cysteine 106 and formation of a disulfide bridge between C23-C46, to stimulate 
autophagic pathways and augment cell function and survival. Progressive oxidative 
cellular stress stimulates redox-sensitive mitochondria to release molecules activating 
the caspase cascade to trigger apoptosis. As damage progresses with an increasingly 
inflammatory profile, this culminates in a conformation which stimulates MD2/TLR4 in 
the context of inflammasome activation and pyroptosis. Finally, at extreme levels of 
oxidative stress, severe mitochondrial permeability transition (MPT) or even the rupture 
of the mitochondrial membrane, promotes collapse and HMGB1 is leaked out of the cells 
in two forms: (1) Disulfate HMGB1 resulting in cytokine production via TLR4/MD2 
interaction and (2) All thiol HMGB1, leading to chemotaxis via release and subsequent 
binding to CXCL12 and CXCR4. Adapted from (G. Li, Tang, et al. 2013) 
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1.3.7  HMGB1 receptors and intracellular signalling 
When HMGB1 is released into the extracellular space, it binds to receptors to elicit 
specific responses. The number of receptors implicated in its subsequent 
signalling is growing, alongside our understanding of their synergistic 
interactions. The best established receptors comprise RAGE, TLR2, -4, -9 and 
CXCR4 (Yang et al. 2013).   
RAGE: this was the first receptor identified which bound HMGB1 in rat brain 
extracts at amino acid residues 150-183 (Hori et al. 1995) ( figure 1.1). Signalling 
through RAGE is important for maturation of immune cells, cellular migration and 
upregulation of surface receptors such as TLR4 and RAGE itself (Yang et al. 
2007)(Rouhiainen et al. 2004; I E Dumitriu et al. 2005) and autophagy as 
discussed earlier. Neurite outgrowth was stimulated via RAGE, and subsequent 
work has shown the signalling pathways involved include cdc42/ Rac, concerned 
with both cytoskeletal regulation and cell migration (Huttunen & Rauvala 2004).  
HMGB1 ligation of RAGE also stimulates transcription of genes important in 
migration control including VCAM-1, ICAM-1,and the AMIGOs. AMIGO1 
(Amphoterin-Induced Gene and ORF) was originally identified based on RAGE 
ligation by HMGB1 (Zhao et al. 2011; Kuja-Panula et al. 2003). These molecules 
will be discussed in further detail in section 1.3.6, below. 
Ligation of RAGE can also result in activation of MAPKs e.g. p38, stress-activated 
protein kinase/c-jun N-terminal kinase and ERK1/2, leading to NFkB activation 
and production of pro-inflammatory cytokines.  
TLR-4:Despite the central role that RAGE plays in HMGB1 function, it was shown 
that RAGE-knockout macrophages were still able to produce TNFα upon 
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stimulation by HMGB1. In contrast, TLR4-knockout macrophages were not able to 
produce TNFα upon the same exposure, introducing a role for TLR4 in the pro-
inflammatory function of HMGB1 (Yang et al. 2010). This work showed that 
HMGB1 binds to TLR4-MD2 (using surface plasmon resonance), and that both 
binding and signalling require reduction of cysteine 106. This results in nuclear 
translocation of NfKB and production of TNFα. HMGB1 has also been shown to 
bind to TLR2 (Yu et al. 2006) secondary to LPS stimulation and TLR3 (Mina Son 
2012) seondary to viral antigens or mimics to induce signalling via NFkB and 
leading to cytokine release.  
The current dogma is that HMGB1 signalling takes place via RAGE in endothelial 
and somatic cells and via TLRs in myeloid cells (Andersson & Tracey 2011). The 
interaction, if any, between these respective receptor complexes is still not clear. 
Speculation that HMGB1 did not always operate alone and could form 
heterocomplexes with other molecules to trigger receptor activation is suggested 
by subsequent work, in particular concerning TLR9 and CXCR4. Tian et al 
demonstrated that HMGB1-DNA complexes activate TLR9 to augment maturation 
of immune cells as well as cytokine secretion (Tian et al. 2007). In addition, pivotal 
work by Schiraldi et al found that redox modification of HMGB1 also allows 
formation of a heterocomplex with CXCL12, associating with its cognate receptor 
CXCR4 to boost chemotactic activity (Schiraldi et al. 2012).  
1.3.8  HMGB1 and adaptive immunity 
Available data regarding the interaction of HMGB1 with lymphoid cells, in contrast 
to the myeloid lineage, is surprisingly limited. However, there is clear in-vitro 
evidence to suggest that it is secreted by activated natural killer cells to promote 
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DC maturation during the immune response (Semino et al. 2005; Semino et al. 
2007). In addition, HMGB1 translocates and is secreted by human DC following 
LPS stimulation, acting as a pro-inflammatory cytokine. Thereafter, it plays an 
important role in promoting expansion, survival, and Th1 polarization of CD4+ 
(Ingrid E Dumitriu et al. 2005; Jube et al. 2012), and Th17-cells  (He et al. 2012; Su 
et al. 2011; Shi et al. 2012), including when signals would otherwise result in 
suboptimal T-cell stimulation. 
In contrast, human CD4(+)CD25(+)CD127(-)Tregs express significantly higher 
levels of RAGE on the cell surface than CD4(+)CD25(-)CD127(+)-conventional T-
cells, while levels of TLR4 were similar.HMGB1 apparently induced migration and 
prolonged survival of Treg’s and significantly increased IL-10 release and Treg 
suppressive capacity in a RAGE-dependent manner. Finally, they noted that 
HMGB1 directly suppresses IFNγ release from T-cells and inhibited their 
proliferation via TLR4 (Wild et al. 2012).  
1.3.9  The role of HMGB1 in systemic disease 
The vast majority of HMGB1 research has been linked to its role in systemic 
disease, and relate mainly to its extracellular, proinflammatory actions. Sepsis 
gained the most attention initially, given the original identification of LPS acting 
to trigger HMGB1 release from macrophages (Wang 1999) and other acute 
inflammatory diseases similarly reported its relevance such as in haemorrhagic 
shock and acute lung injury (Fan et al. 2007; Barsness et al. 2004). Attention 
rapidly turned to its role in potentiation of chronic inflammation e.g.in arthritis. It 
exemplifies why HMGB1 is thought to have a role in chronic inflammatory and 
autoimmune diseases; namely due to (a) identification of HMGB1 in serum or 
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other biofluids eg urine, synovial fluid (b) upregulation of HMGB1 expression in 
pathological tissue, including in the extracellular compartment (c) recapitulation 
of disease characteristics when HMGB1 is administered exogenously in vitro/ in 
vivo and (d) efficacy in ameliorating disease phenotype in animal models using 
HMGB1 blockade. Current studies in tumour biology have also yielded important 
insights into the role of HMGB1 in this disease process, and its relevance to many 
other diseases  (G. Li, Tang, et al. 2013). 
1.3.10  The role of HMGB1 in CNS disease 
Despite its extranuclear role being originally identified in the brain, relatively little 
attention had focussed on the role of HMGB1 in the CNS. This is reflective of the 
usual limitations concerning experimental access to CNS tissue, where unlike a 
skin biopsy or synovial fluid aspirate, sampling of CNS material presents obvious 
difficulties. However, studies into several neurological diseases have successfully 
demonstrated the pathological importance of HMGB1. Traumatic brain injury 
(Laird et al. 2014) (Okuma et al. 2012), CNS infection (Tang et al. 2008; Asano et 
al. 2011) (Höhne et al. 2013a), epilepsy (Zurolo et al. 2011; Maroso et al. 2010), 
ALS (Casula et al. 2011), Alzheimer’s disease (Takata et al. 2003; Takata et al. 
2004), Parkinson’s disease (Lindersson et al. 2004) (Gao et al. 2011) and, 
importantly, stroke (Kim et al. 2006) (Qiu et al. 2007) (Kim et al. 2012; Kim et al. 
2006) (Hayakawa et al. 2010; Hayakawa, Pham, et al. 2012; Hayakawa, Nakano, et 
al. 2010; Hayakawa, Miyamoto, et al. 2012) have highlighted both detrimental and 
beneficial  roles for HMGB1.  
MS: HMGB1 expression has been examined in MS patients (Andersson et al. 
2008)and will be discussed in detail in Chapters 3 and 4. However, this study 
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predominantly examined the expression pattern in active lesions only and did not 
consider changes that may be occurring in NABT.  
1.3.11  Summary of HMGB1 function 
HMGB1 is vital to both cell life and death, and has an important role in sensing 
increasing degrees of cellular stress. In response to significant levels of oxidative 
stress, it orchestrates predominantly innate and some adaptive immune 
mechanisms, with both chemotactic and cytokine-like functions. The latter is 
largely effected via TLR and RAGE-mediated NFkB signalling in macrophages to 
produce deleterious effects in the surrounding tissue. In conditions of lower levels 
of oxidative stress in somatic cells in particular, it also demonstrates protective 
properties, via activation of RAGE and non- NFkB signalling pathways. Given the 
sensitivity of HMGB1 in identifying cellular stress, and our understanding that NABT 
changes can reflect diffuse aspects of MS pathology it is possible that it could act as a 
marker of pathology in these regions. However, it has many other potential roles in 
MS also, from immune cell recruitment and cytokine release, to possible 
autophagic responses in resident cells exposed to the pathological environment in 
MS brain tissue. Thus, exploration of downstream molecular changes following 
HMGB1 stimulation is of particular interest as this may offer a more targeted 
approach to managing HMGB1-related pathology. 
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1.4  Leucine-rich repeat and Ig-domain containing (LRRIG) molecules 
The leucine-rich repeat (LRR) sequence in proteins was discovered in 1985 and 
are solenoid-patterned, protein-ligand interaction motifs (Takahashi et al. 1985). 
They are present in a diverse range of proteins with heterogenous functions and 
sub-cellular locations (Kobe 2001). The number of LRRs is variable though are 
generally 20–29 amino acids in length. Structurally, each LRR consists of a β-
strand and anα-helix connected by loops, in a repeating pattern arranged as a 
curved, horseshoe-shaped structure parallel to a common axis- see figure 1.7.       
                       
Figure 1.8. The three-dimensional structure of the LINGO-1 ectodomain: an 
illustration of typical structural features of a leucine-rich repeat molecule. The α-
helices form the outer convexity of the horse-shaped molecule, whilst the inner β-
helices form the exposed sheet to which ligands can bind, creating a large and versatile 
binding region. Adapted from (Loizou et al. 2014).  
 
Some LRR proteins are anchored to the cell membrane and it is this group which 
frequently demonstrate brain-enriched expression, suggesting CNS-specific 
functions, and their importance in this context is increasingly recognised (de Wit 
et al. 2011; Chen et al. 2006). These include the neuronal cell surface Nogo-66 
receptor (NgR) (Fournier et al. 2001; Thallmair et al. 1998) and its ligands e.g. 
oligodendrocyte myelin glycoprotein (Omgp) (Vourc’h et al., 2004) and LINGO-1 
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(Mi et al.,2004) as well as the AMIGO molecules (Chen et al.,2011; Kua-Panula et 
al.,2003). The latter two CNS-enriched families form a distinct class of LRR,type I-
membrane proteins with a domain normally associated with adhesion molecules, 
the C2-type Ig-like domain; hence ‘LRRIg’ designation. The LRR domain 
differentiates these molecules from the Ig-like family of cell adhesion molecules, 
whilst the transmembrane domain distinguishes them from the family of secreted 
proteoglycans with LRRs. Our interest lies in the AMIGO family, primarily due to 
their close association with HMGB1 and to LINGO-1; a molecule extensively 
studied in the context of MS biology and for whom phase-2,anti-LINGO-1 clinical 
trials for MS treatment are underway.   
1.4.1  AMIGO molecules 
As mentioned earlier, neurite extension of embryonic neurons on a plate coated 
with HMGB1 or amphoterin as it was then known, induced gene expression of 
AMIGO-1 which was an unidentified molecule at the time. The upregulated 
transcript was subsequently named AMIGO (AMphoterin-Induced Gene and Open 
Reading Frame) and was cloned along with its homologues, AMIGO-2 and AMIGO-
3. All the molecules demonstrated both homophilic and heterophilic biding with 
each other. The crystal structure of AMIGO-1 was recently elucidated and 
demonstrated that homophilic binding takes place via its LRR region. Subsequent 
BLAST searches using the AMIGO-1 ectodomain have further demonstrated 
sequence homology with Slit-proteins (axon guidance) and the Nogo-66 receptor 
(NgR1) (Zhao et al. 2014a). The latter is of particular interest with regards to 
AMIGO-3, as it was recently shown to mediate neurodegeneration via RhoA 
activation by acting at NgR1, analogous to LINGO-1 (Ahmed et al. 2013). AMIGO-1 
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and -2 did not demonstrate this function, despite the potential association at the 
NgR suggested by BLAST searches and instead, other researchers have 
demonstrated a clear role for them in CNS development, especially in the 
formation of fasciculated fibre tracts (Zhao et al. 2014b) and Andres, 2004) and 
LINGO-1 (Mi et al. 2004), as well as the AMIGO proteins (Chen et al. 2011; Kuja-
Panula et al. 2003). Using a combination of reverse transcriptase PCR, in-situ 
hybridisation and IHC in mice, AMIGO-1 expression appeared to be CNS-specific, 
especially in hippocampal neurones. Both AMIGO-2 and AMIGO-3 displayed 
relatively more widespread tissue expression, though the latter was highly 
expressed in the CNS.  
Functionally, AMIGO-1 has been found to associate closely with the Kv2.1 
potassium channel and to directly affect central neuronal excitability via this 
association (Peltola et al. 2011), and also appears to regulate expression of Kv2.1 
in the adult brain (Zhao et al. 2014b). The immunostaining pattern in mouse brain 
demonstrates striking co-localisation and clustering of both kv2.1 and AMIGO-1, 
in a characteristically punctate pattern, around the neuronal soma and proximal 
dendrites- see figure 1.8. 
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Figure 1.9. Colocalization of AMIGO and Kv2.1 in 24 days in vitro cultured 
hippocampal neurons. Single confocal plane from the basal surface of the cell. The 
classically punctate staining pattern around neuronal soma and proximal dendrites was 
evident. Scale bar = 10μm. Adapted from (Peltola et al. 2011). 
 
The identification of AMIGO-2 (‘alivin-1’) was reported, coincidentally, at around 
the same time as Kuja-Panula et al published the original ‘AMIGO’ paper in 2003. 
It was found to be enriched in cerebellar granule cells and in a specialised region 
between CA1 and CA3 in the rat hippocampus (Ono et al. 2003b). More 
importantly, they noted that its mRNA transcription was dependent on neuronal 
activity, regulated by potassium chloride/ NMDA in culture media and tightly 
correlated to depolarisation-dependent survival. More recently, Laeremans et al 
reported that its hippocampal expression is in fact located in CA2 and CA3 of the 
Ammon’s Horn; a region particularly resistant to neuronal injury/ toxicity 
(Laeremans et al. 2013). Thus AMIGO-2 was identified as an important cell 
survival- promoting factor. At a similar time, AMIGO-2 was also identified as a 
gene differentially expressed in human gastric adenocarcinomas (DEGA) in 
around 45% of tumour vs. control tissue from subjects with gastric cancer, 
highlighting a potential role in tumorigenesis (Rabenau et al. 2004), likely relating 
to its pro-survival functions (Ono et al. 2009a; Ono et al. 2003b).  
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1.4.2  Interaction between HMGB1 and AMIGO molecules 
The interaction between HMGB1 and AMIGO-1 in particular has been studied 
recently (Zhao et al. 2011) but their exact relationship remains unclear. Antisense 
morpholino oligonucleotides specific for HMGB1 produced downregulation of 
HMGB1 expression as expected, but also of AMIGO-1 expression, as assessed by 
western blotting. High-resolution immunostaining in this study also 
demonstrated partial co-localisation of the proteins at the plasma membrane; 
suggesting that HMGB1 effects are not only on gene upregulation of AMIGO-1 but 
may have a more direct role in their interaction. Furthermore, injection of AMIGO-
1 cRNA in the HMGB1 zebrafish knockdown morphants produced a rescue effect 
by increasing neuronal network development to around the same levels as with 
HMGB1 cRNA itself. The authors conclude that the expression and function of 
AMIGO-1 may be linked to HMGB1, at least in the context of forebrain 
development, and should be included in the signalling pathway through which 
HMGB1 regulates neural progenitors. Clearly, the physiological interaction of 
HMGB1 with AMIGO-1 may be distinct from a pathophysiological one, but given 
their close association, it seems plausible that AMIGO-1 may have a role in 
HMGB1-mediated inflammation, although whether in this context it has neurite 
outgrowth promoting or inhibiting properties is unknown. Recently, Chen et al 
(Chen et al. 2011) found that AMIGO-1 expression in rat and mouse brain was 
more widespread than previously suggested, with astroglial and oligodendroglial 
expression also seen; a difference presumed to be related to different AMIGO-1 
antibody specificities. In neurones, they found that endogenous AMIGO-1 localised 
to the dendritic tree, responsible for forming synaptic connections. Interestingly, 
they reported that upon removal of the leucine-rich repeat molecules using DNA 
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manipulation, the molecule relocated to the axonal surface. However, elucidation 
of the crystal structure of the AMIGO-1 dimer has recently revealed that 
homophilic binding occurs through its LRR domains (Kajander et al. 2011). Thus 
it would appear that fasciculation of neurites and synaptogenesis require the LRR 
regions. 
The association between HMGB1 and AMIGO-2 and -3 rests with their potential 
association with AMIGO-1, and little work has been done to explore any further 
link. LINGO-1 has no recognised connection to HMGB1, other than being from a 
similar family to the AMIGO molecules. 
1.4.3  LINGO-1 
LINGO-1 is the best characterised LRRIg molecule, in terms of cellular expression 
profile and function. Its potential role in MS has been comprehensively assessed 
in pre-clinical work, such that anti-LINGO-1 phase 2 trials are now underway 
following these findings.  
It is established that as the nervous system matures, neuronal connections are 
stabilised, and the potential for structural remodelling or regeneration following 
injury becomes restricted. Postnatal structural plasticity is limited to “critical 
period”- a set developmental time window. Closure of the critical period coincides 
with myelination, and myelin-associated proteins are major factors in limiting 
structural plasticity in the adult CNS (although other myelin-independent 
mechanisms also exist). Inhibitory myelin-related proteins include Nogo66 
(NogoA) (Chen et al. 2000),  oligodendrocyte-myelin glycoprotein (Omgp) (Wang 
et al. 2002) and myelin-associated glycoprotein (MAG) (McKerracher et al. 1994; 
Schnaar & Lopez 2009). These three myelin proteins bind to the Nogo receptor 
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(NgR1) and inhibit neurite growth via two co-receptors containing p75 or TROY 
(Park et al. 2005; Shao et al. 2005; Wang et al. 2002). 
LINGO-1 was initially discovered as a component of this NgR1complex, 
functioning as a natural inhibitor of neurite growth. It was also shown to be 
important in regulating oligodendrocyte differentiation and myelination, in the 
context of inhibitory myelin-related proteins (Mi et al. 2004; Mi et al. 2005). This 
inhibitory effect of myelin proteins on neurons is mediated by Ras homolog gene 
family, member A (RhoA) after binding with the NgR1 complex. RhoA itself is a 
small GTPase protein known to regulate the actin cytoskeleton in the formation of 
stress fibres, acting upon the effector protein ROCK1 (Rho-associated, coiled-coil 
containing protein kinase 1). LINGO-1, forms a ternary complex with the NgR1 and 
p75/TAJ/TROY to signal through the Rho-GTP cascade to inhibit CNS axon 
regeneration. Following activation of ROCK by RhoA (via RhoA kinase) this 
stimulates the actin-binding LIM kinase, which then stimulates cofilin (involved in 
the disassembly of actin filaments). Together, this results in reorganisation of the 
actin cytoskeleton of the cell. In the case of neurons, activation of this pathway 
results in growth cone collapse, thus inhibiting the growth and repair of neural 
pathways and axons. In addition to myelin-associated proteins, further 
constraints on axon regeneration are related to deposition of the glial scar, which 
also contains inhibitory ligands (e.g. semaphorins, ephrins, chondroitin sulphate 
proteoglycans (CSPG)). Some of the functional consequences of antagonism of this 
protein complex, via Anti-NgR1 antibodies (W. Li et al. 2004), soluble NgR1 (S. Li 
et al. 2004) and p75NTR antagonists, include the promotion of CNS axonal 
regeneration in vivo (Lee et al. 2003). In addition to its role in axon growth, LINGO-
1 is involved in oligodendrocyte differentiation and remyelination, possibly 
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mediated through NGF and TrkA (figure 1.9) (Mi et al. 2005). Inhibition of 
oligodendrocyte differentiation requires its cytoplasmic domain, leading to 
downstream signalling via the RhoA pathway. Whether binding of LINGO-1 to a 
secreted or membrane-bound ligand, in cis or in trans, is required to initiate 
intracellular signalling is currently unknown. Importantly, LINGO-1 expressed on 
the axonal surface also inhibits oligodendrocyte differentiation and myelination, 
both in oligodendrocyte-neuron co-cultures and in transgenic mice 
overexpressing LINGO-1 (Lee et al. 2007a). This suggests that LINGO-1 signals 
from axon to oligodendrocyte to inhibit oligodendrocyte differentiation. The 
nature of this signal is not yet clear, but does not apparently involve the LINGO-1 
binding proteins NgR1 and p75NTR. 
 
Figure 1.10. Putative signalling pathways for LINGO-1. Reproduced from (Rudick et 
al. 2008) 
 
Furthermore,  the NgR1-LINGO-1-p75/TROY complex may also participate in cell 
death following neuronal injury (Barker 2004; Bhakar et al. 2003; Florez-McClure 
et al. 2004). LINGO-1 antagonists or gene knock-out knock-out mice were found 
to promote OPC differentiation (Mi et al. 2005; Lee et al. 2007b), reduce apoptosis 
and promote survival of OGD and neurons, as well as enhancing recovery of 
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function after spinal cord injury (Ji et al. 2006). In addition, in vivo work has 
shown that attenuation of LINGO-1 activity promotes axonal remyelination, 
regeneration and functional recovery in an EAE model (Mi et al. 2007).  
Its expression in human brain has also been studied, where Satoh et al found that 
LINGO-1 was expressed in neurons, reactive astrocytes and macrophages/ 
microglia but not in OGD, when using non-lesional and chronic actively 
demyelinating lesional tissue (Satoh et al. 2007). The lack of expression in OGD in 
this work is in stark contrast to the findings as discussed above by Mi et al, and 
this discrepancy has not been resolved thus far..  
Despite LINGO antagonism leading to a significant increase in neurite outgrowth 
using in vitro assays, the importance of the protein in vivo is less clear, as LINGO-
1 inhibition in CNS injury models as detailed above only led to delayed and then 
modest levels of regeneration (Lee et al. 2007b). This raises the possibility of 
functional redundancy, with alternative binding partners existing for NgR and 
p75NTR. 
1.4.4 AMIGO-3 blockade may enhance neuroregenerative processes more 
than LINGO-1 
Recent work performed in the University of Birmingham suggests that specific 
members of the AMIGO family of proteins may function as alternative binding 
partners to LINGO-1 at the NgR (Ahmed et al. 2013). AMIGO3 levels were found to 
be significantly higher than those of LINGO-1 in the early phase following dorsal 
root ganglion neuron (DRGN) crush in rats and suppressed in the retina in a model 
of optic nerve regeneration. Functional outcome data showed that AMIGO3 
interacts with NgR1-p75/TROY in both non-neuronal transfected cells and in 
brain lysates, with evidence of RhoA activation in response to CNS myelin extracts. 
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Knockdown of AMIGO-3 in primary DRG and retinal cultures in the presence of 
myelin resulted in disinhibited neurite outgrowth when stimulated with 
neurotrophic factors. This data suggests that AMIGO3 substitutes for LINGO-1 in 
the NgR1-p75/ TROY inhibitory signalling complex and mediates myelin-induced 
inhibition of axon growth acutely in the CNS itself. The authors concluded that 
antagonising AMIGO3 as opposed to LINGO-1 immediately after CNS injury may 
be a more effective therapeutic strategy for promoting CNS axon regeneration. 
The situation is likely to be complex, given much of the work regarding the AMIGO 
molecules has been related to roles in neurite outgrowth. However, the molecules 
may well have differing functions, depending on the pathological context,   
  
 56 
 
1.5  Summary 
The relationship between inflammation and neurodegeneration in MS remains 
unclear. This is partly due to apparent dissociation between focal lesions and 
diffuse inflammatory processes, which we know are prominent during the 
progressive phase of the disease in particular (Kutzelnigg et al. 2005). Global 
pathological changes are thought to better reflect disability outcomes than focal 
inflammatory lesions (Gallo et al, 2005), therefore greater understanding of the 
mechanisms responsible for widespread changes in MS brain tissue is important.  
 HMGB1 has been implicated in many diseases, and serves as a link between sterile 
injury and inflammation. HMGB1 expression is known to be increased in active MS 
lesions, predominantly in macrophages/ microglia (Andersson et al. 2008). If 
HMGB1 can be detected in the periplaque white matter, this may provide a 
molecular representation of inflammation spreading centrifugally from the lesion 
core out into the surrounding tissue. Other work has demonstrated that HMGB1 
is also produced from activated plasma cells (Vettermann et al. 2011), which we 
know are present in ectopic B-cell follicular structures in the meninges of MS 
patients (Serafini et al. 2004). Thus, it is possible that secretion from both 
infiltrating macrophages and B-cells mean it may be detectable in the CSF also.  
Exploring the link between the LRRIG proteins and HMGB1 in MS is a novel area 
of MS research. Given the myriad different roles that HMGB1 plays, blocking its 
action in vivo may have less predictable consequences. Focussing on associated 
markers such as AMIGO molecules, induced downstream from HMGB1 activation, 
may allow a more rational interpretation of findings. 
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1.6  Hypotheses underpinning thesis 
1. The expression pattern of HMGB1 reflects damage-related changes 
emanating from the active lesion core into the peri-plaque region  
 
2. HMGB1 is detectable in the subarachnoid space and CSF and levels are 
increased in MS patients vs. controls  
 
3. Expression of molecular targets potentiating neurodegenerative pathways, 
such as LINGO-1 and AMIGO-3, are influenced by HMGB1 stimulation 
 
1.7  Aims of thesis 
1. To compare HMGB1 expression using neuropathological tissue from    
             MS and non-MS control patients, in both lesional and non-lesional regions 
 
2. Assess CSF HMGB1 levels in MS patients compared to non-MS controls      
 
3. Explore the expression pattern of LRRIG molecules, including effects of  
            HMGB1 stimulation 
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2.  
General Methods 
 
 
 
 
 
 
2.1  MO3.13 cell culture 
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2.1.1  MO3.13 cell line 
This human-human hybrid cell line was developed using postmitotic CNS cells that 
expressed oligodendrocyte (OGD)-specific proteins and mRNA. The primary OGD 
cultures were originally obtained from surgical resections for intractable epilepsy, 
with the actual tissue used for primary cells taken distal to the electrically active 
site. The tumour parent for the MO cell line was RD- a rhabdomyosarcoma cell line 
from ATCC (Rockville, MD). An aminopterin-sensitive mutant of RD lacking 
hypoxanthine phosphoribosyltransferase (EC 2.4.2.8) by selection in 6-
thioguanine was developed and designated RD.TG6. Primary glial cells were fused 
to adherent RD.TG6 cells by a phytohemagglutinin P-enhanced, polyethylene 
glycol- mediated procedure modified from Fournier (1981). Because of the lack of 
HPRT, the inhibition of de novo DNA synthesis by aminopterin results in death of 
all cells which are not fused to the RD.TG6 cells. However,growth of the hybridoma 
cells in the presence of aminopterin is permitted due to utilisation of the salvage 
pathway, allowing cells to incorporate exogenous hypoxanthine and to synthesise 
purines. Using a combination of flow cytometry, IHC, CNPase activity, Northern 
and immunoblotting, the hybrid clone M03.13 demonstrated membrane-bound 
immunoreactivity (IR) for galactosyl cerebroside and intracellular IR for myelin 
basic protein (MBP), proteolipid protein (PLP), and glial fibrillary acidic protein 
(GFAP). Serum deprivation or chronic treatment with a protein kinase C activator 
4-6-phorbol12-myristate 13-acetate (PMA) increased OGD phenotypic markers 
with down-regulation of GFAP expression, demonstrating their potential utility 
for in-vitro OGD modelling experiments (Buntinx et al., 2004; McLaurin et al., 
1995). Extrapolating data generated using this immortalised cell line to processes 
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occurring in primary OGD is subject to caveat, but it provides a window into how 
OGD may respond to the multiple stimuli presented in the context of MS pathology.  
2.1.2  Cell proliferation 
Frozen MO3.13 cells were obtained via a material transfer agreement between the 
University of Birmingham and Cedarlane Corporation, CELLutions Biosystems Inc. 
(Ontario, Canada), via the UK distributors, VH Bio (Gateshead, UK). All cell culture 
procedures were carried out under aseptic conditions in fume hoods. Cells were 
cultured in a high glucose formulation of DMEM (Sigma-Aldrich, Dorset, UK) 
supplemented with 10% Fetal Bovine Serum Gold (Sigma-Aldrich, Dorset, UK) and 
designated ‘high serum media’. Although not an absolute requirement, we also 
added Penicillin/Streptomysin at 1X (Invitrogen: 15140-148). The cells were 
maintained in 75cm2 tissue-culture flasks (Greiner Bio-One, Frickenhausen, 
Germany) at 370C in a humidified atmosphere with 5% CO2. Cells were passaged 
once 70% confluency was reached, at which point 2ml of Trypsin-EDTA solution 
(Sigma Aldrich, Dorset, UK) was added and the flask agitated by tapping on the 
bench. The approximate total cell count was generally 1x107 following cell 
counting and was subsequently split 1:10, giving a concentration of approximately 
1x106cells/ ml. For experiments, 0.5ml cell suspension was added to 2ml of high 
serum media in each well and seeded into 6-well plates. Plates were left for 24h 
for adherence and the media was then replaced with a low-serum media, with 
0.5% serum present instead of 10% and cells were left for a further 24h. As 
described earlier, serum reduction was employed as it has been reported that this 
led to the expression of the mature oligodendrocyte marker (GST-π) in this cell 
line (Haq et al. 2003).  
 61 
 
2.1.3  Freezing down cells 
Cells grown in TC flasks were trypsinised at 70% confluence, re-suspended in 
10ml of high-serum media and centrifuged at 400g for 5 minutes. Media was 
aspirated and the pellet carefully re-suspended in 10% DMSO and 90% high 
serum media. Samples were aliquoted into cryovials and placed in ‘Mr Frosty’ Cryo 
Freezing containers (Nalgene, Hereford, UK), containing isopropanol and frozen 
at a rate of 1OC minute-1, or kept in liquid nitrogen for long-term storage. 
2.2  RNA extraction 
The RNEasy Mini kit (Qiagen, Hilden, Germany) was used. Samples were lysed in 
each well, using a buffer containing a highly denaturing guanidine-thiocyanate–
containing buffer, which immediately inactivates RNAses to ensure purification of 
intact RNA. Following addition of the buffer to each well, the cell monolayer was 
disrupted by passing the lysate through a 20-gauge (0.9 mm) needle attached to a 
sterile plastic syringe ⩾10 times until a homogeneous lysate was achieved. 70% 
ethanol was added to provide appropriate binding conditions, and the sample 
applied to an Rneasy Mini spin column, where total RNA binds to the membrane 
and contaminants are washed away following a series of washing and 
centrifugation steps (≥8000g). RNA is then eluted in 30–100 μl water.  
2.2.1 RNA quantification 
The quantity of RNA was measured using NanoDrop ND-2000 Spectrophotometer 
(Thermofisher, Surrey, UK). The absorbance of 1μl of RNA at 260nm and 280nm 
and the OD260/OD280 ratio indicates the RNA purity. Only OD260/OD280 ratios in the 
range of 1.9- 2.1 were used. All measurements were made with respect to a blank 
consisting of nuclease free water. Once RNA concentration was determined, 
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samples were diluted using nuclease-free water to produce a standardized 
amount of RNA in 100μl. 
2.3  Reverse Transcription (RT) reaction  
We used the high capacity RT kit from Applied Biosystems (Warrington, UK) for 
the RT reaction. X2 RT mastermix was constituted using the reagents as outlined 
in table 2.1 in 1.5ml eppendorfs. 
Reagent Volume/ sample (μl) 
10x RT buffer 2 
25x dNTP Mix (100mM) 0.8 
10x RT random primers 2 
Multiscribe RT 1 
Nuclease-free water 4.2 
Total/ reaction  10 
Table 2.1. Reverse transcriptase reaction volumes 
Samples were then loaded into a thermal cycler (Bio-Rad, Hemel Hempstead, UK), 
for incubation at 250C 10 minutes (denaturing and annealing stage); 480C for 30 
minutes (transcription); and 5 minutes at 950C (inactivation). Samples were then 
removed and stored at -200C until PCR was performed. 
 
2.4  Relative Quantitative (real-time) PCR   
Real-time PCR was performed using a Roche LightCycler480 system (Roche, 
Sussex, UK). GAPDH was used as the ‘house-keeping gene’, acting as the internal 
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reference for RNA expression in the samples used. Reactions were performed in 
duplicate, in 5µl volumes using white 384-well plates. The Lightcycler® 480 
Probes Master (Roche, Sussex, UK) and Applied Biosystem “assay on demand” 
primer-probes (Applied Biosystems, Warrington, UK) for target and house-
keeping (GAPDH) genes were used as shown in table 2.2. All reactions were 
multiplexed with primers specific for GAPDH RNA with VIC-labelled probes, 
whilst target genes had FAM-labelled probes. 
REAGENT VOLUME (μl)/ WELL  
Mastermix 2.5 
Nuclease-free water 0.2 
Primer-probe reference 0.5 
Primer-probe target 0.5 
cDNA 1.3 
Total/ reaction  5 
Table 2.2 Real-time PCR reaction volumes 
Reactions were as follows: 50°C for 2 minutes, 95°C for 10 minutes; then 40 cycles 
of 95°C for 15 seconds and 60°C for 1 minute.  Data were expressed as cycle 
threshold (Ct) values (the cycle number at which logarithmic PCR plots cross the 
calculated threshold line) and used to determine ∆Ct values (∆Ct = Ct of the target 
gene minus Ct of the housekeeping gene). Arbitrary units (AU) were calculated 
using the ∆Ct [AU = 1000 x (2-∆Ct)] whilst relative mRNA levels using treatment – 
control values, and were expressed as fold changes (2-∆∆Ct). 
2.5  Protein extraction 
 64 
 
Cell monolayers were placed on ice and washed with cold, sterile PBS. 150μl of 
RIPA buffer (Sigma-Aldrich, Dorset, UK; supplemented with protease inhibitor 
cocktail (PIC; Roche, Sussex, UK)) was then added to each well of the 6-well plate. 
PIC is used to maintain protein integrity as once the cells are lysed, all the 
proteases are released and may alter the properties of the protein of interest due 
to unchecked degradation. Wells were scraped, lysates collected and placed at 4°C 
for 15minutes. They were then centrifuged at 8000g for 10minutes at 4°C and the 
clarified protein supernatants placed on ice. 
2.6  Protein concentration assay 
5μl of each of the clarified lysates was transferred to a 96-well plate, leaving the 
first 3 columns of the plate free. Bovine serum albumin (BSA) 5mg/ml was diluted 
in distilled water to establish a dilution series (0 mg/ml, 0.125 mg/ml, 0.25 
mg/ml, 0.5 mg/ml, 0.75 mg/ml, 1.0 mg/ml, 1.5 mg/ml and 2.0 mg/ml). 5 μl of each 
protein standard was transferred, in triplicate, to the first 3 columns of the 96 well 
plate. Standard protein assay reagents using the BioRadDC kit (Bio-Rad, Hemel 
Hempstead, UK) were then added to each well using an automated pipette. The 
samples were incubated at 37°C for 10 minutes to facilitate the chromogenic 
reaction. The absorbance of each well was then read at 630 nm using the BioTek 
Synergy HT machine (BioTek, Winooski, USA). A standard curve was plotted from 
the known protein concentrations and used to calculate unknown protein 
concentrations from the samples.  
2.7 Immunoblotting 
For all molecules, 40μg of denatured protein was resolved on Novex® NuPage® 
4-12% Bis-Tris protein gels under reducing conditions (Invitrogen, Paisley, UK). 
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The gels were run at 200V/115 mA for approximately 60 minutes. Proteins were 
then transferred to PVDF membranes using the Trans-Blot® Turbo™ machine 
(Bio-Rad, Hemel Hempstead, UK), for 10 minutes. Membranes were then washed and 
blocked in 10ml of 5% Marvel (milk) for 1 hour at room temperature with constant 
agitation. They were then incubated overnight at 4°C on an orbital shaker with 
primary antibodies. After generous washing, secondary antibody incubation was 
performed at room temperature with constant agitation. After washing again, 
immunoreactive bands were generated using the ECL detection kit (GE 
Healthcare, Bucks, UK) and visualised using the ChemiDoc™ XRS system. 
Densitometry was calculated using the in-built ImageLAB software, following β-
actin band detection (see below). Membranes were then stripped to remove 
bound primary and secondary antibodies by incubating in stripping buffer (Tris-
buffer 0.1%SDS, 1.5% glycine and 1% Tween-20 in pure water; addition of acid to 
a final pH of 2.2.) The membranes were then thoroughly washed and re-probed 
for HRP-conjugated β-actin 1:5000 (Genscript, New Jersey, USA) to act as a protein 
loading control. 
 
 
 
 
2.8   Immunohistochemistry 
We used the Bond Polymer Refine Detection system that utilises amplification  
techniques to prepare polymeric HRP-linker antibody conjugates. 
 66 
 
       
Figure 2.1 Schematic diagram illustrating the Bond Polymer Refine Detection 
system for immunohistochemical analysis in tissue. Amplification of signal generated 
from the antigen-antibody reaction is demonstrated with the use of polymer backbone 
technology with multiple molecules of peroxidase enzyme attached to this. An example of 
a rabbit anti-human antibody, with a corresponding anti-rabbit secondary antibody with 
a linked polymer backbone is illustrated. However, the Polymer Refine kit is a universal 
system with both anti-mouse and anti-rabbit secondary (‘post-primary’) antibodies with 
linked polymers included in the reaction mixture.  
 
The detection system avoids the use of streptavidin and biotin, and thus 
eliminates non-specific staining as a result of endogenous biotin. The main 
purpose of this is to enhance the signal to noise ratio i.e. to enable specificity whilst 
maintaining a low level of background staining. Figure 2.1 illustrates the principle 
behind this.  
8μm thick sections of formalin-fixed, paraffin embedded human brain tissue was 
obtained from the UK MS Brain Bank as outlined in Chapter 4.  (Hammersmith 
Hospital, London, UK). Tissue slides were deparaffinised and treated with Epitope 
retrieval solution 1, pH 6(Leica Biosystems, Germany) at 98°C for 20 minutes.  The 
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tissue was then washed and incubated with 1% hydrogen peroxide to quench 
endogenous peroxidase activity for 10 minutes. Primary antibodies were then 
used following optimization procedures and sections incubated for 30 minutes. 
‘Post-primary IgG linker reagent’ localised mouse antibodies whilst ‘poly-HRP IgG 
reagent’ localises rabbit antibodies, and both were included in the post-primary 
mixture as a universal system enabling primary antibodies with different 
specificities to be used in the same run. This step lasted for 10 minutes, as did the 
subsequent chromogenic DAB reaction following washing steps. Once IHC was 
complete, haematoxylin (blue) counterstaining- allowing visualization of cell 
nuclei was also performed whilst still on the platform. Slides were then removed 
and progressively dehydrated with alcohol, cleared in xylene and mounted with a 
non-aqueous mounting medium for microscopy. 
2.9  Immunocytochemistry (ICC) 
Cultured MO3.13 cells in an 8-well chamber slide were washed with sterile PBS 
then fixed in 4% PFA for 15 minutes at room temperature (RT). After washing, 
they were blocked in 3% bovine specific albumin (BSA) for 20 minutes, and then 
incubated directly in the rabbit polyclonal anti-HMGB1 antibody for one hour at 
RT (Abcam, Cambridge, UK). Cells were washed and incubated in Alexa-Fluor-488-
conjugated anti-rabbit secondary antibody for a further hour at RT, in the dark. 
After washing, the chambers were removed and the slide mounted in DAPI-
containing aqueous mounting medium (Vector Laboratories, Cambridgeshire, UK) 
and stored in the dark at 4°C for subsequent microscopy. 
2.10 Enzyme-Linked Iuhmmunoabsorbance Assay (ELISA) 
2.10.1  Neurofilament-light chain assay 
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The ELISA was performed according to manufacturer’s instructions and the 
principle outlined in figure 2.2. 
 
Figure 2.2. Principle for quantitative assay of Neurofilament-light chain in 
biological samples using the ‘sandwich’ ELISA technique. (1) plate is coated with a 
capture antibody (2) sample added and any antigen present binds to the capture antibody 
labelled with biotin (3) biotin-linked detecting antibody added (4) streptavidin-HRP 
added which binds to biotin-labelled antibody (5) substrate added and converted by HRP 
to detectable form. 
 
 In brief, the freeze-dried standards (purified bovine spinal cord with a purity 
> 98%) were reconstituted with 240 µL of sample buffer in a 1.5 mL Eppendorf 
vial to give a concentration of 40 ng/mL. The vial was gently swirled until 
thoroughly dissolved and then left at room temperature (RT) for 10 min. A series 
of eight Eppendorf vials were prepared, with the first vial containing 900 µL of 
sample diluent and vials 2 to 8, 600 µL of sample diluent. 300µL of the lyophilized 
standard was then added to the first vial to give a concentration of 10 µg/L. A 
doubling dilution using 600 µL in each step was performed and vial 8 was left only 
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with sample diluent to give the blank reading, corresponding to the following 
concentrations in ng/mL: 10000, 5000, 2500, 1000, 500, 100 and 0 ng/mL NfL. 
CSF samples were diluted 1:1 with sample diluent buffer to a total volume of 
100ul. Wells to be used were washed with 300µl buffer x3, with removal by 
tapping the plate sharply against clean absorbant towels. 100µl standards/ 
samples were then added in duplicate and incubated for 1 hour at room 
temperature (RT; 20-250C) with agitation (800rpm). The wells were then washed 
x3 as described earlier, and 100µl tracer (biotin anti-NfL) added to each well and 
incubated for 45 minutes at RT with agitation as above. The wells were then 
washed again x3 and 100µl conjugated enzyme (streptavidin-HRP) added to each 
well. Following a 30 minute incubation at RT with agitation, the wells were 
washed x3 and 100µl tetramethylbenzidine (TMB) added as substrate to visualise 
the reaction, for 15 minutes at RT with agitation. 50µl ‘stop’ solution (8%v/v 
H2SO4) was added to each well to terminate the substrate reaction and absorbance 
read at 450nm using the BioTek Synergy HT machine (BioTek, Winooski, USA). 
The standard curves generated were analysed with 4 parameter logistic 
regression as recommended by the manufacturers, with values greater than the 
top part of curve capped to the maximum sensitivity of 10000ng/ml 
 
 
2.10.2 HMGB1 assay 
The assay was performed according to manufacturer’s instructions, using digital 
multichannel pipettes to minimise pipetting error. In brief, the standards were 
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reconstituted and diluted as directed, corresponding to the following 
concentrations in ng/mL: 10, 5, 2.5, 1.25, 0.625, 0.313 and 0. CSF samples were 
diluted 1:1 with sample diluent buffer to a total volume of 100ul. 100ul standards/ 
samples were then added to the wells in duplicate and shaken briefly for 
30seconds. The plates were then covered with adhesive foil and incubated for 24 
hours at 370C. The following day, the incubation solution was discarded and plates 
washed x5 with 400ul of wash buffer, tapping the plate against clean absorbant 
towels in between washes. 100µl of enzyme conjugate was then added into each 
well, the plates covered with adhesive foil and incubated for 2 hours at RT. After 
washing x5 again, 100ul colour solution (a combination of TMB and buffer 
containing 0.005M hydrogen peroxide) was then added to each well and 
incubated for 30 minutes at RT. The reaction was stopped by the addition of 0.35M 
H2SO4 and absorbance read at 450nm using the BioTek Synergy HT machine 
(BioTek, Winooski, USA).  
Using the goodness of fit test, linearity of the standard curve produced an R2 of 1.0 
and deviation from linearity using the runs test was not significant (p=0.3). Thus, 
interpolated values from the curve were calculated using linear regression. 
          
Figure 2.3. HMGB1 standard 
curve. (Y) axis: optical density 
(OD); (X) axis: concentration of 
HMGB1 (ng/ml). Dashed lines 
represent exact concentrations used 
in standard curve i.e. 0.313, 0.625, 
1.25, 2.5, 5, 10ng/ml. 
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2.11 Statistical analysis 
GraphPad Prism for Mac Version 5.0 (La Jolla, California, US) was used to perform 
statistical analysis. For in-vitro work, data was normally distributed and 
parametric tests were used. PCR data, statistical tests used both δCt and fold-
change values in statistical tests. Comparisons between multiple treatments were 
analysed using one-way analysis of variance (ANOVA) with Tukey’s post-hoc 
multiple comparison test used to account for type 1 errors. Continuous data was 
expressed as mean and standard error of the mean (SEM). Statistical analysis of 
both neuropathological ex-vivo and CSF in-vivo human data used non-parametric 
testing. The data are represented as medians, with multiple comparisons 
performed using a Kruskal-Wallis test with Dunn’s post-hoc correction. Two-
group comparisons were performed using a Mann-Whitney U test for unpaired 
continuous measures. Spearman’s rank correlation coefﬁcient was used to 
evaluate the statistical dependency of two variables. The threshold for statistical 
significance was set at p<0.05. 
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3  
Characterisation of early active lesional 
changes in a patient with clinically 
isolated syndrome, using classical and 
novel markers. 
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3.1  Introduction 
The history of MS research commenced with the clinicopathological observations 
of the 19th century (Chapter 1; section 1.1). Neuropathological analysis of human 
tissue offers a window into pathological processes occurring in patients with 
disease. This chapter is concerned with the expression profile of HMGB1, an 
important mediator which potentially links inflammation and degeneration, in 
human MS tissue taken at biopsy.  To our knowledge, examination of HMGB1 
expression at an early time-point in a patient’s disease using biopsy tissue, has not 
been performed before. 
 
HMGB1 has pleiotropic roles, with much of the early literature based upon its 
important function in propagating pro-inflammatory loops following secretion by 
macrophages (Yang et al. 2013; Andersson & Tracey 2011; Fang et al. 2012). 
However, in recent years, the field of HMGB1 research has highlighted roles in 
diverse processes, from immune cell recruitment to autophagy. Research into a 
number of neurological disorders have also demonstrated an important role for 
HMGB1, linking neuroinflammation with degenerative processes (Gao et al. 2011; 
Fang et al. 2012; Kim et al. 2006); these studies have been discussed in detail in 
Chapter 1 (section 1.3).  
HMGB1 expression has been examined in MS autopsy tissue, in addition to 
examination in spinal fluid using western-blotting techniques and comparison of 
the staining pattern in the murine model of MS, EAE (Andersson et al. 2008). The 
neuropathological component of the latter report used a large series of patients 
for immunohistochemical analysis, exclusively commenting on microglial/ 
macrophage cytoplasmic translocation in active lesions from both progressive and 
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‘acute’ MS patients- although the latter group are not clearly defined. They also 
reported that astrocytes did not demonstrate cytoplasmic translocation upon 
colocalisation with HMGB1, but did not comment upon expression in other cell 
types, such as oligodendrocytes (OGD), in either MS patients or controls. In 
addition, they did not consider the changes occurring in the normal-appearing 
brain tissue (NABT). As discussed in chapter 1, understanding molecular events 
taking place in these non-lesional areas in MS brain is critically important as it 
remains unclear as to whether lesions arise from these regions or the other way 
around. Interestingly, in situ hybridisation examining the spinal cord of relapsing 
EAE mice demonstrated that HMGB1 reactivity was widespread throughout the 
spinal cord, not just affecting lesional regions. They did not comment upon the 
significance of this in non-lesional regions, but concluded it suggested de novo 
HMGB1 synthesis during EAE relapses. 
 
A study by Zeis et al also examined changes in non-lesional white matter regions 
using biopsy tissue (Thomas Zeis et al. 2009). They described a similar clinical 
presentation in a single patient who underwent stereotactic biopsy, with 
subsequent reporting of findings both in the active MS lesion and in the distal non-
lesional tissue. They found that neuronal nitric oxide synthetase (nNOS) was 
upregulated in myelinated white matter with evidence of reactive-nitrogen 
species-mediated damage to OGD in these regions also, in the absence of overt 
inflammation. In addition, markers such as HIF-1α were upregulated in this 
region, suggesting OGD are held in a precarious balance of function and 
dysfunction in non-lesional tissue. 
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However, as stated earlier, the most striking findings in the study by Andersson et 
al were in the ‘acute’ and ‘active’ lesional tissue types, as opposed to ‘chronic 
lesions’ and non-MS control white matter, underlining its importance in active 
inflammatory processes. As will be detailed below, our biopsy tissue was taken 
from a patient with fulminant inflammatory demyelinating disease, such that the 
main differential prior to biopsy was of a neoplastic, gliomatous process. We 
would therefore predict that this type of tissue would exemplify the inflammatory 
aspects of HMGB1-related pathology described in highly active lesions by 
Andersson et al, thus enabling us to compare our findings directly with these. In 
addition, as noted by Zeis et al., abnormalities in non-lesional regions have also 
been observed in similar tissue types. Despite mounting evidence of its role in 
chronic neuroinflammatory and degenerative processes, detailed analysis of 
HMGB1 responses in early active MS brain lesions is novel and thus it would be of 
interest to investigate this using biopsy material. 
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3.2 Hypothesis 
1. HMGB1 expression is increased in macrophages/ microglia of active lesional 
biopsy tissue.  
2. Macrophages/ microglial expressing HMGB1 demonstrate evidence of 
cytoplasmic translocation 
3. HMGB1 expression will be increased in peri-lesional regions, but this 
expression will decrease with increasing distance from the lesion border  
 
3.3 Objectives 
1. Perform a detailed characterisation of biopsy tissue from patient MS1 with a 
clinically isolated syndrome, using a range of established markers to delineate 
lesional and non-lesional regions.  
2. Examine HMGB1 expression patterns to observe molecular changes occurring 
in active inflammatory lesions 
3. Analyse HMGB1 expression in CNS-resident cells in regions distal to active 
inflammatory lesions 
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3.4 Methods 
 
Stereotactic brain biopsy was performed at University Hospital Birmingham 
(UHB) for diagnostic evaluation. Tissue was fixed in neutral buffered formalin and 
then embedded in paraffin. Five blocks of interest were selected by Consultant 
Neuropathologist, Dr Martyn Carey and supplied to the Human Biorepository 
Resource Centre (HBRC) following informed consent for participation in research 
studies, under local ethical approval of the HBRC Tissue Bank 
(LREC11/H1211/1). Of these, 4 blocks contained a mean tissue area available for 
analysis of 2.01cm2, with the final block having a relatively smaller area of 
22.42mm2. These areas are far in excess the minimum often used to study biopsy 
material, where other studies have specified an area >1mm2 is required as a 
minimum suitable area for analysis (Metz et al. 2014). Blocks were then sectioned 
at 8μm thickness using a steel microtome, with routine stains used to delineate 
lesion borders initially and further dedicated immunohistochemical stains to 
either verify this or to confirm identity of different cell populations in the different 
regions of tissue.  
3.4.2 Analysis of neuropathological tissue 
Biological tissue demonstrates limited natural contrast using light-microscopy. 
Staining is thus used to provide contrast in addition to highlighting interesting 
features. Haematoxylin and eosin (H&E stain) is a widely used histological stain. 
Hematoxylin is a basic dye, staining nuclei blue due to an affinity to nucleic acids. 
In contrast, eosin is acidic and stains cell cytoplasm pink. This enables 
identification of cell borders and morphological assessment based on factors such 
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as nuclear size and density of staining, in addition to cytoplasmic pattern of eosin 
staining. IHC was carried out using the Leica Bondmax automated stainer as 
described in chapter 2 (Leica Biosystems, Germany). Antibodies used were anti-
MBP, -CD68, -CD3, -GFAP and –HMGB1 as described in table 3.1. Staining of 
sequential sections was performed in order to delineate the lesion border and 
cellularity.  
 
Protein target Antibody 
type 
Source Concentration 
used (µg/ml) 
Myelin-basic protein Mouse MC Abcam 1 
CD68 Mouse MC Dako 5 
CD3 Rabbit MC Abcam 10 
Glial fibrillary acidic protein Rabbit PC DAKO 0.3 
HMGB1 Rabbit PC Abcam 2.5 
HMGB1 peptide control - Abcam 2.5 
IgG isotype control Rabbit PC Abcam 2.5 
 
Table 3.1. List of antibodies used in IHC experiments. 
 
Stained sections were then mounted using xylene with glass coverslips. 
Preliminary microscopy was performed in order to assess staining success then 
whole slides were scanned using the Leica SCN400, and stored on the Digital 
Image Hub ‘cloud’ system, based at the University of Birmingham. 
3.5 Results 
3.5.1   Case report 
This previously healthy 33 year old male patient presented with significant 
reduction in visual acuity in the right eye over a week. This was followed by 
progressive weakness affecting the left arm and leg, along with cognitive deficits 
including memory disturbance and he was admitted to his local hospital within 
 79 
 
two weeks of symptom onset. Initial CT and MRI scans revealed a mass lesion in 
the parieto-occipital region suggestive of a malignant process and he was 
transferred to the Neurosurgical Unit at University Hospital Birmingham. Cranial 
nerve examination revealed reduced visual acuity with finger counting on the 
right and 6/9 on the left, with a left homonymous hemianopia. Peripheral nervous 
examination showed pyramidal signs on the left, with associated weakness of 2/5 
and hemisensory alteration. Power and sensation were preserved on the right-
hand side at this stage. Plantar responses were bilaterally extensor. Further MRI 
evaluation revealed a multifocal process with increased T2 signal in the right 
occipital lobe, spread across the splenium of the corpus callosum to the left (see 
Appendix 2, figure A1). Another discrete lesion in the left occipital lobe was noted, 
in addition to further moderately- sized lesions in the right frontal and parietal 
lobes, with patchy enhancement of the large right occipital and the callosal lesion. 
There was no significant mass effect. A stereotactic brain biopsy was performed 
the day after transfer from his local hospital, which demonstrated necrotic tissue 
with non- specific findings. A repeat biopsy demonstrated reactive astrocytes and 
some inflammatory changes, but again changes were non-specific and he was 
transferred to Neurology. Laboratory serum tests for rheumatic factors, ANA, 
ANCA, anti-cardiolipin antibodies, toxoplasma, syphilis, HTLV-1 and -2 and HIV 
were all negative. Initial CSF examination revealed no inflammatory cells although 
he had received steroid therapy (dexamethasone) whilst under the 
neurosurgeons. CSF analysis for herpes viruses, cytomegalovirus, varicella zoster 
virus, Enterovirus, EBV, Tropheryma whippelii, toxoplasma and acid-fast bacilli 
were all negative. CSF TB culture was also negative as were immunophenotyping 
of inflammatory cells. Oligoclonal band analysis was negative on two occasions 
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but subsequently positive. His clinical course was complicated by multiple medical 
problems and once stabilised, a third and final biopsy was carried out, which 
revealed changes described below. It supported evidence of a demyelinating 
process of recent onset and favoured a diagnosis of multiple sclerosis over ADEM, 
with no evidence of lymphomatous or neoplastic processes. He was treated with 
intravenous methylprednisolone, and soon after the final biopsy, he was 
commenced on Tysabri treatment and prednisolone was gradually tapered. In the 
subsequent 4 years, he developed classical RRMS. 
3.5.2   Evidence of early active lesions consistent with MS 
Figure 3.1 demonstrates florid perivascular cellular inflammatory infiltrate and 
throughout the parenchymal white matter. The region borders are ill- defined but 
despite fragmentation, there is preservation of myelin as shown by MBP staining, 
thus classifying this as an early active lesion. The predominant cell types are 
CD68-positive foamy macrophages, or lipophages, in 3.1C, with perivascular 
cuffing of CD3-positive lymphocytes in 3.1D, in addition to a few scattered 
lymphocytes in the parenchyma. There is a significant upregulation of GFAP 
reactivity shown in figure 3.1E, indicating astroglial activation, and their large 
bloated appearance denotes the presence of gemistocytes (3.1A and –E).  
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Figure 3.1. Characterisation of an early active lesion in FFPE biopsy tissue of a 
patient (MS1) with Clinically Isolated Syndrome (CIS), and corresponding HMGB1 
expression pattern (continued overleaf).  
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Figure 3.1. Characterisation of an early active lesion in FFPE biopsy tissue of a 
patient (MS1) with Clinically Isolated Syndrome (CIS), and corresponding HMGB1 
expression pattern. (A) H&E stain shows inflammatory cell infiltration over a large area, 
throughout the lesion. Inset illustrates perivascular inflammation as well as presence of 
hyperactivated/ gemistocytic astrocytes with evidence of multi-nucleation or large, pale 
nuclei (arrowheads). Extensive perivascular foot-processes are also evident (arrow). (B) 
anti-MBP IHC demonstrates that complete demyelination has not yet occurred at this 
stage of lesion evolution, although there is clear evidence of myelin fragmentation and 
peri-venous demyelination, demonstrated at higher magnification in the inset (C) shows 
significant anti-CD68-cell positivity throughout the lesions, representing activated 
macrophages/ microglia. Morphologically, the cells are predominantly foamy 
macrophages or lipophages (arrowhead). Inset shows higher magnification view of lipid-
laden, perivascular macrophages. (D) anti-CD3-positive staining, denoting cells with a T-
lymphocyte cell lineage, shows marked perivascular infiltration (inset) with 
dissemination into the parenchyma (arrowhead). € Widespread upregulation of anti-
GFAP-positive cells on IHC, representing activated astrocytes. As noted on H&E, the 
bloated cells with pale cytoplasm, often displaying nuclear atypy or multinucleation and 
with extended processes, represent gemistocytes. (F) anti-HMGB1 IHC demonstrates 
strong, predominantly nuclear immunoreactivity most markedly in activated 
macrophages. Inset (i) shows multinucleate gemistocytes with little evidence of nuclear 
HMGB1 and very pale cytoplasmic staining, compared to intensely stained inflammatory 
cells around it. Inset (ii) shows perivascular staining at higher magnification, 
demonstrating likely HMGB1-positivity for perivascular lymphocytes also.  Scale bar= 
100μm; inset scale bar=10μm  
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3.5.3 HMGB1 immunoreactivity is evident in macrophages/microglia in 
early active MS lesions 
In this context, anti-HMGB1 IR is clearly evident, predominantly in macrophage/ 
microglial cells, with intensely stained nuclei as shown in figure 3.1F, but also with 
some evidence of cytoplasmic translocation in these cells. Interestingly, astrocytic 
staining appears to be less marked compared to myeloid cells, with little nuclear 
staining evident in particular. However, faint cytoplasmic staining is evident, as 
shown in 3.1F(i), inset, although this non-specific pattern is frequently seen in this 
cell type (M. Carey, personal communication). OGD staining is also evident, 
although number of olig2-positive cells were not counted. 
3.5.4 HMGB1 immunoreactivity is evident in peri-lesional regions 
Similar staining patterns in the active lesion are evident in different blocks from 
the same tissue biopsy. However, with the wide field of view from the scanned 
image, peri-lesional white matter tissue displaying normal MBP staining patterns, 
also demonstrates changes including CD68-positive cell reactivity and persisting 
CD3-positive peri-vascular cuffing. In particular, CD3-postive perivascular 
lymphocytes are also evident at the grey-white matter border, as shown in figure 
3.2C, in the vicinity of layer VI pyramidal neurons. The border of the active lesion 
is highlighted by CD68-positive macrophages, which change morphologically into 
activated microglial cells into the peri-lesional WM. 
HMGB1 staining is widespread, predominantly affecting myeloid cells as 
described earlier, but is also notably increased in oligodendroglial cells in the peri-
lesional white matter. Astrocytes, once more, display little nuclear staining and 
only faint cytoplasmic reactivity. In addition, IR is prominent in the non-lesional 
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grey matter adjacent to the lesion as shown in figure 3.2D, which will be examined 
in more detail below.  
Of note, three control methods were employed in order to delineate the possibility 
of non-specific HMGB1 immunoreactivity: (i) omission of the primary antibody, 
(ii) IgG isotype control (iii) using the specific peptide which the anti-HMGB1 
antibody was raised against, as a blocking agent. The staining pattern using the 
range of controls was weak and suggested that the HMGB1 staining was antigen-
specific (see Appendix 2, figure A2). The IgG control demonstrated clearly reduced 
staining but a few perivascular cells were shown to be positive, possibly reflecting 
IgG-positive B-cells. Although we did not stain for complement specifically, the 
presence of immunoglobulin when using the IgG control (figure 3.2E) 
demonstrates a probable pattern II lesional subtype (see Introduction; section 
1.3.3.4).  
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Figure 3.2. Early active, peri-lesional and non-lesional tissue in FFPE biopsy tissue 
of a patient (MS1) with Clinically Isolated Syndrome (CIS) (continued overleaf).   
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Figure 3.2 (overleaf). Peri-lesional and non-lesional tissue in FFPE biopsy tissue of a 
patient (MS1) with Clinically Isolated Syndrome (CIS). (A) Anti-MBP staining 
highlights the white matter lesion by demonstrating myelin fragmentation, with the 
lesion border shown by the dotted line. The peri-lesional white (PWM) and grey matter 
(GM) borders are identifiable, with normal myelination patterns evident. (B) anti-CD68 
IHC demonstrates massive macrophage infiltration within the WML. As shown in the inset 
at higher magnification, advancing lipophages form a border juxtaposed with cells of 
activated microglial morphology in the PWM (C) anti-CD3-positive staining shows 
multiple small blood vessels with lymphocytic infiltration throughout the tissue (arrows), 
including into non-lesional GM ((inset); arrowhead=neuron) (D) anti-HMGB1 IHC again 
demonstrates widespread increased immunoreactivity (IR) in macrophages within the 
WM. However, the wide field of view also demonstrates increased IR in CNS-resident cells 
in the adjacent, non- lesional tissue region, including in the GM. Inset shows gemistocytes 
with clear nuclei and pale cytoplasmic staining compared to other glial cells in the vicinity. 
(E) IgG isotype control antibody demonstrating limited IR although some perivascular 
cells are positive and likely to represent Ig-producing B-cells (arrowhead). (F) Blocking 
peptide specific to HMGB1 demonstrates virtually no IR. WML= white matter lesion; 
PWM= perilesional white matter; GM= grey matter; Scale bar=100μm; inset scale 
bar=10μm except CD68=100μm. 
 
 
3.5.5 HMGB1 immunoreactivity persists into non-lesional regions 
Non-lesional white matter was initially identified by being >7mm distance from 
the white matter lesion border on this block, in this plane (figure 3.3A). The white 
box shows a representative area here. MBP staining demonstrated a normal 
myelination pattern and minimal CD3-positive inflammatory cell infiltrates. A 
number of CD68-positive cells populated this region, as shown in figure 3.3B and 
these cells contribute to the intense HMGB1 IR in the non-lesional WM. However, 
oligodendrocytes appeared to be the predominant HMGB1-positive cell type. They 
were identified morphologically by parameters including size, roundedness and 
characteristic ‘fried-egg’ appearance, referring to the well-recognised artefactual 
regression of tissue immediately surrounding oligodendroglial cells (Greenfield’s 
Neuropathology, Volume I; 8th Ed.). Again, astrocytes show evidence of faint 
HMGB1 cytoplasmic reactivity, in stark contrast to the staining pattern in other 
glial cells. 
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Figure 3.3. Demonstration of non-lesional white matter in FFPE biopsy tissue of a 
patient (MS1) with Clinically Isolated Syndrome (CIS). (A) Anti-MBP staining 
highlights the white matter lesion (‘WML’) described in figures (3.1) and (3.2) at the 
extreme left of the image. The cytoarchitecture of white matter and grey matter borders 
are clearly identifiable, with normal myelination patterns evident. The inset shows a 
representative region of non-lesional white matter and (B)-(D) demonstrate IR in this 
region for different markers, at higher power (B) anti-CD68 IHC demonstrates microglial 
infiltration (C) anti-CD3 IHC staining shows virtually no positive cells in this region (D) 
anti-HMGB1 IHC again demonstrates widespread increased immunoreactivity in CNS-
resident cells. Scale bar= 100μm; inset scale bar=10μm. 
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3.5.6  Cortical regions remote from white matter lesions demonstrate 
specific  HMGB1-positive expression patterns 
Non-lesional: Anti-MBP IR in Figure 3.4A shows a normal myelination pattern but 
despite this, significant abnormalities are evident in all layers of the cortex. Some 
relatively normal pyramidal neurons can be seen as in figure 3.4C, but cells with 
condensed, pyknotic nuclei are widespread, in addition to changes suggestive of 
chromatolysis (figure 3.4D; circle). Other than a small number of scattered 
perivascular lymphocytes, there are few CD3-positive lymphocytes in the cortical 
parenchyma (figure 3.4E). However, they can clearly be seen in overlying 
meningeal vasculature, although no follicular-like structures were seen. Microglial 
cells with extended processes in close association with pyramidal neurons are 
seen with CD68-staining (figure 3.4F).  
Anti-HMGB1 IR is widespread in the cortex and demonstrates significant IR in 
most neuronal nuclei, (figure 3.4G). Interestingly, satellite oligodendrocytes- in 
their classic configuration in apposition with neurons- show particularly intense 
IR. These were frequently adjacent to neurons with evidence of cytoplasmic 
translocation (figure 3.4I). In addition, dystrophic neurons with pyknotic nuclei 
also strongly expressed HMGB1. Other conformations of interest show intensely 
IR glial cells aligning longitudinally (figure 3.4H). Morphologically they are OGD, 
supported by lack of CD68 or CD3 reactivity in sequential sections and appear to 
group along blood vessels. Figure 3.4J further demonstrates neuronal cytoplasmic 
expression of HMGB1, with apparent membranous ‘blebbing’. This may represent 
HMGB1 expression at the membrane near the soma or else may highlight evolving 
apoptotic change within neurons. 
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Figure 3.4. Demonstration of non-lesional grey-matter tissue in FFPE biopsy tissue 
of a patient (MS1) with Clinically Isolated Syndrome (CIS) (A-D). This region of grey 
matter is situated >5mm away from the active lesion border as shown in figure 3.2. (A) 
anti-MBP IHC demonstrates a normal myelin pattern in this region of the cortex. (B) H&E 
stain at low magnification demonstrating cortical layers of the grey matter, with overlying 
meningeal blood vessels (C) and (D) high magnification representation of neuronal 
changes. Pynknotic neurons are evident, with nuclear condensation and cytoplasmic 
retraction (arrowhead), whilst larger pyramidal neurons with normal morphology are 
also evident in the vicinity (arrow). There is also evidence of chromatolysis (circle). NB 
molecular layer (I) of pyramindal neurons is demonstrated next to the the external 
granular layer (II) to highlight cortical anatomy (continued overleaf). 
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Figure 3.4 (continued). (E) anti-CD3: positive cells in the overlying meningeal vessels are 
seen (inset; arrowhead), occasional parenchyma cells seen near blood vessels (arrow). 
(F) anti-CD68 IHC demonstrates microglial activation in the cortex surrounding neurons 
(arrowhead) (G-J) anti-HMGB1 IHC (G) increased IR throughout the cortex, with granular 
layers demonstrating intense IR. Most neurons e.g. layer III demonstrate nuclear IR with 
characteristic chromatin staining pattern evident (inset) (H) markedly increased IR in 
dystrophic neurons (arrow), whilst strongly HMGB1-positive OGD also seen, possibly 
along vessels (inset) (I) neurons with evidence of cytoplasmic translocation into the soma 
and proximal dendrites demonstrated intensely stained OGD immediately adjacent to 
them, in their classical configuration (arrowhead). (J) other pyramidal neurons displaying 
cytoplasmic translocation are shown with apparent HMGB1-positive membranous 
‘blebbing’. Scale bar= 100μm; inset scale bar=10μm. 
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Lesional: Figure 3.5A, demonstrates a sub-pial type III cortical lesion in this biopsy 
tissue (Bo et al. 2003), with a significant inflammatory cell infiltrate in the 
meningeal vessels overlying it, as shown in figures 3.5B and 3.5C. Whilst there are 
few CD3-positive cells in the parenchyma, there are numerous CD68-positive cells 
throughout, which morphologically appear to be activated microglial cells, with 
no evidence of lipophages. A number of activated astrocytes are evident in the 
cortex, as shown in figure 3.5D, though the cells are not gemistocytic in 
appearance as seen in the white matter lesions, suggesting they may be 
performing an alternative function here. HMGB1 IR is evident in the external 
granular layer but IR is less intense overall and there is evidence of much more 
widespread cytoplasmic translocation. The high stromal background staining may 
be artefactual. 
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Figure 3.5. Type III demyelinating cortical lesions are evident in active lesional 
tissue blocks, with evidence of overlying meningeal inflammatory cells. (continued 
overleaf) 
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Figure 3.5 continued. (A) Anti-MBP IHC demonstrates reduced immunoreactivity, 
consistent with a type III cortical lesion due to its sub-pial location. A few cells in the 
overlying meningeal blood vessels are also positive for MBP, suggesting myelin 
breakdown products are carried by these cells (arrowhead). (B) anti-CD68 IHC 
demonstrates many positive cells in the overlying meningeal blood vessel, which appear 
to be lipid-laden macrophages given the findings on anti-MBP staining as above 
(arrowhead). In addition, there are numerous CD68-positive cells in the molecular layer, 
which appear to be activated microglial cells, and down into the cortex below. (C) anti-
CD3-positive staining shows scattered cells in the meninges (arrowhead) but few in the 
underlying cortex (D) ant-GFAP-positive cells are evident in the cortical parenchyma, 
representative of activated astrocytes (E) anti-HMGB1 IHC demonstrates widespread 
increase in cortical IR, particularly in neuronal cells with evidence of cytoplasmic 
translocation. Scale bar= 100μm 
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3.6 Discussion 
3.6.1 Early active lesional changes demonstrate overlapping 
immunopattern II/III pathology  
We have examined early active lesional changes using biopsy tissue from a patient 
who presented with a clinically isolated syndrome and subsequently developed 
RRMS. The changes found here are in accordance with established descriptions of 
early active white matter lesions (www.icdns.org). Based on preliminary analysis, 
the data presented here demonstrates features of pattern II pathology, given the 
evidence of perivascular T-cells, numerous macrophages with lipid proteins and 
relative preservation of OGD. However, especially in those blocks where we had a 
more complete area of the lesion, the borders were rather diffuse, with clear 
evidence of widespread microglial activation in the vicinity in addition to evidence 
of IgG positivity, although it is important to note that we did not stain for 
complement. Thus, our patient may represent a pattern II/ III overlap by the 
definitions posed by Lucchinetti et al and discussed in the General Introduction, 
section 1.3.3.4. This has important implications as discussed previously, as it may 
be explained by the concept of stage-specific vs patient-specific pathological 
heterogeneity (M H Barnett & Prineas 2004; Metz et al. 2014). In essence, the 
latter pattern suggests that some patients are likely to respond to specific 
therapies, for example immunomodulation with plasma exchange for patients 
with exclusive pattern II pathology, more predictably. However, if the changes are 
stage-dependent, technically all patients may benefit from this approach, but this 
would depend upon the stage of disease they present with (Barnett et al. 2009). 
This issue was addressed comprehensively by Metz et al, in a recent study, where 
1321 surgical biopsy specimens with pathologically-confirmed MS were screened. 
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This study concluded that pathological heterogeneity was indeed limited to 
individual patients, and did not appear to be stage-specific when examined 
longitudinally over the course of a patient’s disease. When examining these 
findings more closely, of the 1321 specimens initially screened, 79 were biopsied 
⩾2 times or had autopsy material from the same patient, allowing longitudinal 
assessment of the individual patient’s case. From this group, only 22 cases met the 
stringent inclusion criteria, which included presence of early active brain lesions 
from at least 2 time-points from the same patient, with reliable tissue staining and 
sufficient area for analysis (>1mm2).  
Importantly, 5 patients demonstrated type I, 14 patients demonstrated type II and 
only 2 patients demonstrated type III immunopatterns, with 1 overlap case (type 
II/III). In addition, 8 out of the 22 subjects had been exposed to some form of 
immunosuppression prior to biopsy, and 7 patients received steroids shortly after 
the first biopsy. Given that the median duration between the first and second 
biopsy/ autopsy was 50 days, it is possible that this treatment may have 
influenced the pathological findings. The same is true of our case also, as he had 
received dexamethasone therapy prior to biopsy sampling, and thus may have 
influenced our findings to a degree. It is impossible in clinical practice to withhold 
steroid therapy if it is clinically indicated, and this highlights inherent difficulties 
in drawing conclusions from material like this. However, in attempting to define 
true pathological heterogeneity, this is an important factor that must be 
considered carefully. The authors state that no correlation was identified between 
immunopattern and therapy given, but concede that small numbers precluded 
definitive conclusions. It is also of interest that the two patients demonstrating a 
type III immunopattern had a median EDSS of 7, vs 4 and 3 in patterns I and II 
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respectively, despite similar symptom duration prior to biopsy. However once 
again, they do not specify which of these patients had immunosuppression.  
They also reported one case with an overlap between type II/III immunopatterns, 
possibly similar to our case. However, the authors describe this as an exceptional 
case as the other pattern II subtypes- the majority of cases- failed to show 
pathological overlap over time. Thus, although this work is of an exceptionally 
high standard given the number of samples screened and the stringent inclusion 
criteria, it is inevitably hard to draw definitive conclusions given the inherent bias 
in analysing tissue from this type of cohort. It appears that the final consensus has 
still not been reached therefore, and it is still possible that pathological 
heterogeneity may not be specific to individual patient. 
3.6.2 Anti-HMGB1 IR may reflect pro-inflammatory activity in early active 
lesions 
The HMGB1 staining pattern in the active lesion is in agreement with previously 
published work (Andersson et al. 2008), with massive HMGBI-positive 
inflammatory cell influx- predominantly of macrophages, into the active lesional 
tissue. Cytoplasmic translocation was evident in macrophages/microglia, 
supporting the contention that HMGB1 may be released into the inflammatory 
milieu of the developing active MS plaque. Release of NO and reactive oxygen 
species produce a highly inflammatory environment and based on available 
literature, it is probable that HMGB1 released from macrophages in this context is 
oxidised and post-translationally modified, and likely to produce tissue damage as 
a result (see figure 1.6). In this model, activated macrophages or other immune 
cells e.g. plasma cells (Vettermann et al., 2011) release HMGB1 which further 
activates macrophages via ligation of TLR-4, initiating NFkB signalling and pro-
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inflammatory cytokine release such as IL-1β. which in turn stimulates 
macrophages to produce more HMGB1, and propagates the cycle of chronic 
inflammation and tissue destruction. Release of HMGB1 into the extracellular 
space could theoretically be measured in the CSF and this is considered in Chapter 
5. We also know that HMGB1 can form a complex with CXCL12 (Schiraldi et al. 
2012) potentially enhancing chemotactic activity and this may propagate the 
profound inflammatory cell infiltration following BBB breach. In this study, we 
also identified perivascular lymphocytes which also appeared to be HMGB1-
positive although as discussed below, this would need to be examined in more 
detail, including using in-situ hybridisation techniques to ascertain production. 
 
It is worth noting, however, that without characterising the phenotype of these 
macrophages i.e. M1 or M2, it is not possible to ascertain whether this is an 
entirely pro-inflammatory response based on these findings. Classically activated 
or M1 macrophages have cytotoxic and proinflammatory attributes as above 
whilst alternatively activated or M2 macrophages promote tissue repair by 
secreting anti-inflammatory cytokines and extracellular matrix molecules. 
Macrophages can be polarised in vitro by stimulating with IFN-γ or 
lipopolysaccharide (LPS), whilst M2 phenotype induction results from stimulation 
by cytokines such as IL4 (Vogel et al. 2013). Recent work has shown that 
macrophages within MS lesions express M1 markers as one might expect, 
including CD40, CD86, CD64 and CD32 (Vogel et al,2013). Interestingly, however, 
double-staining revealed 70% of the CD40-positive i.e. M1 macrophages also 
expressed the mannose-receptor (MR), an established marker of the M2 
phenotype. This suggests that macrophages in active lesions in fact express an 
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‘intermediate’ activation status in response to endogenous signals. On balance 
however, current data suggests that the role of extracelllar HMGB1 in this context 
is likely to be destructive.  
3.6.3 HMGB1 expression is evident in both peri-lesional white matter and 
in regions distal to the lesion border 
Intense anti-HMGB1 IR was also shown to extend into the perilesional region. 
CD68+ HMGB1+ cells were clearly seen, with evidence of perivascular 
lymphocytic cuffing even into the lower layers of the cortex at the grey-white 
matter junction in figure 3.1D, suggesting that the fulminant inflammatory 
reaction in the active lesion causes widespread pathology including into the 
cortex.  
 
What is also striking however, is the intensity of staining in the myelinated regions 
distal to identified white matter lesions, with distances of ≥7mm in those blocks 
with non-lesional tissue. This is less consistent with our original hypothesis that 
anti-HMGB1 IR reflects centrifugal diffusion from the lesion centre given the 
significant distance from the lesion border in this plane, although there are clear 
caveats to this interpretation (see below). In the study by Metz et al, the minimum 
area of tissue available for analysis needed to be 1mm2- a relatively large area and 
sufficient to draw conclusions about the question in hand i.e. pathological 
phenotype. In addition, over 1000 specimens were analysed and thus area for 
analysis would need to be relatively constrained in this context also. However, as 
I only reviewed the changes in a single patient, I was able to assess the changes 
over a larger area, with a mean of 2.01cm2 per block of tissue available for analysis 
(i.e. >8cm2 total tissue area analysed). This was valuable when assessing tissue 
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changes overall, including in non-lesional regions, utilising the whole slide 
scanning technology in capturing the images.   
In the white matter, strongly positive OGD are evident, although activated 
microglia also contribute to total number of HMGB1-positive cells. As discussed in 
more detail in the following chapter, OGD expression of HMGB1 or amphoterin in 
rodent brain has been reported in one previous study (M. M. Daston & Ratner 
1994). This was particularly marked during CNS development, with relatively 
weak expression in the adult animal. 
 Interestingly, throughout the tissue in both lesional and non-lesional areas, 
astrocytes did not generally show evidence of HMGB1-positivity in the nucleus 
and only weak staining in the cytoplasm. This differential staining pattern, which 
is remarkably consistent, also suggests relative specificity of anti-HMGB1 IR. This 
pattern may be because astrocytes do produce HMGB1 but it is ‘emptied’ from the 
nucleus into the cytoplasm and extra-cellular space, thus producing falsely-
reduced cellular staining. However, in agreement with Andersson et al (Andersson 
et al. 2008)- who asserted that astrocytes did not express HMGB1- it may be that 
HMGB1 is not expressed as highly as in macrophage/ microglial and 
oligodendroglial cells. It is known that astrocytes express toll-like receptors on 
their surface (Bsibsi et al. 2002), and so extracellular HMGB1 released by 
microglia, for example, may target TLRs on astrocytes and activate 
proinflammatory, or indeed anti-inflammatory (Nair et al. 2008), signalling in this 
way.  
3.6.4 HMGB1 expression pattern in both non-lesional grey matter and in 
cortical lesions is striking 
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The changes in myelinated grey matter are revealing, with intensely stained 
HMGB1-positive neurons, predominantly in the nucleus. The intensity of staining 
suggests that HMGB1 may be performing specific functions related to 
transcriptional regulation, one of its best known functions in both health and 
disease. Further exploration of this is considered in Chapter 6, section 6.6.8. Some 
HMGB1-positive neurons clearly demonstrate cytoplasmic translocation from the 
nucleus, with others also showing possible early apoptotic changes or else appear 
to be frankly pyknotic and dying (figure 3.4G-I). Wallerian degeneration 
secondary to remote but connected white matter lesions is one potential 
explanation for these changes. Thus, increased HMGB1 reactivity in pyknotic cells 
may just be reflecting its condensation in preparation for cell death following 
trauma sustained distally to the neuronal soma. However, widespread presence 
of activated microglial cells was evident once again, and it is known that microglial 
activation can also trigger neurodegeneration via ligands acting at TLR4 
(Lehnardt et al. 2002; Lehnardt et al. 2003), of which HMGB1 is an important 
example. The translocation evident may also represent autophagic activity in the 
face of metabolic insult, as we know that HMGB1 can translocate into the 
cytoplasm to augment the latter.  
Interestingly, cytoplasmic translocation in neurons appeared to be accompanied 
by intensely IR satellite OGD, perhaps providing trophic support to neurons 
undergoing cellular stress (Lee et al. 2012). Of further interest were multiple 
examples of what appeared to be oligodendroglial-like cells lining up near to blood 
vessels. This phenomenon has been shown to occur in CNS injury, where OGD-
precursor cells expressing MMP-9 accumulated peri-vascularly and were 
associated with BBB leakage prior to overt demyelination taking place (Seo et al. 
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2013). Further characterisation of these oligodendroglial-like cells is required to 
investigate this in the context of MS. 
Although this was a preliminary assessment of changes in OGD cells in this study, 
our findings have highlighted a possible disturbance in their function through 
their intense expression of HMGB1 in non-lesional regions. However, given 
HMGB1 is expressed in adult rat brain, albeit weakly (M.M. Daston & Ratner 1994) 
it is difficult to conclude from this without corresponding non-MS control tissue. 
Cortical lesions were identified independently of white matter lesions in some 
blocks, and were found to be infiltrated by CD68-positive activated microglial cells 
throughout the lesion, and in the overlying meningeal vessels. The latter also 
showed numerous CD3-positive lymphocytes, although there were very few in the 
cortical parenchyma proper. HMGB1 staining was less intense than in myelinated 
grey matter, and demonstrated widespread neuronal cytoplasmic translocation. 
Whilst others have found little evidence of active inflammation in the cortex (Bo 
et al. 2003), the results arising from analysis of the biopsy specimen from this 
single patient would tend to support the findings of Lucchinetti et al in a much 
larger study of similar patients (Lucchinetti et al. 2011b) with regard to evidence 
of inflammatory cortical demyelination. Their group and others (Magliozzi et al. 
2007b) postulate that in the context of inflammation and breach of the BBB, toxic 
mediators in the CSF released from activated B-cells amongst others, penetrate 
the underlying cortical tissue and propagate damage, including to OGD (Lisak et 
al. 2012). HMGB1 is known to be released from activated plasma cells 
(Vettermann et al. 2011) and so it is possible that HMGB1 is one of these 
mediators, causing activation of microglial cells via TLRs or RAGE and effecting 
pro-inflammatory damage in the local tissue. Given its known propensity to 
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potentiate pro-inflammatory loops, HMGB1 may be important in perpetuating 
damage long after the initial wave of active inflammation has passed. The HMGB1 
staining pattern may well reflect this resultant abnormality, although as discussed 
below, a larger cohort and comparison with non-MS control biopsy tissue would 
be required to characterise this fully in our hands. In addition, the possibility that 
HMGB1 is acting to promote neuroprotective responses cannot be ruled out (G. Li, 
Liang, et al. 2013), particularly as characterisation of M1/M2  macrophages was 
not done. 
 
The main limitation to drawing conclusions from this body of work is that it 
describes findings in a biopsy specimen from a single patient. It would have been 
helpful to compare the staining patterns found in this CIS patient with non-
neurological biopsy brain tissue, in addition to other non-MS, neurological disease 
and this type of tissue is currently being processed for this purpose. 
Comparative material would give an idea whether the apparently increased 
HMGB1 expression is specific to MS, or whether it reflects other, procedural 
factors such as the speed of fixation given the smaller size of these specimens 
compared to the whole brain, as used in post-mortem analysis. Furthermore, 
biopsy specimens do not have issues regarding post-mortem interval (PMI) time 
and the potential degradation of antigens in this period. However, as De Groot et 
al reported, PMI had less impact on IR of a panel of inflammatory markers in brain 
tissue than formalin fixation itself, which was most likely to mask epitopes (De 
Groot et al. 2001). These and related issues will be discussed in Chapter 4.  
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Additional criticisms include the possibility that studies examining biopsy 
material from similar patients are not representative of typical MS patients due to 
their unusually aggressive clinical presentation. However, it has been highlighted 
that studying extreme representations of disease can often offer insights into 
disease-specific pathomechanisms that would not otherwise be identifiable 
(Calabresi 2011).  
Other potential confounders include demographic factors such as the patient’s 
young age and also the biopsy process itself producing artefact. Regarding the 
latter, although Lucchinetti et al described very similar findings to ours with 
respect to neuronal dystrophy (Lucchinetti et al. 2011b), but most 
neuropathologists are aware that neuronal abnormalities such as pyknosis can 
result as an artefact of biopsy and do not reflect a neurodegenerative event per se 
(M. Carey, personal communication). However, we also observed changes 
suggestive of chromatolysis which may reflect Wallerian degeneration, possibly 
secondary to remote white matter lesions.  
With regard to classification of non-lesional tissue; it is difficult to ascertain how 
far from active lesional changes any part of the tissue is. Although we measured 
>7mm away from the lesion border, it is possible that another lesion above or 
below the apparently non-lesional tissue in this plane affected our assessment. 
However, the presence of normal myelin staining patterns and paucity of 
lymphocytic perivascular cuffing would support the contention that these areas 
are not actively inflamed, despite increased CD68-positive cells as reported before 
(Thomas Zeis et al. 2009).  
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It is rare to obtain neuropathological tissue sampled at the earliest stages of MS. 
However we were able to perform a detailed description of changes occurring in 
early active lesional (EAL) biopsy tissue, using a number of conventional stains 
and IHC analyses. Preliminary analysis demonstrated a pattern II/III pathology, 
suggesting that not all patients demonstrate unique subtypes only. At this earliest 
stage of MS, we have also demonstrated HMGB1 expression in biopsy tissue for 
the first time and confirmed its expression in EAL. A predominantly nuclear 
expression pattern was observed in macrophages/microglia, OGD and neurons, 
with evidence of cytoplasmic translocation in lesional macrophages. The tissue 
alterations and changes in HMGB1 expression in non-lesional regions are striking 
in this tissue type and suggests a more widespread alteration in MS tissue. It is 
tempting to speculate this may have preceded active lesion formation (Thomas 
Zeis et al. 2009), but requires further verification. Therefore, we wished to carry 
out an extended study, examining lesional and non-lesional areas using autopsy 
tissue in both MS patients and non-MS control subjects. These findings will be 
discussed in the following chapter. 
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4  
 
Post-mortem study of HMGB1 
expression patterns in MS and 
non-MS control patients 
 
 
 
4.1 Introduction 
As discussed in chapter 3, immunohistochemical (IHC) analysis of brain tissue 
offers an insight into potential pathogenetic mechanisms of MS. Studies examining 
HMGB1 expression using immunohistochemistry (IHC) in human 
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neuropathological tissue have been performed in patients with other neurological 
diseases such as epilepsy/ cortical malformation (Zurolo et al. 2011; Maroso et al. 
2011; Maroso et al. 2010), alcoholism (Crews et al. 2013; Zou & Crews 2014) and 
amyotrophic lateral sclerosis (Casula et al. 2011).  
Neuropathological examination of HMGB1 expression in MS patients and controls 
has been reported by Andersson et al (2008). In this study, the autopsy MS tissue 
comprised six patients with ‘acute’ MS, seven patients with RRMS, 18 with SPMS 
and 11 patients with PPMS. The authors did not provide clinical details for the 
patients classified as having ‘acute’ MS. They found that HMGB1 immunoreactivity 
(IR) was marked in the nucleus and cytoplasm of microglial/ macrophage cells 
within active lesions, and identified these cells morphologically. The methodology 
of how they collected the data regarding number of macrophage and microglial 
cells/mm2 is not clear; for example number of frames sampled. They also do not 
comment on IR in other cell types, except astrocytes where co-localisation 
analysis revealed that HMGB1 immunoreactivity (IR) was not identified. They 
reported that the staining pattern in control white matter was nuclear, although 
do not provide pictorial evidence to demonstrate the cellular staining pattern in 
all cells here. This is of interest as some of the cells in the chronic active lesional 
tissue image demonstrated in figure 1 of this study appear to be OGD 
morphologically. Given that this is a critically important cell in MS-related 
pathology as well as my findings described in chapter 3, it would have been useful 
to compare expression patterns between MS and non- MS patients. In addition, in 
the animal study, HMGB1 mRNA levels are especially high in the grey matter of 
the spinal cord, although they do not comment on this specifically. However, the 
high levels overall are postulated to reflect de novo synthesis due to continuing 
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loss from the cytoplasm, and use the IHC analysis to demonstrate this dynamic 
process by the cytoplasmic localisation in macrophage/ microglial cells. They also 
describe diffuse extracellular staining in the protein analysis of rat spinal cord 
using immunofluorescence techniques, although these images are not presented.  
 
Furthermore, the HMGB1 expression pattern in non-lesional regions was not 
specifically assessed. Identifying the presence of HMGB1 in non-lesional tissue is 
important as it may reflect a more global disease process, as has already been 
discussed in Chapter 1. Understanding changes taking place in the normal-
appearing brain tissue (NABT) is fundamentally important in MS research, as we 
increasingly understand that these areas may demonstrate endogenous 
mechanisms whereby the brain limits new lesion formation. They also give an 
insight into how it may be that these mechanisms fail in order to produce the 
characteristic lesional changes of MS pathology. However, whilst there is 
increasing evidence implicating NABT changes in MS pathology, our 
understanding of the molecular changes occurring in these regions is incomplete. 
Given the unique role of HMGB1 in propagating inflammation in the context of 
neurodegeneration (Gao et al. 2011; Fang et al. 2012), this potentially allows an 
insight into disease mechanisms in MS that have not been explored before.  
 
The present study is the only comprehensive assessment of HMGB1 expression in 
MS brain tissue which includes non-lesional regions and highlights an important 
role of HMGB1 in this context. The main goal of the study is to further our 
understanding of disease processes occurring in these regions and thus consider 
how these observations could be exploited therapeutically. 
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4.2 Hypothesis 
The hypothesis underpinning this chapter is that HMGB1 expression reflects more 
widespread processes than immune cell infiltration alone, and that expression will 
be increased in both lesional and non-lesional regions. Given the findings in 
chapter 3, we hypothesize that OGD demonstrate increased immunoreactivity in 
both peri-lesional and non-lesional regions in MS brain. 
 
4.3 Aims 
Using immunohistochemistry: 
1. Assess HMGB1 expression in non-MS control tissue  
2. Assess HMGB1 expression in active lesions in patients with chronic MS 
3. Compare HMGB1 expression in non-lesional MS brain tissue with non-MS 
control brain tissue 
4. Evaluate evidence for cytoplasmic translocation of HMGB1 in CNS tissue 
 
 
 
 
4.4 Methods 
4.4.1 Post-mortem brain tissue 
The majority of autopsy material was supplied by the MS Society Tissue Bank at 
Imperial College, London, using a UK-wide prospective donor scheme with full 
ethical approval (08/MRE09/31+5). Two non-MS control cases were supplied by 
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the Oxford Brain Bank, University of Oxford (07/H0606/85). One non-MS control 
case was supplied by the Neuropathology department, University Hospital 
Birmingham, following research ethics consent under local guidelines. Storage of 
the tissue at the University of Birmingham was approved by local research ethics 
committee approval (LREC 11/H1211/1).  
For the UK MSBB tissue, a summary clinical history for each case was prepared by 
MS  neurologists. The clinical and post-mortem details of the MS and control cases 
used in this study are given in Table 4.1, including age at death, post-mortem 
delay, sex and type of MS.  
Upon receiving the post-mortem brains at the UK MSBB, the material for this study 
was fixed in 4% formalin for 4 weeks and then the entire brain was divided into 
multiple blocks. The blocks were numbered in a standard fashion by the brain 
bank. The brain was divided into anterior (A) and posterior (P) halves at the level 
of mamillary bodies. One centimetre thick coronal slices were then cut through 
the brain with the first slice anterior to the mamillary bodies named A1, and the 
second A2 etc. The first slice posterior to the mamillary bodies was named P1 and 
so on. Each slice was then cut into 2 by 2 cm blocks identified by letters (A–E) in a 
vertical plane, with A as the left superior block, and by numbers in the horizontal 
plane (1–5) with 1 as the left superior block. For this study, 22 blocks were used 
for analysis from 20 patients, taken from anatomically-defined regions within the 
frontal lobe (13/21), parietal lobe (2/21), occipital lobe (3/21) and temporal 
lobes (4/21). Control blocks were predominantly taken from the frontal lobe, 
apart from 2 blocks, from the Oxford Brain Bank which were sampled from the 
temporal lobe. The hippocampus and parahippocampal gyri themselves were 
avoided when analyzing HMGB1 and LRRIg immunoreactivity due to its unique 
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anatomy when compared to other regions of the brain, in either control or MS 
patients. The blocks used for this study were fixed in formalin and embedded in 
paraffin. Sections were then cut at a thickness of 8µm and used for initial lesion 
characterisation at the tissue bank and then and for subsequent analysis by other 
researchers, including our group. Confirmation of the diagnosis of MS in each case 
was provided by experienced neuropathologists based at Imperial College London 
using a variety of markers and stains. These included H&E, Luxol Fast-blue (LFB)/ 
MHC Class II and LFB/ periodic-acid Schiff (PAS) and other immunohistochemical 
markers such as anti-myelin-oligodendrocyte (anti-MOG) antibody to further 
delineate myelination patterns. Once lesions were identified using the above 
techniques, they were classified as ‘active lesional’, ‘chronic active lesional’ and 
‘normal-appearing white matter’. The latter blocks were at least 1cm in all 
directions away from identified white matter lesional zones. The UK MSBB kindly 
donated all of the original diagnostic slides to us for characterization purposes, in 
addition to the FFPE sectioned material. 
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4.4.2 Immunohistochemical analysis 
IHC analysis was performed as described in Chapter 2, Materials and Methods, and 
was carried out using the Leica Bondmax automated stainer. Antibodies used 
were anti-MBP, -CD68, -CD3, -GFAP and –HMGB1 as described in table 3.1. HMGB1 
staining in particular was extensively optimised in order to achieve an acceptable 
balance between signal: noise, especially as staining in all non-MS control samples. 
Sequential sections were used to delineate lesion borders and cellularity by 
staining with H&E, MBP and CD68 in order to verify presence of ‘active’ and 
‘chronic active’ lesions in-house. This was also useful for confirming the absence 
AGE SEX
MS	
SUBTYPE	
DISEASE	
DURATION	 PMI	(H) CAUSE	OF	DEATH
MS
57 M PR 33 21 MULTIPLE	SCLEROSIS
50 M SP NK 24 BRONCHOPNEUMONIA
73 M PP 52 20
LEFT	VENTRICULAR	FAILURE,	
BRONCHOPNEUMONIA
77 F SP 21 7 BRONCHOPNEUMONIA
39 F SP 21 18 BRONCHOPNEUMONIA
53 M SP NK 46
ASPIRATION	PNEUMONIA;	
MULTIPLE	SCLEROSIS
44 F SP 19 20 URINARY	TRACT	INFECTION;	SEPSIS
53 M SP 33 14 SEPTICAEMIA	DUE	TO	UTI
77 M SP 39 19
BRONCHOPNEUMONIA;	
MYOCARDIAL	INFARCTION
59 F SP 42 8
BRONCHOPNEUMONIA;	HEART	
FAILURE
59 M SP 39 22 MULTIPLE	SCLEROSIS
72 M SP 43 11
BRONCHOPNEUMONIA;	MULTIPLE	
SCLEROSIS
55 M SP 20 19 MULTIPLE	SCLEROSIS
60 F SP 34 10
ADVANCED	SIGMOID	COLON	
CANCER;	MULTIPLE	SCLEROSIS
CONTROL
93 F N/A N/A 9 BRONCHOPNEUMONIA/	CVA
82 M N/A N/A 21 NK
78 F N/A N/A 33 MYELOID	LEUKAEMIA
67 F N/A N/A 33
ACUTE	ARRHYTHMIA,	INTESTINAL	
OBSTRUCTION
71 F N/A N/A 24 ACUTE	BRONCHITIS
85 F N/A N/A 48 NK
Table 4.1.  Details of MS and control cases. PR= progressive relapsing; SP= secondary 
progressive; PP= primary progressive; NK= not known 
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of active inflammatory demyelination in the ‘normal- appearing white- matter’ 
tissue blocks in our hands, as well as in non-MS control tissue. 
4.4.3 Image processing and selection of areas for analysis 
All stained sections were scanned using the Leica SCN400, and stored on the 
Digital Image Hub ‘cloud’ system, based at the University of Birmingham. In some 
of the ‘active lesion’ blocks, the original inflammatory, demyelinating lesion as 
identified on the diagnostic slides supplied by the UK MSBB was not clearly 
evident in our sections. This was likely to be due to their small size within the 
block, and may have already been sampled by the tissue bank. In all of these cases 
however, significant CD68 infiltration- which morphologically appeared to be 
activated microglia or macrophages- were apparent in the immediate vicinity and 
thus it was possible locate where the lesion was originally situated. In these cases, 
they were not used for assessment of active lesions but were included when 
analysing immunoreactivity scores for ‘non-lesional’ regions. In identifying the 
latter, regions ⩾ 1500µm were used from the lesion borders in active and chronic 
active lesional blocks to delineate non-lesional tissue for image acquisition. In 
addition, anti-MBP staining was used in order to identify cortical lesions and the 
same distance measurement was used to delineate non-lesional grey-matter. 
Thus for each section, regions were identified as (i) active/ chronic active lesion 
(ii) chronically demyelinated white matter (without significant inflammatory cell 
infiltrate) (iii) peri-lesional regions (within 300µm of the lesion border) (iv) non-
lesional white matter ⩾ 1500µm  from the lesion border (v) non-lesional grey 
matter (vi) demyelinated grey matter.  Images were then captured using the Leica 
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‘Slidepath’ software in each of these regions to fully ascertain the pathological 
changes occurring across the tissue in each section.  
4.4.4 HMGB1 immunoreactivity scoring (IR) analysis 
IR scoring was performed for HMGB1 stained sections, using active/ chronic 
active lesional and normal-appearing white matter tissue blocks from MS patients 
and controls. The regions used for semi-quantitative scoring were (a) non-lesional 
white matter and (b) non-lesional grey matter. Images were captured at x10, x20 
and x40 magnification using the Leica Slidepath software and IR scoring was 
performed using x40 magnification images. The average area covered by each 
image was 45,656 µm2 and the images were coded to maintain blinding. 
IR scoring was assessed as previously described (Vandeputte et al. 2002; Geurts 
et al. 2003; Ravizza et al. 2006; Casula et al. 2011), with both immunostaining 
intensity and frequency of cells combined to produce a semi-quantitative ‘IR 
score’. Staining intensity was evaluated using a scale of 0–3 (0: −, nil; 1: ±, weak; 
2: +, moderate; 3: ++, strong IR). The approximate proportion of cells showing 
HMGB1 reactivity at the stated intensity (1) single to 10%; (2) 11–50%; (3) >50% 
was also scored to give information about the relative number (‘frequency’ score) 
of positive cells within the HMGB1 specimens. The product of both of these 
measures then gave rise to the composite “IR score’ as shown in figures 
Four assessors independently scored the material, one of whom was myself. The 
other three assessors included two neuropathologists at University Hospital 
Birmingham (Dr Martyn Carey and Dr Santhosh Nagaraju) and one senior 
neuroscientist with extensive experience in the assessment of neuropathological 
tissue, from the University of Birmingham (Dr Ana Maria Gonzalez). These three 
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assessors were entirely blinded to any clinical details. Semi-quantitative anti-
HMGB1 IR scoring showed an inter-rater consistency of 0.8 which was deemed 
acceptably similar in order to use median values for calculation of comparative IR 
scores for each patient.  
4.4.5 CD68 quantification 
Two-dimensional cellular quantification analysis using sectioned material is 
subject to certain limitations, related to section thickness and size of objects 
counted, as reviewed in the discussion of this chapter, and we did not routinely 
assess this using a microcator. However, in this aspect of the study, we simply 
wished to ascertain whether anti-CD68 IR changed between the different lesion 
types and between controls. 6 non-overlapping fields from non-lesional tissue as 
defined above, at x20 resolution, were used per section; x3 from non-lesional 
white matter and x3 from non-lesional grey matter.  Each field covered an area of 
approximately 200,000 µm2. An unbiased counting frame was placed over the 
whole field and positive cells were identified and counted manually. Average 
values per section for both grey matter, white matter and combined data was 
recorded.  ImageJ software was used to verify total number of cells using 
haematoxylin staining and thus proportion of CD68-positive cells from this 
number was calculated.  
4.4.6 Assessment of cytoplasmic translocation  
Using the Leica Biosystems’ Tissue IA software, cellular nuclei are first located on 
the basis of counterstain and shape. A decomposition algorithm is then used, 
based on the Voronnoi tessellation method, to delineate cell and hence 
cytoplasmic boundaries. Any further calculations e.g. assessing amount of DAB 
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stain in the nucleus vs. cytoplasm are thus determined by the algorithm. With 
regards intensity, it is accepted that DAB reactivity is not a stoichiometric reaction, 
in that ‘amount’ of DAB cannot be extrapolated to ‘number’ of HMGB1 molecules 
in a linear fashion. Having said that, the Leica IA software has devised various 
techniques to quantify the DAB colour, by utilising a histogram model with a range 
of 0-255, where 0=black and 255=white. Intensity of pixels in each cell 
compartment (i.e. nucleus or cytoplasm) is measured and average intensity 
calculated based on positive readings. For example, average cytoplasmic staining 
intensity is calculated as the following: 
Mean cytoplasmic staining intensity =  
mean total staining intensity of cytoplasmic+ve pixels in all cytoplasmic+ve cells  
 
number of cytoplasmic positive pixels in all cytoplasmic positive cells. 
 
Absorbance is calculated in a similar way, but also takes into account the 
background tissue threshold, i.e. the designated cut-off for positive staining in 
tissue. Although effects of light absorbance (e.g. from glass slides) or the non-
stoichiometric nature of the DAB stain are not accounted for in this algorithm, it 
enables quantification of immunostaining in different cellular compartments. 
Neuronal nuclei are unique as compared to glial nuclei as they are larger and, 
because of their prominent nucleolus, are more heterogenous. We used these 
differences to generate two algorithms for ‘neurons’ and ‘glia’. This allowed us to 
separate the analyses to produce data corresponding to glial and neuronal 
parameters. Thus, as captured images from each section included grey matter 
regions, we used the neuronal analysis parameters to ascertain amount of DAB 
stain in nuclear and cytoplasmic compartments in these identified cells.  Given our 
 116 
 
interest in evaluating HMGB1 translocation from nuclear to cytoplasmic 
compartments, and bias inherent in subjective assessment, we found this to be an 
acceptable tool for this purpose. I devised this algorithm with help from the 
technical experts at Aperio/ Leica Biosystems, and they are now taking this 
forward for further validation in-house. 
 
4.5 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism software, V5. 
Differences across multiple groups were assessed using the Kruskall-Wallis test 
with Dunn’s post-hoc correction for multiple groups, or the Mann-Whitney U test 
if pairs of groups were compared. Single measure intraclass correlation 
coefficients using an absolute agreement definition and based on a two-way 
random effects model were calculated using IBM SPSS Statistics Version 22, and 
were performed with the help of a statistician (Dr Peter Nightingale).  
 
 
 
 
 
 
 
 
 
4.6 Results 
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4.6.1 HMGB1 expression is increased in active lesional tissue in patients 
with progressive MS compared to non-MS controls 
This series of lesions within the designated ‘AL’ tissue blocks comprised material 
taken from patients with chronic MS but who still demonstrated ongoing 
inflammatory, demyelinating lesional pathology. LFB/ Class II staining identified 
the lesion in the diagnostic slides and our assessment demonstrates positive MBP 
staining in the context of CD68-positive cells. Whilst lipophages were evident, they 
were less prominent, appearing around and within lesions, thus classifying all the 
plaques in this series as late active or chronic active lesions.  Cytoplasmic 
translocation was evident in macrophages/activated microglia, with 
characteristic short, fattened processes and rounded/ amoeboid cell bodies. In 
accordance with the findings from Andersson et al (2008), figure 4.1 
demonstrates low IR in the white matter of non-MS control patients which was 
consistent across all subjects, with both frontal and temporal lobe regions being 
assessed.  
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4.6.2 HMGB1 expression is increased in non-lesional white matter 
compared to non-MS controls 
 
Figure 4.2 demonstrates normal myelination patterns in the control tissue with 
some CD68-positive cells evident. These predominantly had ramified morphology 
suggestive of resting microglial cells, with occasional perivascular macrophages 
seen. Most CD68+ cells also appeared to HMGB1+,, although dedicated co-
localisation analysis is required to confirm this. In the inset of figure 4.2G, HMGB1 
staining is also seen in the nucleus of oligodendrocytes, as suggested by their 
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density, roundedness and presence of tissue artefact around them- giving them a 
characteristic ‘halo’ appearance- and their staining pattern is relatively weak. 
Stromal intensity was higher in one of the control subjects, but the cellular 
staining remained relatively weak in both the white and grey matter.  
In contrast to this, when assessing tissue from both the NAWM and AL tissue 
blocks, HMGB1 staining was consistently increased, most obviously affecting 
oligodendrocytes. In addition, shrunken OGD with an intense IR staining pattern 
were frequently seen in non-lesional regions of both NAWM and AL tissue blocks 
(figure 4.2H; inset). Occasionally, apparent evidence of cytoplasmic translocation 
in OGD was also seen (figure 4.2H; inset).  
When assessing staining intensity, late active and chronic active scores were 
combined due to their similar staining patterns in non-lesional regions. The visual 
differences described above were reflected in the semi-quantitative analysis, 
where increased anti-HMGB1 IR scores in MS vs non-MS controls were 
consistently seen, and this difference was statistically significant (p=0.0005). The 
majority of NAWM blocks also showed increased HMGB1 staining, although this 
did not reach statistical significance. Possible reasons for this are discussed below. 
 
 
 
 
 
 120 
 
 
 
 
Figure 4.2. HMGB1 expression is increased in non-lesional white matter compared 
to non-MS controls. (Continued overleaf). 
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Figure 4.2. HMGB1 expression is increased in non-lesional white matter compared 
to non-MS controls (continued). (A-C) Anti-MBP immunoreactivity (IR); (D-F) Anti-
CD68 IR; (G-I) Anti- HMGB1 IR. 
(A, D, G): Control tissue block. A normal myelination pattern is evident in 4.2A, with a 
few CD68-positive cells including perivascular macrophages. Anti-HMGB1 
immunoreactivity (IR) is evident in figure 4.2G, particularly in OGD (inset, arrowhead) 
but intensity is weak. (B, E, H) MS: NAWM tissue block. (B) normal myelination pattern 
is evident with slightly higher numbers of CD68-positive macrophages/ microglia seen in 
I, although most demonstrate a ramified morphology. CD68-positive cells are generally 
HMGB1 positive (H) but OGD in particular show increased expression. The inset 
demonstrates the presence of both morphologically normal (arrow) and possibly 
apoptotic (arrowhead) OGD. (C, F and I) MS: AL tissue block show the staining pattern in 
non-lesion region from a block containing active lesions. The myelination pattern is 
normal but there are numerous CD68-positive cells throughout the parenchyma 
(arrows). The HMGB1 staining is increased as seen in the NAWM blocks (4.2H and –I), 
particularly in OGD. The inset shows an intensely staining OGD with evidence of 
cytoplasmic translocation. The adjacent cell is likely to be another glial cell, possibly an 
astrocyte as demonstrated on GFAP staining on sequential sections. (J) semi-
quantitative IR scoring: demonstrated IR scores from each tissue block with significant 
differences across the groups, particularly between AL and control tissue blocks.  NB 
‘active’ refers to both active and chronic active lesional tissue blocks- see text Statistical 
analysis: Kruskal-Wallis with Dunn’s post-hoc correction. ***p=0.0005. Scale bars=100µm. 
 
4.6.3 HMGB1 expression is increased in non-lesional grey matter 
compared to non-MS controls 
Normal myelination patterns are shown in these cortical regions, taken from layer 
3 of the pyramidal cortex. The IR in control tissue was consistently low across all 
non-MS control patients. The most obvious difference in MS tissue was the 
presence of intensely positive ‘satellite’ oligodendrocytes, in their classic 
configuration in close proximity to pyramidal neurons, as shown in the insets in 
figures 4.3H and 4.3I. Translocation of HMGB1 into the neuronal cytoplasm was 
also seen, where long cytoplasmic processes were often noted- a finding not 
observed in the control tissue. There was greater variability in the NAWM blocks, 
with some patients demonstrating less intense staining than others, but the 
overall intensity was consistently greater than non-MS controls.  
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Further examination of this staining pattern at both low and at higher 
magnifications revealed striking differences in sub-cellular localisation, as shown 
in figure 4.4. We observed clear anti-HMGB1 IR in neuronal nuclei of non-MS 
control patients, where molecules of HMGB1 were observed in close association 
with chromatin (4.4C; inset, arrowhead). The cause of death for this non-MS 
control patient shown was acute arrhythmia and chronic myocardial ischaemia. 
The finely granular, perinuclear blush of anti-HMGB1 IR may represent 
cytoplasmic staining although subsequent immunofluorescent analysis of control 
tissue also demonstrated autofluorescence suggestive of lipofuscin-related 
artefact. In the grey matter of the NAWM block shown in figure 4.4D, clearly 
increased IR is shown, with some cells displaying cytoplasmic staining with very 
little nuclear IR (arrowhead), where others showed intense nuclear IR and 
relatively less cytoplasmic staining (arrow). The presence of HMGB1 in the 
cytoplasm likely represents translocated HMGB1 from the nucleus into the 
cytoplasm. Again, oligodendrocytes demonstrated consistently increased IR in 
close apposition with neurons. In non-lesional regions of AL blocks, many neurons 
demonstrated cytoplasmic translocation, often with extended axonal processes as 
shown in figures 4.4E-H. However, unlike the neuronal dystrophy observed in the 
early active lesions seen in Chapter 3, this was rarely seen in this cohort of 
progressive patients.  
The presence of HMGB1-positive cells likely to represent endothelial cells is also 
shown in figure 4.4H (asterisk), where anti-CD68, -CD3 and –GFAP reactivity are 
absent. It is unclear whether this represents expression or uptake of HMGB1 and 
further in-situ hybridisation studies are required. 
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Figure 4.4 (A-D). HMGB1-positive cells in MS cortex demonstrate significantly 
greater cytoplasmic staining vs non-MS control tissue. (A, C) Control tissue; (B, 
D) NAWM tissue block. (A) Low power magnification demonstrates that HMGB1 IR 
is reduced across all layers of non-MS control cortex compared to MS cortex (B). (C) 
demonstrates a predominantly nuclear HMGB1 staining pattern, in close association 
with the chromatic structure (arrowhead). (D) shows differential staining pattern in 
NAWM tissue blocks with some neurons displaying increased nuclear stain but 
relatively little cytoplasmic staining (arrow), whereas others showed minimal 
nuclear staining but more prominent cytoplasmic staining (arrowhead). In all cases, 
intense HMGB1 IR was observed in OGD, especially in satellite cells (continued 
overleaf). 
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Quantitative analysis of cytoplasmic translocation using Leica IA software showed 
this pattern in active lesional blocks was increased compared to non-MS controls 
(p=0.004), (figure 4.4I). As discussed, the analysis parameters were set to detect 
larger objects with heterogenous nuclei (representative of the prominent 
nucleolus of neurons) and so the majority of cells assessed represented neurons. 
Thus, the difference focusses mainly on assessing neuronal cytoplasmic 
translocation, which is increased in MS vs control tissue. 
4.6.4 HMGB1 expression is decreased in demyelinated vs. myelinated 
regions of the brain 
 
We compared the HMGB1 expression in myelinated regions of MS tissue with non-
MS control tissue and, as reported earlier, increased IR was observed in both the 
grey and white matter of MS tissue as seen in figure 4.5A-D. Interestingly, 
however, chronically demyelinated regions of the white and grey matter (Figure 
4.5E-F) showed a return to basal levels of HMGB1, even lower than that seen in 
non-MS control patients. MBP-staining in controls was also carried out, and did 
not reveal demyelination in the regions assessed, therefore this was unlikely to be 
contributing to the reduced expression in these subjects. In the grey matter, the 
reduction in HMGB1 staining in MS tissue was not related to type of tissue block 
i.e. active or NAWM, and related solely to signs of chronic demyelination. OGD with 
increased expression were rarely noted, as were macrophage/ microglial-type 
cells. This discrepant pattern in the grey-matter often occurred within the same 
section, as shown in figure 4.5D and 4.5F. Interestingly, regions of subpial 
demyelination sometimes demonstrated deep sulcal meningeal blood vessels, full 
of HMGB1-positive cells (4.5F, inset), which were CD68+CD3+ (data not shown). 
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Figure 4.5. HMGB1 expression is decreased in demyelinated regions of MS brain 
tissue. (A,B) Control tissue: demonstrates low basal expression of HMGB1. (C,D) non 
lesional region of ‘AL’ tissue block demonstrates increased HMGB1 IR in both white and 
grey matter. I shows a demyelinated region within the same section containing an AL, 
with reduction in cell density overall evident. HMGB1 IR is reduced in this setting. (F) 
Cortical demyelinating lesions (type III, subpial in this case) demonstrate decreased 
HMGB1 IR also, in contrast to (D), which is a myelinated region within the same section. 
Inset demonstrates the presence of deep sulcal meningeal blood vessels which show 
florid infiltration of HMGB1-positive cells. (A, C, E)=white matter; (B, D, F)= grey matter. 
Scale bars A, C, E=10µm; B, D, F=100 µm. 
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4.6.5 CD68-positive cells are increased in normal-appearing white 
matter (NAWM) and active lesional tissue blocks in MS patients 
 
Given the known relationship between HMGB1 and macrophage/ microglial cells, 
we sought to determine whether proportion of CD68-positive cells differed 
between tissue types in non-lesional regions. We found that proportion of CD68-
positive cells was found to correlate with semi-quantitative IR scores as shown in 
figure 4.6. In addition, proportion of CD68-positive cells was markedly increased 
in non-lesional tissue within active lesional blocks (p<0.0001) and also in NAWM 
tissue blocks (p=0.03) compared to non-MS control tissue, as shown in 4.7. 
Interestingly, the proportion of CD68-positive cells in CAL was similar to the 
values found in non-MS control tissue, and significantly lower than in NAWM and 
AL tissue blocks (4.7G; images not shown). Of note, all CD68-positive cells were 
counted and no distinction was made on the basis of morphology. However, we 
did observe the presence of so-called ‘microglial nodules’, in both myelinated 
regions of AL tissue blocks as well as NAWM blocks (4.7C; inset). 
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4.7 Discussion 
4.7.1   Increased HMGB1 expression in active MS lesions in SPMS patients 
highlights ongoing inflammation-related damage in chronic disease  
 
It is well-known that patients with chronic disease have active lesions and the data 
presented here also demonstrates this. This is borne out by the fact that both 
longitudinal analysis of MS brain tissue using MRI, and pathological studies have 
shown that lesions continuously arise and regress during the long course of the 
disease. The profound destruction following inflammatory cell infiltration from 
the periphery is well-documented and gives rise to classical inflammatory, 
demyelinating MS lesions. We have confirmed the findings by Andersson et al, and 
our own findings in Chapter 3; that HMGB1 IR was clearly increased in active MS 
WML compared to non-MS control white matter.  
HMGB1 reactivity in endothelial cells was also noted in both active lesional and 
non-lesional regions. Previous work has shown that HMGB1 acts upon endothelial 
cells via RAGE and that this can lead to upregulation of ICAM-1 and VCAM, leading 
to adherence of inflammatory cells (Fiuza et al. 2003). In addition, it is now 
established that HMGB1 can complex with CXCL12, acting at CXCR4 to propagate 
T-cell recruitment through the BBB. Anti-HMGB1 monoclonal antibody therapy 
has been used to attenuate ischaemia-related neuroinflammation by reducing 
blood-brain barrier permeability, suppressing microglial activation, matrix 
metalloproteinase-9 activity and cytokine release by immune cells such as IL-17 
(Liu et al. 2007; Zhang et al. 2011). All of these pathological processes are relevant 
to MS and amelioration of clinical signs were observed when using a monoclonal 
antibody to HMGB1 in EAE (A Uzawa et al. 2013). These authors postulated that 
anti-HMGB1 therapy could be used clinically during relapses, when the BBB is 
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known to be more permeable, allowing penetration of anti-HMGB1 Ig molecules 
into the CNS and exert its anti-inflammatory function. 
4.7.2 HMGB1 expression is increased in non-lesional regions of MS brain 
compared to non-MS control tissue 
 
Despite the changes above, what remains unclear is the nature of the earliest 
alterations within MS brain tissue which go on to form this archetypal lesion. MRI 
studies have shown that not all early alterations in brain texture suggestive of MS-
related pathology go on to become classical MS lesions, as discussed in chapter 1. 
This suggests that at some level, there is intrinsic regulation, which can limit lesion 
formation at the earliest stages. Understanding this process better may allow 
development of therapeutic strategies that could augment this endogenous, 
protective response. 
In this context, our finding of increased HMGB1 IR in non-lesional regions is 
profoundly important in furthering our understanding of the molecular changes 
taking place in these areas of MS brain tissue. The changes were markedly 
different compared to non-MS control patients in both NAWM and AL tissue 
blocks, although the latter showed strikingly consistent increase in IR whereas 
there was more heterogeneity in the NAWM tissue. This is reflected when 
comparing IR between groups, where difference in semi-quantitative scoring 
between controls and MS patients was strongly significant in the AL tissue group 
but not in the NAWM group. This is likely to be due to greater heterogeneity within 
patients as discussed but also to smaller numbers in this group (NAWM n=5 vs. 
AL/CAL n=10). Despite this, IR was greater in all MS patients vs controls, 
highlighting a potential disease-specific effect. We would need to carefully 
examine white matter regions from patients with neurological diseases other than 
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MS in order to ascertain this, but IR staining patterns in this series clearly 
differentiates between MS and non-MS control patients.  
4.7.3 HMGB1 expression in OGD is significantly upregulated in MS brain 
tissue compared to non-MS controls 
Aside from macrophages as already reported (Andersson et al, 2008), it was 
particularly interesting to note that the main cell type demonstrating these 
differences were oligodendrocytes, assessed morphologically. Given the increased 
IR in NAWM tissue blocks in particular- technically at least 1cm from identified 
white matter lesions- this may reflect endogenous HMGB1 expression in OGD. Its 
function in this context may be different to those resulting from exposure to 
exogenous HMGB1 released by macrophages/microglia, for example.  
 
HMGB1 has been shown to be expressed in both neurons and OGD, in an early 
report describing amphoterin expression, as it was then known, in rats (M M 
Daston & Ratner 1994). It is fascinating to note that in this study, HMGB1 
expression in OGD was most intense in early postnatal development i.e. in 
immature OGD-lineage cells, whereas in adults, expression of positive cells was 
more widely scattered and less intensely immunoreactive. Of additional interest 
was the finding that amphoterin-positive cells did not co-localise with GFAP-
positive cells, thus independently confirming both our findings and those of 
Andersson et al. The authors concluded that amphoterin/ HMGB1 was involved in 
neuron-glial interactions (adhesion) in the developing CNS, by enabling pre-
myelinating OGD to act as a permissive substrate for fasciculation of neurites, or 
may have a role in the segregation of axons by developing OGD. Given the 
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profound upregulation in immature OGD, they also suggested that amphoterin/ 
HMGB1 be used as a novel marker of OGD development.  
The widespread increase in oligodendroglial anti-HMGB1 IR in MS brain tissue, as 
opposed to non-MS control tissue, raises the possibility that the phenotype of 
some of these cells may be relatively immature. It is well-known that re-
expression of developmental pathways often occur under conditions of cellular 
stress. NG2 cells, for example, have been shown to clear β-amyloid peptide via 
endocytosis and augment autophagy (W. Li et al. 2013).  In MS itself (John et al. 
2002), OGD precursor cells (OPCs)  are known to accumulate in and adjacent to 
MS lesions (Guus Wolswijk 1998; Chang et al. 2000a) but it is unclear how 
widespread the presence of these cells is. Further co-localisation work using 
established markers e.g. NG2 or –O1 for immature cells and –O4, Nogo and CAII 
for mature cells would be of particular interest in ascertaining at what 
developmental stage HMGB1 expression is closest to. Whether our observation of 
widespread HMGB1 IR in OGD is reflective of a similar process in MS is 
unexplored. 
Given the widespread expression pattern in MS tissue, it is also possible that OGD 
themselves are producing HMGB1. Certainly, microglial cells in proximity to OGD 
contain the receptors required for transduction of HMGB1-mediated signalling, 
such as TLRs and RAGE if this reached the extracellular space (Bsibsi et al. 2002). 
This action may reflect chronic damage affecting oligodendrocytes as a result of 
other proinflammatory cytokines diffusing from local activated microglia or distal 
lesional regions, activating receptors for HMGB1 on OGD and thus producing a 
pro-inflammatory cytokine ‘wave’ through the MS brain. Alternatively, it may be 
an endogenous response to an unknown trigger, stimulating production of 
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HMGB1 in OGD. Given the well-known difficulty in visualising cytoplasmic 
processes of OGD, it is unclear from which sub-cellular compartment this 
increased production would arise.  
Our work also demonstrates that semi-quantitative HMGB1 IR scores were 
positively correlated with proportion of CD68-positive cells in myelinated white 
matter, suggesting that they may be related to pathological processes occurring in 
non-lesional as well as lesional tissue. Their role in this context may not be the 
same as the highly reactive macrophage/ lipophages observed in the EAL in 
chapter 3, and again M1/M2 phenotyping would be of interest here. 
Oligodendroglial abnormalities in non-lesional tissues have been noted in 
numerous previous reports and were discussed in Chapter 1 (section 1.2.7) (Amor 
et al. 2010; Jack van Horssen et al. 2012; Van Noort et al. 2010; Singh et al. 2013; 
Van der Valk & Amor 2009; van Noort et al. 2010; Zeis et al. 2008; Graumann et al. 
2003; Ingram et al. 2014; Bsibsi et al. 2013b; Barnett et al. 2009). The overall 
consensus at present is that oligodendroglial activity in non-lesional regions of MS 
brain is largely protective. Graumann et al performed microarray analysis and 
quantitative PCR to screen for upregulated genes using carefully characterised 
NAWM blocks from the same source as our tissue, the UK MSBB (Graumann et al. 
2003).  They found significant upregulation of genes related to maintenance of 
cellular homeostasis, in addition to neuroprotective mechanisms induced upon 
ischemic preconditioning. This was exemplified by the upregulation of the 
transcription factor HIF-1α, members of its associated PI3K/Akt signalling 
pathways and the latter’s target genes such as VEGF-receptor-1, although it is 
important to note that HIF-1α is not purely anti-inflammatory in its function. They 
postulated the pattern highlights a general neuroprotective reaction against 
 135 
 
oxidative stress which they discussed could either be a response to chronic 
damage or else a trigger to subsequent pathology. Interestingly, HMGB1 
expression was also found to be upregulated in 6 out of 11 MS subjects, but overall 
failed to reach statistical significance. They pointed out that subsequent 
quantitative PCR of promising candidate genes revealed the microarray data to 
significantly underestimate the upregulation found, and may be why HMGB1 
upregulation failed to reach significance. In reality, however, this lack of 
significant gene upregulation is unsurprising in the particular case of HMGB1 as 
under physiological conditions, constitutive levels of the protein itself are already 
high with at least 1x106 molecules within the nucleus alone. It may be that it is the 
mobilisation and subsequent function of this large amount of stored HMGB1, 
either as a transcription factor within the nucleus or else within the cytoplasm or 
indeed extracelluar space, that is pathologically relevant and will be discussed 
further, below.  
Zeis et al (Zeis et al. 2008) extended the findings above and screened similar tissue 
from the same brain bank and found other genes upregulated in NAWM tissue, 
including STAT6, JAK1, IL-10 and IL-4R in addition to Hif-1α as shown previously. 
Whilst these mediators do not have purely anti-inflammatory effects, taken 
together the authors postulate a protective phenotype overall. Pro-inflammatory 
genes such as STAT4, IL-1β and MCSF were also upregulated but less consistently. 
Immunofluorescence colocalisation analysis of human brain tissue demonstrated 
oligodendroglial expression of STAT6, JAK1, IL-13R  and IL-4R and whilst STAT4 
expression was predominantly found in microglia. These findings further 
reinforced the concept that a CNS-specific inflammatory reaction takes place 
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throughout the whole of the white matter in MS brain tissue, and that OGD were 
important in mediating anti-inflammatory or protective strategies. 
 
Other work examining NAWM changes has shown increased expression of alpha-
B-crystallin, a small heat-shock protein also known as HSPB5, as discussed in 
Chapter 1. Several groups have documented up to 20-fold increased expression of 
HSPB5 in multiple sclerosis brain and its absence in control brain tissue. It was 
also found to be a target of CD4+ T-cell-mediated damage to the myelin sheath 
(Ousman et al. 2007a). Further work demonstrated it was a potent negative 
regulator of pro-inflammatory pathways in both the immune system and CNS. 
Compared to wild-types, HSPB5 -/- mice demonstrated worse clinical outcomes 
in EAE during both acute and progressive phases,with higher Th1 and Th17 
cytokine secretion from T cells and macrophages, and generally more profound 
CNS inflammation. Potential anti-apoptotic functions were also shown and 
antibodies to HSPB5 were detected in CSF from MS patients and in sera from EAE 
mice. Lastly, administration of recombinant HSPB5 improved clinical EAE 
outcomes (Ousman et al. 2007b).  
Recent work has shown that ‘stressed’ OGD produce HSPB5 (Duvanel et al. 2004; 
van Noort et al. 2010), which acts as an intracellular chaperone, attenuating the 
effects of oxidative stress. Secreted HSPB5 then activates microglia within 
‘microglial nodules’ or ‘pre-active lesions’ in close proximity to OGD, to produce 
widespread TLR2-mediated anti-inflammatory or protective responses 
throughout the normal-appearing brain tissue during MS (Van Noort et al. 2010; 
Bsibsi et al. 2014). In addition to TLR2, microglia were shown to express HSPB5 
receptors TLR1, CD14 and other markers including multiple antiviral genes, 
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including RIG-1. These were induced by HSPB5 stimulation, all of which are 
otherwise inducible by type 1 interferons. Whilst the authors tentatively suggest 
that the type 1 INF-like response induced may be mimicked by IFN-β treatment in 
patients, it is likely that the IFN signature in MS brain overall is not anti-
inflammatory. However, the critically important finding from this body of work is 
the identification that the immunoregulatory environment maintained by OGD-
microglial interaction is subject to change upon exposure to mediators such as 
IFN-γ from circulating T-cells, for example. Here, the microglial response changes 
sharply to a pro-inflammatory, destructive phenotype. This may explain in part, 
why there appears to be a precarious balance between protective and destructive 
mechanisms in non-lesional brain tissue, and further argues that changes in these 
regions precede frankly demyelinating lesions.  
 
Both HMGB1 and heat shock proteins are thought to be DAMPs, released in 
response to cellular stress as outlined above (Tsan & Gao 2004; Tsan 2011; 
Bianchi 2007). An important study linking HSP function with HMGB1 in the 
context of autophagy and mitophagy has recently been reported (Tang et al. 
2011a). The authors reiterated that targeted deletion of HMGB1 (e.g. using shRNA 
transfection to produce HMGB1-/- cells) leads to mitochondrial fragmentation, 
deficits in mitochondrial respiration and ATP synthesis. These changes were 
similarly observed with disruption of the HSPB1 gene in embryonic fibroblasts, 
and forced HSPB1 expression in HMGB1 knock-out cells reversed the 
phenomenon. As discussed in Chapter 1, previous reports had identified the 
critically important role that HMGB1 plays in autophagic surveillance and 
mitochondrial quality control (Tang et al. 2010). However, this study identified 
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that nuclear HMGB1 acts as a master regulator of HSPB1 levels at the 
transcriptional level, and that the latter was the downstream effector molecule 
delivering the pro-autophagic directives of HMGB1 (Tang et al. 2011b). Whilst the 
work in MS has dealt predomominantly with the role of HSPB5 in NAWM, all of the 
small HSPs have been shown to be involved in regulation of cell survival and death 
(Acunzo et al. 2012). Thus, it is possible that HMGB1 interacts with HSPB5 also, in 
orchestrating autophagic responses. Molecular work of this complexity regarding 
HMGB1 function has not been carried out in oligodendroglial-like cells, but it 
would be of great interest to investigate the effects of HMGB1 on regulating levels 
of HSPB5, for example.  
A final and purely speculative possibility alludes to HMGB1’s role as a 
promiscuous sensor of viral proteins, discussed in Chapter 1, where chronic (vs. 
acute) infection of some OGD may engage HMGB1 to orchestrate specific anti-viral 
responses via HSPs, and produce an immunoregulatory environment. 
  
Regardless of the cause of OGD stress, the widespread expression and hence 
similarity to other molecules such as HSPB5, suggests that HMGB1 may also serve 
as a protective mediator in the NAWM of MS brain tissue. However, we can 
speculate that upon exposure to pro-inflammatory cytokines such as IFN-γ, the 
switch to a pro-inflammatory environment may induce HMGB1 to take on a more 
damaging role, as demonstrated in active lesions, or else be secreted from 
infiltrating macrophages and function entirely independently from endogenous 
HMGB1, expressed by CNS-resident cells.  
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4.7.4 HMGB1 expression is reduced in demyelinated regions of both 
grey and white matter 
 
HMGB1 IR was reduced in demyelinated regions of MS brain tissue. This may be 
due to reduced cell numbers overall, which is an accepted pathological 
consequence of chronic demyelination over time, giving rise to an apparent 
reduction as observed in both our work and by Andersson et al (Andersson et al. 
2008). However, as seen in Chapter 3, IR was also significantly reduced in 
demyelinated regions of biopsy tissue taken from a patient at an early stage of the 
disease. Thus, reduced cell density of HMGB1-expressing cells over time may be 
insufficient to explain reduced IR, and instead may reflect a dynamic reduction in 
expression. Of particular interest was the fact that deep sulcal meningeal blood-
vessels were sometimes overlying subpial demyelinated regions. A florid 
inflammatory cell infiltrate could be observed in this situation,and the majority of 
cells were HMGB1+ and CD68+ and/ or CD3+ using sequential staining (latter data 
not shown).  
4.7.5 HMGB1 expression patterns demonstrate widespread abnormality in 
non-lesional grey matter regions of MS brain tissue 
 
HMGB1 was previously identified as a promoter for neurite outgrowth in 
developing neurons, and enhances neuronal survival (Huttunen et al. 2000; 
Rouhiainen et al. 2000). It is well established that in pathological settings, 
processes usually restricted to CNS development can re-emerge in an effort to 
maintain neuroprotection. This may be the case for HMGB1, and unlike the heavily 
post- translationally modified, extracellular HMGB1 released from macrophages 
which is pro-inflammatory (see Chapter 1), endogenously produced HMGB1 in 
settings of chronic neuronal damage may well be tuned to repair rather than 
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destruction, as alluded to earlier in this chapter. However, the post-translational 
phenotype of HMGB1 molecules in this setting has not been explored in detail in 
brain tissue as yet. 
The finding of increased anti-HMGB1-IR in OGD/ satellite cell expression in MS 
NAGM was striking, in their classic configuration in apposition with neurons. OGD 
are known to provide trophic support to neurons (Wilkins et al. 2003; Wilkins et 
al. 2001) (Lee et al. 2012). In addition to direct cell-cell contact, many studies have 
shown that OGD- or OPC-conditioned media provide soluble factors which are 
essential for normal neuronal functioning, such as BDNF (Ghosh et al. 1994) and 
IGF-1 (Wilkins et al. 2001).  
Intense OGD IR was often associated with cytoplasmic translocation in neuronal 
somata in non-lesional GM. This pattern in AL and also in a number of NAWM 
tissue blocks was significantly different to that observed in non-MS control tissue. 
It was rarely observed in chronically demyelinated regions however as outlined 
above, suggesting that these changes occurred early in the disease process. As in 
the case of NAWM, whether these NAGM changes represent a distal effect of 
cortical and/ or white matter lesions, or precede their development is not clear.  
The consequences of cytoplasmic translocation are unclear, and it is also not 
established whether it is released from the cell in MS. In the necrotic core of 
murine models of ischaemic stroke, neurons were shown to rapidly empty their 
nuclear and then cytoplasmic cellular content of HMGB1 into the surrounding 
tissue (Qiu et al. 2007). Interestingly, peri-lesional neurons- unlike those cells at 
the necrotic core- were shown to translocate HMGB1 from the nucleus but then 
retain it within the cytoplasm for an extended period and did not release it into 
the media. They did not further explore the reason for this, but subsequent studies 
 141 
 
highlighting the critically important role of HMGB1 in autophagy and bioenergetic 
preservation of compromised cells, as delineated above and in Chapter 1, may 
contribute to the explanation. Clearly, neurons are under significant metabolic 
stress in the context of demyelination in MS, exacerbated by the redistribution of 
sodium channels and subsequent energy inefficiencies in these large cells. It was 
particularly interesting to note that large pyramidal neurons were more likely to 
demonstrate cytoplasmic translocation than smaller neurons in the internal and 
external granular layers- which are responsible for synapsing over relatively 
shorter distances. We have not explored this further as yet but it is an important 
observation that warrants further investigation. In addition, non-lesional grey 
matter in NAWM tissue blocks sometimes showed intense nuclear expression of 
HMGB1 but cytoplasmic translocation was relatively less pronounced. This 
suggests a temporal sequence, where increased nuclear expression is followed by 
cytoplasmic translocation and this in turn is followed by globally reduced HMGB1 
expression in the context of chronic demyelination, possibly because the HMGB1 
has ‘emptied’ from the cell and not been replenished. This is highly speculative 
and needs further verification by additional techniques such as in-situ 
hybridisation. However,it raises interesting possibilities as to the development of 
neuronal changes over time in MS brain tissue. The lack of association of CD68-
positive cells and HMGB1 IR scores in this tissue type further supports an 
independent mechanism of HMGB1-related activity between neurons and OGD in 
progressive MS patients. Again, its role here may in fact be important in mediating 
protective responses in this dysfunctional CNS environment. 
4.8 Limitations of study 
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Autopsy tissue is well-known to produce artefact when examining protein 
expression. Both post-mortem interval and formalin fixation have an impact in 
both under and over-expression of antigens. In addition, age also has an impact on 
antigen expression and detection, which is especially difficult in the setting of MS 
research, as patients are relatively young when they die and control subjects are 
usually elderly. Finally, sex-specific effects cannot be ruled out but again, MS 
research is hindered in this respect due to the female preponderance of the 
disease. It was not possible to fully control for these factors, therefore their 
potential impact must be taken into consideration. Larger studies and age/ sex-
matching would be required in future studies to ensure any differences were not 
related to these factors. 
Despite a great deal of research into NABT in MS, no consistent definition has been 
reached neuropathologically, as to what constitutes ‘normal’ tissue in MS brain. A 
distance of 1500µm from the lesion border was chosen in this study based on 
appearances within the tissue sections overall using a variety of stains and IHC (F. 
Roncaroli, personal communication) and in accordance with other published 
papers and theses, where a minimum of 900 µm has been used. With regards to 
image selection, only one image was used for scoring but raters were also given 
low power views to place this image into context when scoring, with these views 
covering a large area of approximately 1mm2.  
IR scoring is a subjective assessment of antigen expression, and as mentioned 
previously, the DAB reaction used in this study is not stoichiometric and therefore 
absolute expression cannot be calculated. Despite this, the methodology has been 
used in a number of other studies, to semi-quantitatively reflect the pattern of IR 
in the whole group and not just in the images presented. In this study, three 
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different raters, experienced in neuropathological assessment of tissue and 
blinded to the clinical history, were used to provide a robust analysis and the 
resultant correlation between rating scores was good. 
The manual counting of CD68-positive cells is subject to obvious limitation as 2-
dimensional counting of objects can introduce inaccuracy. However, any errors 
were likely to be applied to all sections assessed, as one rater was used to count.  
Assessment of cytoplasmic translocation using the Leica IA software was novel 
and, therefore the technique has not undergone an established standardisation 
process. In addition, it was not possible to identify which cell types demonstrated 
the greatest cytoplasmic translocation, which was responsible for the final 
calculation. Thus, it required this tool to be used in conjunction with visual 
assessment to identify which cells in a particular tissue type (GM vs. WM) were 
likely to have contributed to this the most when interpreting the results. 
Nonetheless, it provides an objective assessment of translocation and further 
work is currently being done to develop this within Leica Biosystems.  
Finally, whilst it appeared that HMGB1 IR was prominent in OGD, this was based 
on morphological appearance in the white matter especially and by classical 
configurations in the grey matter, in close apposition to neurons. The only way to 
confirm that these are indeed OGD would be to perform co-localisation studies 
with established markers such olig2, using immunofluorescence techniques. In 
addition, in-situ hybridisation studies would demonstrate mRNA expression of 
HMGB1, confirming expression of the molecule in specific cell types. This work is 
planned and will be undertaken as discussed in ‘Future work’; section 7.3.  
 
4.9 Conclusions  
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I have performed a detailed examination of HMGB1-related neuropathological 
changes occurring in NABT of MS patients and shown that anti-HMGB1 IR is 
profoundly increased in non-lesional regions of both GM/WM in this series of MS 
patients compared to non-MS controls. The fact that expression was increased in 
NAWM tissue potentially refutes our original hypothesis of HMGB1 reflecting 
centrifugal diffusion from the lesion core to the surrounding perilesional tissue. 
Oligodendrocytes clearly expressed HMGB1 in non-lesional WM and in satellite 
cells in close apposition with neurons in myelinated GM. Increased endogenous 
HMGB1 expression may upregulate downstream molecules such as HSPs in OGD, 
which are also known to have roles in autophagy and mitochondrial quality 
control. Neurons in grey matter demonstrated evidence of cytoplasmic 
translocation of HMGB1 which may also signify autophagic rather than 
destructive effects, given the established role of HMGB1 here. In addition, the 
possibility that marked anti-HMGB1 IR in OGD may reflect widespread alterations 
in their developmental phenotype, also warrants further exploration. 
Given the potentially beneficial role of HMGB1 in pre-lesional MS pathology 
therefore, a simple HMGB1-blocking approach as seen in the EAE work may not 
be successful in the long-term treatment of MS patients. Similar caution was raised 
in the work by Andersson et al (Andersson et al. 2008). It is theoretically feasible, 
however, that drugs targeting very specific post-translational modifications, such 
as the disulphide-linked form of heavily oxidised, extracellular HMGB1, could be 
used therapeutically in active disease.  
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5.  
Cerebrospinal fluid biomarkers of 
damage, inflammation and 
degeneration in Multiple Sclerosis 
 
 
 
 
 
 
 
5.1   Introduction 
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5.1.1 CSF biomarkers in MS 
The use of biomarkers such as MRI have profoundly changed our understanding 
and management of neurological illness, but tissue confirmation of disease 
processes remains the gold-standard. CSF sampling can therefore be viewed as a 
‘liquid biopsy’, as its proximity to the brain substance is the often the best chance 
clinicians have in capturing disease processes in real-time (Giovannoni 2006).  
A biomarker in body fluids is ‘a characteristic that is objectively measured and 
evaluated as an indicator of normal..(and) pathogenic processes, or 
pharmacological responses to a therapeutic intervention’ (Floyd & McShane 
2004.). A ‘perfect’ biomarker in MS would reflect neuropathological changes 
occurring in MS lesions and then be validated in patients with neuropathologically 
confirmed MS. It would also have a high specificity and sensitivity for prediction 
of neurodisability and should be reliable, non-invasive, simple to use, and cheap.  
Accurate diagnosis, prognostication and monitoring of disease progression are 
critical in our management of MS patients. Although MR imaging has emerged as 
our greatest tool to facilitate this to date, it has inherent drawbacks including the 
fact that traditional metrics are poorly correlated with disability outcomes and 
generally measure late disease processes (Fisniku et al. 2008b). Body fluid 
biological markers are potentially of great use as they can aid prognostication and 
responsiveness to treatment [Teunissen 2012]. Molecular biomarkers may reflect 
disease-specific mechanisms (Deisenhammer et al. 2009) and are thus of added 
value.  
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However, despite an explosive effort in the search for appropriate biomarkers in 
MS, there remains a dearth of genuinely useful molecules which could be used for 
monitoring or prognosticating disease progression more accurately for use in 
daily practice. 
5.1.1.1 Free-light chain levels are established markers of intrathecal  
inflammation in MS 
As detailed, we collected a large series of CSF samples from MS patients and a 
range of non- MS control subjects. In order to assess whether this was a 
representative cohort of patients to analyse, we chose to assess CSF free-light 
chain levels as this is an established marker of MS (Presslauer et al. 2014; 
Presslauer et al. 2008; Senel et al. 2014). As discussed in the General Introduction, 
chapter 1, whilst T-cells are critically important in MS-related pathology, 
meningeal ectopic B cell follicles and plasmablasts in the CSF are also likely to 
contribute to the pathology of MS (Aloisi et al. 2010; Meinl et al. 2006). These CNS- 
resident B cells produce intrathecal immunoglobulin, allowing detection of CSF-
specific oligoclonal bands that continue to be an important component of the 
diagnostic pathway for MS (Katsavos and Anagnostouli, 2013; Tumani et al. , 
2009). During active antibody production, FLC are also produced and so serve as 
markers of this process. 
Interestingly, plasma cells release HMGB1 into the extracellular milieu following 
LPS-stimulated maturation (Vettermann et al. 2011). This demonstrates a 
potentially pro-inflammatory effect in autoimmune disease and chronic 
inflammation although other studies have also suggested that the primary role in 
the setting of chronic inflammation is to promote immunosuppression (G. Li, 
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Liang, et al. 2013). However, as FLC reflect antibody production, it may be that 
they are correlated with HMGB1 production also and we wished to examine this. 
5.1.1.2 Neurofilament proteins are established markers of neuroaxonal 
damage 
Neurofilament proteins are widely regarded as the most reliable protein 
biomarker for neurodegeneration (Teunissen & Khalil 2012; Teunissen et al. 
2005; Petzold et al. 2010). Their importance in potentially delineating 
pathological processes as well as their utility in clinical trials and routine 
laboratory practice is being increasingly recognised (Petzold et al. 2010).  
They are the predominant axonal cytoskeleton proteins and comprise three 
elements that differ in molecular size: the light chain (NfL)- 68 kDa, the 
intermediate chain (NfM)- 150 kDa, and the heavy chain (NfH) of 190–210 kDa 
(Petzold 2005). The NfL is the ‘backbone’ to which NfH and NfM chains attach to 
form polymerised neurofilaments. The degree of filamenous phosphorylation 
alters the axonal diameter, as the more phosphorylated it is, the broader the 
diameter (Fuchs 1998). Non-phosphorylated neurofilament has been observed 
within active MS lesions (Trapp et al. 1998) and in murine and primate models 
early during EAE pathology. Following axonal injury, they are released into the 
extracellular space, and subsequently into the CSF and peripheral blood (Petzold 
2005). Thus analysis of CSF or serum NF levels is accepted as a valuable tool to 
estimate extent of axonal damage in patients with MS. 
A number of studies have shown increased NfL levels in the CSF of patients within 
all MS subgroups (Norgren et al. 2003; Lycke et al. 1998; Teunissen et al. 2009), 
and they have demonstrated their potential utility in monitoring therapeutic 
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efficacy (Gunnarsson et al. 2011) as well as serving as possible outcome measures 
in clinical trials  (Romme Christensen et al. 2014). These will be discussed in more 
detail in the discussion, section 4.4.2, below as we wished to corroborate these 
findings to ensure that our cohort is representative of MS and non-MS patient 
groups. In addition, given its detection in patients at early stages of MS, we wished 
to examine the relationship of this sensitive marker of degeneration to other 
inflammatory markers such as cell count or indeed FLC, as the correlation 
between these two established markers of different components of MS-related 
pathology has not been reported before. 
5.1.1.3  HMGB1 is potentially a novel CSF biomarker in MS 
As presented in Chapters 3 and 4, we found widespread expression of HMGB1 
throughout the MS brain, in both lesional and non-lesional regions. Western 
blotting analysis originally demonstrated the presence of HMGB1 in the CSF in two 
MS patients whereas it was not detected in 2 control patients (Andersson et al. 
2008). The lack of a quantitative assay curtailed further exploration of these 
promising findings until IBL-International developed a commercial assay for the 
detection of free HMGB1 in body fluids (Yamada 2003).  Since then, reports of its 
utility in numerous diseases including MS have been reported and will be 
discussed further in section 5.6.3 of this chapter, in the discussion.  
Many of the HMGB1+ cells in the early active biopsy lesion in particular were 
perivascular macrophages and we know that HMGB1 is classically produced by 
these cells (Andersson et al. 2008; Wang 1999). There is limited information of 
HMGB1 function and production by lymphocytes in the literature (I E Dumitriu et 
al. 2005; Sundberg et al. 2009), but our observation of probable CD3+ HMGB1+ 
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lymphocytes suggests that these cells may also have the capability to produce 
HMGB1 in this setting. In the context of BBB compromise, infiltrating HMGB1+ 
leukocytes may enter the CNS space and thus serve as a source of secreted HMGB1 
in CSF. CXCL12 and CXCL13 are detected in the CSF (Krumbholz et al. 2006), and 
these may be involved in HMGB1 function both directly and indirectly. CXCL12 
directly associates with HMGB1 and acts via CXCR4 to increase leukocyte 
chemotactic activity (Schiraldi et al. 2012), whilst CXCL13 is a powerful T- and B-
cell chemoattractant and is implicated in MS pathology (Krumbholz et al. 2006). 
In addition, given recent work suggesting that CSF production may reflect 
parenchymal changes to a greater degree than previously thought, it is possible 
that it may also be secreted from the great numbers of HMGB1+ CNS-resident 
cells. This latter source may be more relevant in the remission phase of the 
disease, as we know from the observations in the neuropathology work that 
HMGB1 expression is increased even in non-lesional tissue, and in patients who 
have ceased to actively relapse. 
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5.2 Hypotheses 
1. Classical (FLC and NfL) and non-classical (HMGB1) molecules associated 
with MS pathology are increased in the CSF of MS vs. non-MS patients 
2. HMGB1 and FLC levels are correlated due to production by B-cells 
3. The increase in HMGB1 levels is likely to be more marked in the earlier, 
inflammatory disease phase (i.e. CIS/ RRMS), even in non-actively 
relapsing patients 
5.3 Aims  
1. To establish a well-characterised clinical cohort comprising both MS and 
non-MS control patients 
2. Evaluation of this cohort using two well-established protein markers in 
MS: k and λ free-light chain (FLC) and neurofilament-light (NfL) levels 
 3. To investigate CSF levels of a relatively novel biomarker, HMGB1, using a 
quantitative ELISA assay in this patient cohort 
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5.4 Materials and methods 
5.4.1  Study Subjects 
Ethical approval for the study was obtained via the Human Biorepository 
Research Centre (HBRC), University of Birmingham and all subjects provided 
written informed consent to participate in this study. Between February 2011 and 
September 2013, matched serum and CSF samples were prospectively collected 
from 170 patients who underwent routine diagnostic lumbar puncture as elective 
cases on the neurological investigations day-case unit at University Hospital, 
Birmingham (UHB).  The latter represents the main referral centre for the 
region; 86% of the cases were referred from peripheral hospitals for 
diagnostic LP at QEHB. CSF and serum samples from a further 13 patients 
were collected from University Hospital of North Staffordshire (UHNS) for the 
free-light chain study, following local ethical approval. 
The following diagnostic groups were established: C I S  (n=24),  R R M S  
(n=27) and primary progressive MS (PPMS) (n=13)- fulfilling the criteria of 
dissemination in space and time for diagnosis of MS according to recent 
criteria (Polman et al. 2005)- see table 5.1.  The majority of MS patients were not 
receiving any disease-modifying treatment at time of LP except 1 PPMS patient who 
was taking methotrexate. 1 RRMS patient had been on TYSABRI® but had not 
received it in the 30 days prior to LP due to concerns over possible PML, which were 
disproven following the LP. As part of the HBRC ethics, this same patient had 
provided biopsy material whose clinical history and neuropathological findings have 
already been reviewed in chapters 3 and 4. Two of the MS patients (1 CIS and 1 
RRMS) had received a course of steroid therapy in the month prior to CSF collection.  
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Table 5.1. Demographic data from MS and non-MS patients: median (range). MS 
patients were classified into three clinical subgroups: CIS, RRMS and PPMS. Non-MS 
patients were classified according to diagnosis of other inflammatory neurological 
disease (ONID) or other non-inflammatory neurological disease (OND). *denotes 
patients with either missing data or matched bands in the serum and CSF. 
 
In addition, other neurological inflammatory diseases (ONID) (n=18) and 
other neurological diseases (OND) (n=100) comprised the non-MS patient 
groups. We wished to create a detailed database and so carefully reviewed all 
patient records in order to give as accurate a diagnosis at time of review as possible. 
The breakdown of diagnoses in the OND group are shown in figure 5.1. 
 
 
Patient group 
n 
Gender 
M:F 
 
Age 
OCB status+ 
(%) 
Clinically-isolated syndrome 
(CIS) 
24 8:16 38 (21-70) 21/24 
(88) 
Primary-progressive MS   
(PPMS) 
13 5:8 51 (43-72) 10/12* 
(83) 
Relapsing-remitting MS    
(RRMS) 
28 4:24 41 (19-72) 24/26* 
(92) 
Other neurological disease 
(OND) 
100 33:67 43 (17-85) 1/87* 
(1) 
Other neurological 
inflammatory disease (ONID) 
18 10:8 44 (24-83) 1/17* 
(6) 
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Where indicated, extensive diagnostic work-up with clinical/ structural (brain+/- 
spinal MRI)/ laboratory/ functional (EEG/EMG) tests were carried out before the 
majority of patients were given a diagnosis of headache syndrome comprising both 
tension and migrainous headache, or else pain, anxiety or functional syndromes. 
‘Vascular’ diagnoses comprised samples collected many months after the initial 
insult, but whose symptoms were in keeping with chronic sequelae from this. The 
miscellaneous group included diagnoses such as fibromyalgia, chronic fatigue 
syndrome, vasovagal syncope and convergent spasm. ‘CSF pathways disease’ 
collectively referred to patients whose CSF was collected by the neurosurgical team 
for therapeutic drainage to manage symptoms relating to syringes. These subgroups 
of patients are referred to collectively as ‘OND-control’ or OND-C in the NfL analyses, 
as it was important to differentitate between degenerative and non-degenerative 
patient groups (see NfL section 5.3.2), given the knowledge that NfL levels are 
increased in some neurodegenerative diseases. Excluding IIH, these patients were 
likely to be as close to ‘normal’ CSF as possible, although they would not be classified 
as ‘healthy controls’. The ‘acute degenerative’ subgroup comprised motor neurone 
Figure 5.1. Diagnoses comprising ‘other neurological diseases’ (OND), n=100.  
OND-control (OND-C) refers to patients with non-degenerative disease and OND-D 
includes patients with ongoing degenerative disease.  
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disease (n=1), rapidly progressive presentation of normal pressure 
hydrocephalus (n=1), subacute compressive spinal disease +/- myelopathy (n=2) 
and multiple system atrophy (n=1). Chronic neurodegenerative diseases included 
hereditary disorders such as Friedrich’s ataxia, Charcot-Marie tooth disease and 
other long-standing conditions such as axonal neuropathy secondary to previous 
chemotherapy use, or cervical spondylitic lesions. The degenerative diagnoses were 
collectively referred to as ‘OND-degenerative’ (OND-D) for the reasons outlined 
above. 
 Patients categorised with ‘undetermined’ diagnoses were designated thus due to (i) 
the prospective nature of the data collection i.e. insufficient evidence was available 
in order to make a firm diagnosis by the referring/ reviewing clinicians at the time 
when the diagnostic classifications for this study were being generated and (ii) some 
patients moved away or were lost to follow-up at the local hospital, prematurely 
curtailing a full diagnostic work-up. 
ONID diagnoses comprised anti-phospholipid syndrome (n=1), Behcet’s disease 
(n=2), inflammatory neuropathy (n=4), Compressive myelitis (n=2), Neuroretinitis 
(n=1), Sjogren’s syndrome (n=1), idiopathic transverse myelitis (n=3), aseptic 
meningitis (n=1) and Neurosarcoid (n=3).  
5.4.2 Data management 
Given the number of patients included in the study, a systematic approach was 
adopted to establish data integrity. In line with national guidelines, all data 
collected through the HBRC was anonymised, and a unique set of codes (total=7) 
were assigned to each patient, corresponding to serum (x1), EDTA blood (x5) and 
CSF (x1) samples. Patient information was accessed via the Clinical Portal system 
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of University Hospital Birmingham or if obtained from peripheral hospitals, any 
correspondence regarding patient data was obtained using anonymised codes, via 
‘NHS.net’ or secure local hospital email addresses. If patients’ care was not based 
at UHB, MR imaging from peripheral hospitals was transferred over to the UHB 
‘PACS’ system in order to centralise access. Data on patient names, hospital 
numbers and clinical information was carefully filed and stored in a locked office 
in the Centre for Translational Inflammation Research, which nominated clinical 
assessors (GHS and MD) were able to access. Datasets using the anonymised 
patient identifiers were compiled on excel spread-sheets.  
5.4.3 Preparation of CSF and serum 
Samples were prepared as outlined in the methods section in Appendix 1.  
Samples were also analysed for cell counts, protein and glucose concentrations 
and oligoclonal band (OCB) status as part of the clinical laboratory diagnostic 
work-up. Cell counts were analysed in the clinical laboratories by experienced 
technicians using accepted clinical laboratory protocols. In brief, this comprised 
adding two drops of well-mixed CSF to a tube containing 0.1% toluidine blue 
solution. The sample was left for 1 minute to reconstitute with the stain. Capillary 
action was then used to introduce the sample to fill the Kova Glassitic Slide-10 
counting chamber, without introducing bubbles. The number of 
polymorphonuclear, mononuclear and red blood cells were counted by eye using 
the guide shown in figure 5.2, multiplying the final count by the dilution factor if 
this had been necessary.  
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Figure 5.2. Cell differentiation guide (Clinical Microbiology laboratories, University 
Hospital Birmingham (UHB)). Reproduced from documentation kindly provided by 
Yvonne Brocklehurst- Senior laboratory manager, Microbiology department, UHB. 
5.4.4 Analytical procedures 
5.4.4.1 Nephelometric free light-chain (FLC) quantification 
The methods for this part of the chapter are detailed in Appendix 1. 
5.4.4.2 Neurofilament-light (NfL) quantification.  
NfL (predominantly unphosphorylated form) was measured by quantitative 
enzyme-linked immunosorbance assay (ELISA), purchased commercially from 
Uman Diagnostics (Umeå, Sweden, lot #70189) on a total of 117 samples. Assays 
were performed on the same day using carefully designed 96-well plate schemata 
in order to include control and index samples on each plate to account for batch-
to-batch variability. All standards, samples and positive controls were thawed on 
ice on the day of the assay and analysed in duplicate. The intra-assay and inter-
assay variability were determined to be <6% and <9% respectively. The detection 
level for the kit is set at 31ng/L, defined as the mean of blank samples+2SD. The 
assay was performed as outlined in General Methods, chapter 2, according to 
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manufacturer’s instructions and using digital multichannel pipettes to minimise 
pipetting error. 
5.4.4.3 HMGB1 quantification 
HMGB1 was measured in 117 samples by quantitative enzyme-linked 
immunosorbance assay (ELISA), purchased commercially from IBL International 
(Hamburg, Germany). Assays were performed on the same day and all samples 
thawed on ice on the day of the assay as above. As the assay is designed for analysis 
of serum samples, we used the ‘high-sensitivity’ standard curve analysis option, 
given the likelihood of low HMGB1 levels in the CSF of this cohort of patients. The 
intra- and inter-assay variability using the high sensitive range were determined 
to be 3.2-10.2% and 1.3-10.7% respectively. The detection limit or analytical 
sensitivity for the high-sensitivity assay is set at 0.2ng/mL, whilst the limit of 
quantification i.e. the functional sensitivity is set to 0.1ng/ml.  
 
 Statistical Analysis 
Data were analysed using GraphPad Prism 5 (GraphPad Software Inc., CA, USA). 
Non-parametric analyses were used and data represented as medians, with 
multiple comparisons performed using a Kruskal-Wallis test with Dunn’s post-hoc 
correction. Two-group comparisons were performed using a Mann-Whitney U test 
for unpaired continuous measures. Spearman’s rank correlation coefﬁcient was 
used to evaluate the statistical dependency of two variables 
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 Results 
5.6.1  Free-light chain levels are elevated in the CSF of MS patients but not in 
other inflammatory/non-inflammatory neurological diseases 
The results from this section of work are presented within the paper attached to 
the Appendix, section 1 as described earlier.  
5.6.2 Neurofilament light chain levels in the CSF from patients with different 
neurological diseases  
For the purposes of this analysis, the OND group was subdivided into OND-Control 
(OND-C) and OND-degenerative (OND-D). The OND-C group comprised patients 
with a diagnosis of headache disorder, CSF pathways disease, IIH, pain syndrome, 
anxiety, functional and miscellaneous groups. The latter group was included as 
none of the patients in this group had evidence of degenerative disease. The OND-
D group represented patients with diagnoses of chronic or acute 
neurodegenerative diseases as described in section 5.4.1. Median values and 
range are presented in table 5.2. 
Patient group 
NfL levels, median (ng/ml) 
(range) 
CIS* 1362 (664-10000) 
PP-MS  1389 (1028-3235) 
RR-MS  2475 (1014-10000) 
ONID  1400 (487-4902) 
OND-C 905 (262-1912) 
OND-D 1628 (613-10000) 
 
Table 5.2. Comparson of median and range of NfL values in different patient groups. 
*CIS, clinically isolated syndrome; PPMS, primary-progressive MS; RRMS, relapsing-
remitting MS; OND-C, other neurological disease (OND)- OND-control; OND-D, other 
neurological disease (OND)- OND- degenerative; ONID, other neurological inflammatory 
disease. 
Neurofilament levels were increased in all MS groups compared to the OND-C but 
not the OND-D patient groups, as shown in figure 5.3 and table 5.2. This was most 
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apparent when comparing the RRMS vs OND-C group (p<0.0001) and the CIS vs 
OND-C (p=0.003), whilst comparison between PPMS vs OND-C did not reach 
statistical significance (p=0.05). This difference primarily reflects median values 
between the groups, and levels were highest in the RRMS group as compared to 
CIS and PPMS patients. PPMS median values showed the tightest range, whilst the 
OND-D group demonstrated the largest.  
 
Figure 5.3 Neurofilament-light (NfL) levels are elevated in the cerebrospinal 
fluid (CSF) in patients with MS and degenerative diseases. Non-inflammatory 
and non-degenerative CSF samples (OND-C), showed the lowest NfL levels. CIS, 
clinically isolated syndrome; RRMS, relapsing-remitting MS; PPMS, primary 
progressive MS; OND, other neurological disease; OND-C, OND-control; OND-D, OND-
degenerative; ONID, other neurological inflammatory disease. Statistical analysis: 
Kruskall-Wallis multiple group comparison with Dunn’s post-test; **p<0.003; 
***p<0.0005; ****p<0.0001. All other comparisons were not significant. 
a.  
After the RRMS group, median values were highest in the OND-D then ONID 
groups. However differences between the ONID and the other groups failed to 
reach significance despite this, and may reflect either similar median values such 
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as in the PPMS group or else higher absolute values in the other groups over a 
wider range. The OND-D groups comprised patients with chronic and acute 
neurogenerative diseases. Within this group there was a significant difference 
between median values, with higher values in the acute degenerative group 
(p<0.005). Sub-group comparison revealed that median NfL levels were not 
significantly different between RRMS patients- with the highest median values- 
and OND-D patients. 
Age is thought to influence NfL detection and a mild-moderate positive correlation 
of neurofilament levels with age when including all patients was observed 
(r=0.29; p=0.002), shown in table 4.5. Sub-group analysis in order to consider the 
correlation with age in the MS patients alone removed this association (r=-0.07; 
p=0.61), whereas when considering the OND group as a whole, a strong 
correlation was demonstrated, with a corresponding increase in its statistical 
significance (r=0.71; p<0.0001).  
NfL is thought to represent degenerative processes in the CNS, and given the 
importance of understanding how these may interact with inflammation in MS, we 
also sought to correlate NfL levels from the whole cohort with a variety of indices 
representing different aspects of inflammation. Lymphocyte concentration/ml as 
determined by FACS analysis showed a strong correlation with cell count as 
determined by clinical laboratory analysis (r=0.63; p<0.0001) (data not shown). 
However, although increasing lymphocyte count/ml was mildly correlated 
(r=0.25; p=0.01), total cell count measured by lab analysis and encompassing all 
types of inflammatory cells, was better correlated with increasing NfL levels 
(r=0.33; p=0.0003).  
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As described previously, protein measurements in the CSF are important as they 
may indicate endothelial barrier breakdown, allowing more protein to enter the 
otherwise tightly controlled CNS, and we found that levels were moderately 
correlated with NfL values (r=0.37; 0.0001). Finally, a novel correlation was 
identified between kappa and lambda free light chains and NfL (r=0.29; p=0.003 
and r=0.38; p<0.0001 respectively). This was further enhanced by the removal of 
the ‘acute degenerative’ subgroup of patients, who had outlying levels of NfL (see 
brackets in table 5.3), on the basis that they are likely to demonstrate increased 
NfL levels according to current literature, but are unlikely to demonstrate 
increased FLC thus potentially biasing any association. Whilst this artificial 
analysis has some limitations, the strength of association for both κ and λ FLC and 
their statistical significance (r=0.38; p=0.0001 and r=0.49; p<0.0001 respectively) 
were increased. 
Variable Correlation coefficient I p-value 
Age: overall* 0.29 0.002 
Lymphocyte count/ml 0.25 0.01 
Cell count/ ml 0.33 0.0003 
Protein level (g/l) 0.37 0.0001 
kFLC 0.29 (0.38) 0.003 (0.0001) 
λFLC 0.38 (0.49) <0.0001 (<0.0001) 
 
Table 5.3. Correlation of NfL levels with demographic and inflammatory data. 
* A subgroup analysis for age (MS vs non-MS) was also performed, see text. 
Statistical analysis: Spearman’s rank correlation. 
 
 
5.6.3 HMGB1 levels are elevated in the CSF of CIS and ONID patients 
compared to other patient groups.  
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CSF HMGB1 levels were undetectable using this assay in a number of patients, as 
shown in table 5.6, when using the minimum requirement of the blank standard 
as a cut-off for presence of HMGB1. In all plates, the equivalent OD of the blank 
equated to a mean of 116pg/ml, similar to the manufacturer’s ‘functional 
sensitivity’ i.e. limit of quantification of 100pg/ml. The patients with levels 
consistently above the level of detection were the CIS and ONID groups, and this 
reflects their higher median levels compared to the other groups as shown in table 
and figure 5.4.   
Patient group 
Patients with 
detectable* HMGB1 
levels (%) 
Detectable HMGB1 levels, 
median (pg/ml) (range) 
CIS 90 243 (148-518) 
PP-MS  73 221 (151-1131) 
RR-MS  84 193 (142-5216) 
OND  75 179 (105-461) 
ONID  100 267 (237-467) 
 
 
Comparison of HMGB1 levels between patient groups revealed increased levels in 
patients with RRMS and ONID patients when compared with OND patients, as seen 
in figures 5.8 A and B., There was a marginally higher statistical significance in 
RRMS vs OND (0.01) than in ONID vs OND (0.02), although both comparisons were 
weakly significant.  All other comparisons including between CIS and ONID, and 
when examining OND subgroups (OND-C and OND-D- see 5.3.1) and MS or ONID 
groups (data not shown), were not statistically different.               
Table 5.4. Comparison of patients with detectable levels of HMGB1 levels 
(pg/ml) in patient groups, in addition to median values and range in those with 
detectable levels. *detectable defined as >116pg/ml. CIS, clinically isolated syndrome; 
PPMS, primary-progressive MS; RRMS, relapsing-remitting MS; OND, other neurological 
disease (OND); ONID, other neurological inflammatory disease. 
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Analysis of correlation between HMGB1 levels and total cell count showed a mild 
association which was statistically significant (r=0.25; p=0.0085), whilst 
correlation with lymphocyte count showed a weak association, which was not 
statistically significant (p=0.05; data not shown). Correlation with any other 
variable did not reach statistical significance.                          
 
Figure 5.4. HMGB1 levels (pg/ml) are increased in both clinically isolated 
syndrome (CIS) and other neurological inflammatory diseases (ONID) compared 
to other neurological disease (OND) patient groups. Median values were highest in 
CIS and ONID patients. Statistical analysis: Mann-Whitney U test. *p<0.05 
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Figure 5.5 HMGB1 levels (pg/ml) showed a positive correlation with 
cerebrospinal fluid (CSF) cell count/ l, which was statistically significant. 
Statistical analysis: Spearman’s correlation.  
 
 
5.7  Discussion 
Particular strengths of this chapter relate to the collection of a large cohort of 
carefully diagnosed patients, resulting in clearly delineated patient groups. This 
enabled us to examine subgroups of patients and explore correlations which have 
not been performed before. Below I have discussed the results of the three main 
components of this chapter, namely CSF analysis of FLC, NfL and HMGB1 levels. 
5.7.1  Measurement of CSF kappa free light chain levels alone is a sensitive 
and specific diagnostic marker for patients with MS, and does not require 
blood/ CSF index measurements. 
The FLC findings have been discussed in the attached paper in Appendix 1, and 
can be read in conjunction with this section of the thesis. An additional point of 
discussion outlined below relating to further characterisation of an outlying FLC-
negative MS patient is described.  
One outlying RRMS patient had previously been treated with natalizumab a month 
prior to CSF sampling and showed marked suppression of FLC levels, a finding 
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which has been reported with NfL levels whilst on the drug, but not FLC levels 
(Gunnarsson et al. 2011). This suggests that natalizumab may alter B-cell function, 
given that FLC levels had not started to rise despite being off the drug for one 
month. This is in accordance with a previously published report which found that 
OCBs ‘disappeared’ in a proportion of natalizumab-treated patients who had 
initial and follow-up LPs undertaken for the same reason as in our patient, to rule 
out PML (von Glehn et al. 2012). A larger series of 76 patients treated with 
natalizumab went on to find that 16% of previously OCB-positive patients became 
negative following treatment, and the proportion of patients with an intrathecal 
synthesized fraction in the normal range increased from 20 to 45% (Harrer et al. 
2013). Of particular interest, this patient’s OCB status was negative at the time of 
diagnosis and was not re-sent with this LP. His MS was previously highly 
aggressive, necessitating a brain biopsy at diagnosis due to the fulminant clinical 
presentation. His disease progression, however, was ultimately stabilised by early 
natalizumab therapy, which he received as soon as the biopsy results 
demonstrated demyelinating disease, and when he was still technically a CIS 
patient. Given the superiority of FLC analysis and the ease with which the assay 
can be performed over OCB analysis, it would be interesting to include FLC levels 
as an outcome measure in natalizumab-related clinical trials in particular. 
5.7.2  CSF NfL levels are increased in MS patients, and correlate with λFLC 
We have shown that CSF NfL levels are increased in patients with all subtypes of 
MS, particularly RRMS and CIS. The difference was most marked when comparing 
RRMS vs. patients with non-degenerative OND. The absolute levels of NfL in our 
cohort of patients is in keeping with the published literature, but are higher in the 
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MS subgroups, considering most are in remission. Without a perfect biomarker for 
disease, clinical diagnosis and classification cannot be correct 100% of the time, 
but our diagnostic grouping was a rigorous process, and we sought to make every 
effort to accurately classify all disease groups and sub-groups. This may be 
reflective of the high proportion of OCB+ patients in the MS groups, as higher NfL 
levels have been shown to correlate with OCB status. (Norgren et al. 2003). 
As described in section 4.1, several studies have shown increased NfL levels in the 
CSF of patients with all MS subgroups (Malmeström et al. 2003; Lycke et al. 1998; 
Norgren et al. 2003; Teunissen et al. 2009). Patients relapsing have up to 10-fold 
higher levels than those in remission although levels overall were higher in RRMS 
patients vs healthy controls (Malmeström et al. 2003). Our cohort of patients were 
predominantly in remission, and we also found NfL levels were increased when 
comparing MS patients with the OND-C group. The latter is likely to have included 
patients with levels close to the healthy controls, given the normality of their 
investigations.  
NfL concentrations in MS patients have also been found to be independent of age 
and can be either high or low with increasing age (Khademi et al. 2013) (Khalil et 
al. 2013). In accordance with this, we did not find a correlation with age in the MS 
group either.  However, we found a strong correlation between age and NfL in the 
OND group, as also reported previously (Khalil et al. 2013), and probably reflects 
ongoing neurodegeneration in normally aging subjects. It also highlights the likely 
‘normality’ of our OND control group.                                                            
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NfL levels in patients with ONID were also high, although this did not reach 
statistical significance when comparing other groups. This may be due to our 
relatively small cohort and thus may not be able to detect true differences. 
Another possible explanation would be that the type of axonal damage occurring 
in MS is more diffuse, thus enabling higher absolute levels as the acute 
inflammatory damage occurring in active lesions is superimposed upon this 
aberrant background, which may not be as marked in ONID cases.  
However, increased NfL levels have been reported in other CNS inflammatory 
disorders, notably SLE (Trysberg et al. 2003), cerebral vasculitis (Nylén et al. 
2002) and paediatric opsoclonus-myoclonus syndrome (Pranzatelli et al. 2014). 
In the Trysberg paper, 4 of the ‘other inflammatory neurological disease’ group of 
patients were defined as having demyelinating disease, but comparative data 
between the groups was not presented or commented upon. Similarly, data 
directly comparing non-MS inflammatory neurological diseases with MS patients 
is relatively sparse, considering the implications this has on interpreting the 
sensitivity and specificity of the test. One early study demonstrated lower NfL 
levels in patients with ONID compared to MS patients, but they also found that 
levels were greatest in patients with progressive disease vs earlier in the disease 
course, in RRMS patients (Semra et al. 2002). The latter findings in particular have 
not been replicated and may be related to use of different ELISA methods or 
indeed differences in disease activity in the patients studied, leading to differential 
phosphorylation of the NfL proteins and hence detectable levels. 
Of particular interest is the moderately positive correlation between CSF 
pleiocytosis and NfL levels. This has been reported previously (Khalil et al. 2013; 
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Norgren et al. 2003; Norgren et al. 2004), and highlights the important link 
between NfL levels i.e. acute axonal injury and inflammatory disease activity. The 
fact that this relationship is maintained in patients who are not actively relapsing 
underlines the ongoing nature of disease activity in MS, irrespective of relapses. 
Interestingly, the lymphocyte count as determined by sensitive FACS analysis, was 
less strongly correlated than the total cell count as reported in the laboratory 
indices (see figure 5.2). This may be related to the limited range of cell numbers 
in the laboratory counts, inadvertently skewing the association. On the other 
hand, they may represent a genuine biological difference, with monocytes, e.g. 
macrophages, contributing more to the correlation than lymphocytes alone.  
Other notable correlations with NfL levels included increased CSF protein, again 
reflecting its relevance in the active stage of the disease, with breach of the CNS 
endothelium in the context of active inflammation. As before, the fact that the 
majority of patients were not relapsing is of interest although due to relatively low 
clearance, accumulated protein during previous relapses may take some time to 
clear. This association has been noted before (Khalil et al. 2013), although not in 
other reports (Norgren et al. 2003; Norgren et al. 2004). Variations in local 
laboratory analysis may account for some of this discrepancy, and again 
heterogenous patient cohorts are likely to contribute. 
A novel finding from this part of the study has been the observation of an 
association between FLC and NfL. The correlation is stronger with λFLC levels, 
suggesting that NfL may reflect processes occurring slightly later in the disease 
course, possibly when inflammation-related damage is peaking.  
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 The relationship between these two important biomarkers has not been fully 
explored. Interestingly, the outlying RRMS patient whose FLC levels were not 
detectable and who had previously been taking natalizumab one month earlier, 
demonstrated persistently elevated NfL levels (4602.44ng/ml). The reduction in 
NfL levels has been reported to occur 6 months after natalizumab therapy is 
commenced (Gunnarsson et al. 2011) thus at one month off treatment, it is 
possible that CSF levels were already climbing back up, in a patient who was 
known to have an aggressive disease phenotype, as described in Chapter 3 and 
earlier in this chapter (5.4.1). A recent open-label study also found that NfL levels 
decreased following natalizumab therapy over 60 weeks follow-up in a small 
cohort of patients with progressive MS, along with levels of osteopontin and other 
inflammatory markers (Romme Christensen et al. 2014). However, the potential 
dissociation of the sustained inflammatory suppression in this one patient, as 
shown by persistently suppressed FLC levels but continuing neurodegeneration, 
is informative. Clearly, these observations require replication in a larger cohort 
but generate interesting questions nonetheless. 
Although FLC levels have not been considered in relation to NfL, another mediator 
thought to reflect B-cell pathology, CXCL13 has been examined in this context in 
optic neuritis patients (Modvig et al. 2013). However, no correlation was seen in 
this group of MS patients, and may reflect the patient cohort at an early stage of 
MS (optic neuritis). In addition it also potentially highlights different aspects of B-
cell pathology as CXCL13 is chemotactic for B cells, whereas FLC are specific to 
antibody-secreting B-cells. Thus, understanding the relationship between FLC and 
NfL may be more instructive in furthering our understanding of disease 
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mechanisms, as it may shed light on the relationship between neurodegeneration 
and B-cell mediated inflammation. 
The final point of interest is the finding of greatly elevated NfL levels in patients 
with ‘acute’ neurodegenerative disease. The findings are not novel, with motor 
neurone disease, normal pressure hydrocephalus and multiple system atrophy 
(MSA) all demonstrating high levels of NfL (Norgren et al. 2003; Rosengren et al. 
1996; Rosengren et al. 2002; Tortelli et al. 2012; Tortelli et al. 2014; Pyykkö et al. 
2014; Jeppsson et al. 2013). The latter is particularly interesting, as higher levels 
are observed in MSA and progressive supranuclear palsy (PSP) than in the 
classical extrapyramidal disorder Parkinson’s disease (PD), and are thought to be 
due to the extensive deposition of aggregrates throughout the putamen, pallidum, 
pyramids and tracts, brainstem, cerebellum and spinal cord, rather than the 
restricted striato-nigral pathway located deep within the brain tissue, which is 
predominantly affected in PD. The high levels in ALS are also thought to reflect the 
large diameter and extended axons of the pyramidal tract, where 
neurodegenerative changes unsurprisingly liberate large quantities of NfL. There 
is relatively less data on NfL levels in cases of cervical compression leading to 
myelopathy, but it is expected that levels would be elevated in this context also. 
Thus the observation that FLC levels correlated with NfL level suggests that 
inflammation and neurodegeneration may occur in concert from the earliest 
stages of MS and are not necessarily directly linked to relapse status.  
5.7.3  CSF HMGB1 levels are elevated in both CIS patients and in other 
inflammatory neurological diseases, compared to non-inflammatory 
control subjects  
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We found increased HMGB1 levels in the CSF of patients with CIS and ONID as 
compared to OND. This implicates HMGB1 in the earlier phase of MS. However, 
there were methodological issues when analysing the ELISA results, mainly 
attributable to the poor sensitivity of the assay at the lower levels of detection. On 
the other hand, our findings were consistent with the guidance from the 
manufacturers, as we also found that the lower limit of detection was 
approximately 100pg/ml. This ELISA is the only assay currently available for 
quantitative measurement of HMGB1 protein levels in body fluids. It states itself 
that it is designed for measurement of HMGB1 levels in serum, cell culture 
supernatants and BALF, and that assessment of levels in other body fluids would 
need be interpreted carefully in light of this.  Accordingly, the majority of reports 
have concentrated on measurement of HMGB1 using the IBL-International ELISA, 
in the plasma (Ito et al. 2011; Sapojnikova et al. 2014). However, there are 
increasing reports in the CSF also, as shown in table 5.5.  
Neurological 
disorder  
Findings Reference 
H1N1-related 
encephalopathy 
High levels of serum, not CSF HMGB1 correlate 
with poor outcome 
(Momonaka 
et al. 2014) 
Paediatric TBI High levels of CSF HMGB1 correlate with poor 
outcome 
(Au et al. 
2012) 
Post-cardiac arrest High levels of CSF, not serum HMGB1 correlate 
with poor outcome 
(Oda et al. 
2012) 
Canine encephalitis HMGB1 detected in CSF of encephalitic dogs (Miyasho et 
al. 2011) 
Encephalopathy, 
meningitis, non-CNS 
febrile controls 
High levels of CSF HMGB1 in patients with 
bacterial/ aseptic meningitis but not encephalitis 
 (Asano et 
al. 2011) 
   
SAH High levels of CSF HMGB1 correlate with poor 
outcome 
(Nakahara 
et al. 2009) 
 
The most promising current use of the assay is its utility in identifying cases and 
prognosis of bacterial meningitis (Asano et al. 2011), and this is supported by 
Table  5.5. Studies reporting CSF HMGB1 levels using the IBL-International ELISA 
assay in different neurological disorders.  
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western blotting analysis of CSF HMGB1 levels also (Höhne et al. 2013b).  Other 
reports have identified its potential importance as a prognostic marker in other 
diseases (Momonaka et al. 2014; Au et al. 2012; Oda et al. 2012; Nakahara et al. 
2009). Interestingly, the recent study by Momonaka et al reported that serum 
HMGB1 levels were most useful as a prognostic marker in encephalopathy, 
whereas outcome following successful resuscitation following cardiac arrest is 
best predicted using CSF HMGB1 levels, rather than serum. The former may reflect 
the accepted role of HMGB1 in the systemic inflammatory response (Wang et al. 
1999), whereas the latter may reflect the profound neurodegenerative sequelae 
of cardiac arrest. Identification of HMGB1 in the CSF of MS patients was originally 
identified by Andersson et al, who performed western blotting analysis on 
ultrafiltrated CSF samples from 2 MS patients and 2 controls and found increased 
expression in the former (Andersson et al. 2008). Since then, quantitative 
determination of HMGB1 levels using the IBL-International ELISA in MS patients 
have only recently been reported in the literature and are summarised in table 5.6. 
 
 
 
 
 
Study  Plasma/ CSF HMGB1 levels (ng/ml) Reference 
  MS NMO Control   
1 Plasma/ CSF NA ND NA (Glasnović et al. 
2014) 
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2 Plasma 1.33* 3.99* ND (Wang et al. 
2012) 
3 CSF 1.9 ± 1.26 2.34± 
1.29* 
1.26 ± 0.49* (Wang et al. 
2013) 
4 Plasma 2.94 ± 2.78 2.65± 3.91 1.55 ± 2.07 (Akiyuki Uzawa 
et al. 2013) 
 CSF 1.43 ± 0.82 3.56± 3.76 0.85 ± 0.21   
 
 
 
 
Wang et al examined plasma HMGB1 levels in remission-phase MS (n=20) and 
neuromyelitis optica (NMO) (n=29) patients but did not include a control group 
(Wang et al. 2012). They found that levels were significantly higher in the NMO 
group than in the MS patients, whilst univariate logistic regression analysis 
showed a significant association of HMGB1 levels with NMO diagnosis. Despite the 
relatively small sample size, they used an HMGB1 cut-off of ≥2 ng/ml to generate 
a sensitivity of 89.7% and specificity of 95.0% for the diagnosis of NMO over MS. 
This may have a clinical application as although the initial presentation is often 
very similar, the management and prognosis of these two diagnoses is very 
different, thus any discriminatory investigations are of great use.  
Another group then repeated this patient group comparison but using CSF, and 
found no significant difference in HMGB1 levels between MS and NMO patients 
(Wang et al. 2013). However, NMO levels were significantly higher vs. control 
(non-inflammatory neurological disease) samples, although MS levels were not. 
Of note, the MS/ NMO patients included in this study were actively relapsing, but 
had not received any immunosuppression at the time of sampling. This may 
explain why the absolute levels are relatively high compared to our cohort, 
Table 5.6. Studies reporting HMGB1 levels using the IBL-International ELISA 
assay in MS and NMO/ control patients. The source fluid (plasma and/ or CSF) in 
which HMGB1 levels were measured is highlighted in column one. If absolute HMGB1 
levels were reported, this is also shown and describes mean values apart from study 
(1), which reports median values. CSF levels are shown in bold. *indicates significant 
difference between patient groups as highlighted by asterisk.  NA- not available. ND-
analysis not performed. 
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although it is interesting to note that the controls (ALS (n = 2), MSA (n= 3), sciatica 
(n = 4), and cervical spondylosis (n = 5)) themselves had relatively high levels of 
HMGB1 (see table 5.8).  We did not see any association between HMGB1 level and 
these diagnoses (as represented by the acute and chronic degenerative subgroups 
in our cohort) although there may be variation in clinical presentation which 
might account for these differences.  
A third group has also examined HMGB1 levels using the ELISA, but in both plasma 
and CSF and comparing MS/ NMO groups with a non-inflammatory control group 
(ALS n=11, spinocerebellar degeneration n=10, PD n=5 and PSP n=4). Again, all 
the MS/ NMO patients were relapsing and had not received acute treatment at 
time of sampling, although 30% of the MS patients were on DMT or oral 
prednisolone (dose not specified). In addition, there appeared to be considerable 
clinical heterogeneity within the groups, with a median EDSS score of 6.8 for the 
NMO (range: 1.5-9.0) and 3.5 (range 1.0-7.5) for the RRMS patients.  They found 
that NMO patients had higher HMGB1 levels than both MS and control patients 
(p<0.001 in both cases). They also found that MS patients had higher serum 
(p=0.002) and CSF (p<0.001) values vs. control patients, although once again the 
latter had a high mean value of 0.85 ± 0.21ng/ml. Similar to our findings, they also 
found a positive correlation between cell counts and HMGB1 levels, although 
demonstrated a stronger association (r=0.8; p<0.01), perhaps due to the fact that 
the patients were actively relapsing in this cohort. The high CSF HMGB1 levels in 
relapsing NMO patients also had evidence of severe blood-brain barrier 
disruption, with corresponding increases in CSF protein and Qalb and correlating 
with the CSF cell count, thus facilitating access of anti-AQP4 antibodies to 
astrocytes (Akiyuki Uzawa et al. 2013). The difference in HMGB1 levels in NMO vs 
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MS were attributed primarily to the fulminance of this inflammatory reaction, 
which is usually more severe in NMO. In addition, they postulated that another 
source of HMGB1 release would be during cell death processes, either via 
apoptosis or necrosis. The positive correlation between CSF GFAP and HMGB1 
suggested that astroctyes may provide this, given their known derangement in 
this condition (Howe et al. 2014). In keeping with our findings and others 
(Andersson et al. 2008), HMGB1 expression in astrocytes is less marked in the 
context of MS and would explain why they are unlikely to contribute to CSF levels 
compared to NMO.  
The fourth and final study is a recent report by Glasnovic et al (Glasnović et al. 
2014). They describe no difference in CSF HMGB1 levels between MS patients and 
control subjects. The patients had RRMS (2010 McDonald criteria), with a mean 
EDSS of 3.0±0.7 suggesting a reasonable degree of disability given they were 
described at ‘disease onset’. They state that samples were taken ‘..during the 
diagnostic procedure at the disease onset..’ and before receiving any 
immunosuppressive or immunomodulatory treatment. It is not clear how long the 
patients had been symptomatic, or indeed whether they were relapsing at time of 
CSF sampling. The control group had been taken from patients undergoing 
epidural anaesthesia prior to lower extremity surgery, although no detail is given 
of co-morbidities in this group. The data is presented graphically and whilst the 
absolute values are therefore not available for review, the median values seem to 
be lower in both control and MS patient groups compared to previous reports.  
The authors report that this is the first investigation of CSF HMGB1 levels in MS 
patients at ‘clinical onset ’. Our group of non-relapsing CIS patients represents an 
even earlier time-point in the disease course, and this is where we found the 
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difference between patients and controls. In accordance with the correlation with 
cell count, this supports the notion that HMGB1 is secreted by monocytes, 
including macrophages (Andersson et al. 2008). These are present in greater 
number during the early phase of the disease when inflammation dominates as 
well as during relapses, as shown by the reports presented above and in the biopsy 
findings as discussed in chapter 3.  
The possibility that other cell types may be releasing HMGB1 bears consideration. 
Unlike NMO, this is unlikely to be from astrocytes in MS, as shown in previous 
studies (Andersson et al. 2008) and in our own work as shown in Chapter 3 and 4. 
Given the profound neuropathological changes in neuronal cells observed in the 
earlier chapters, it is possible that dying or damaged neurones may also be 
releasing HMGB1 into the CSF.  
This is of particular interest when considering the high values of some the ‘control’ 
groups as described earlier, and may reflect the fact that many of these cases had 
profound neurodegenerative disease e.g. ALS. It is conceivable that HMGB1 is 
released from either inflammatory cells involved in ALS pathogenesis, or else from 
dying neurones themselves, with parenchymal HMGB1 finding its way to the CSF 
as described earlier (Hwang et al. 2013; Casula et al. 2011). Our OND group 
represented a larger cohort than these other studies, with a greater number of 
non-degenerative cases. Whilst sub-group analysis did not show any significant 
differences between degenerative and non-degenerative cases, it may still be 
underpowered to detect any differences, especially as they are likely to be 
relatively small. Certainly, the levels measured in these studies is far lower than 
the values generated in trauma or SAH for example. 
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Of note, none of these studies have included an ‘inflammatory’ neurological 
disease group, other than MS or NMO, which is surprising given the clear 
association between inflammatory cell count and HMGB1 levels. We actively 
sought to identify this group and found a statistically significant increase in CSF 
HMGB1 levels in this group within a relatively narrow range. This again may 
reflect the contribution of inflammatory cells in the generation of extracellular 
HMGB1, and indicates that CSF levels are not specific for MS.  
5.8  Limitations of CSF study  
The clinical cohort is heterogenous but carefully categorised, therefore will serve 
as an important resource for future studies also. However, the cross-sectional 
nature of the study is a limitation and further clinical outcome data would have 
been useful in order to allow prognostication in some of the patient groups. This 
will be done in the future as sufficient time has elapsed since the first recruited 
patients. In addition, further clinical data would have been helpful such as EDSS 
but this was not performed either in the initial consultation prior to LP or at time 
of LP as most patients had not been diagnosed with demyelinating disorder at 
point of sampling. This is related to the design of the study where patients were 
referred by Neurologists, usually from peripheral hospitals to UHB, and diagnosis 
of MS made at subsequent clinic visits. In addition, the relatively small numbers in 
some of the groups eg ONID and PPMS made it difficult to perform meaningful 
statistical analyses in some instances. 
The HMGB1 assay in particular had limitations when examining CSF levels in these 
patient groups. These include poor sensitivity of the assay at low HMGB1 
concentrations, which was relevant for many of the cases (table 5.6). It would be 
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worthwhile generating a standard curve with extra values at lower 
concentrations, in order to confirm accuracy of interpolated values. As it stands, , 
the HMGB1 ELISA assay is not optimised for measuring the relatively low 
concentrations in the CSF. 
In addition, since the assay was developed, the field of HMGB1 research has moved 
on a great deal and amount of HMGB1 as a stand-alone molecule is less informative 
than its modified self. Redox state, acetylation, methylation and other post-
translational modifications are critically important in understanding what 
function HMGB1 may be performing in this extracellular position. Thus, western 
blotting in order to detect acetylated protein, for example, would be worthwhile 
as it would demonstrate qualitative differences that are functionally more 
informative. One may postulate that the HMGB1 measured would be oxidised and 
acetylated, although this would need verification in future studies.  
5.9  Summary  
We collected a large, detailed cohort of CSF samples, which will serve as an 
excellent resource for future studies. Both FLC and NfL data demonstrated that 
the subjects are representative of MS and non-MS cohorts, due to similarity with 
published reports. Novel findings included identification of superiority of kFLC 
levels over OCB in detection of some MS cases, and was found to have a sensitivity 
of 96.2% and a specificity of 98.1% for diagnosing MS. In addition, unlike previous 
reports, we found that an index serum/CSF measurement was not required as 
specificity and sensitivity are maintained when evaluating levels of kFLC. A novel 
association between FLC and NfL was also observed, highlighting the possible 
association between B-cell mediated inflammation and degenerative processes in 
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MS. Finally, our efforts to investigate HMGB1 as a novel biomarker in MS 
demonstrated levels are indeed significantly increased in CIS vs OND control 
patients. However, levels were also significantly increased in the ONID patient 
group and positively correlated with cell count. This suggests that increased CSF 
HMGB1 levels may reflect inflammatory cell production rather than MS-specific 
pathological processes per se. In addition, the HMGB1 measured is not modified 
in any way, which we know has major implications in directing its function. 
Finally, the absolute levels measured were relatively low in this cohort, reflective 
of normal clinical practice as most LPs will not be performed during acute relapse. 
However, the assay is not designed to measure at these low CSF levels, so for all of 
these reasons, we would conclude that the HMGB1 ELISA is not optimised to be 
used as a biomarker in clinical management of MS patients, but it does provide 
useful data for research purposes. 
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6.  
Exploration of the relationship between the LRRIg molecules and HMGB1 in MS 
 
 
 
 
 
 
 
 
 
 
6.1 Introduction 
The widespread increase in HMGB1 expression in MS patients demonstrated in 
the previous chapters adds to our understanding of the changes taking place 
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throughout brain tissue during the course of the disease process. The CSF studies 
detailed in Chapter 5 demonstrate that HMGB1 is elevated in the CSF of early MS 
vs. control patients and that levels correlate with inflammatory cell count, despite 
this being a non-relapsing cohort of patients. Thus, along with release from 
damaged cells, it may also be secreted by inflammatory cells and subsequently 
find its way to the extracellular space to exert pro-inflammatory functions as 
previously suggested (Andersson et al. 2008).  
In addition, I have demonstrated increased HMGB1 expression in non-lesional 
regions compared to non_MS control patients. This raises the possibility that 
another facet of HMGB1 expression may reflect endogenous protective 
mechanisms in OGD. This is due in part to the large number of cells demonstrating 
increased expression of HMGB1, in addition to recent reports suggesting this 
function, although there is likely to be a delicate balance between protective and 
destructive function (T Zeis et al. 2009; Zeis et al. 2008; Bsibsi et al. 2013b).  
As discussed in Chapter 1, the biology of HMGB1 is complex and its eventual 
function depends on both post-translational modification and sub-cellular 
localisation. Thus, a simple knock-down solution is unlikely to result in disease 
modification in MS, although it may be used in relapse akin to steroids, as 
suggested by others (Andersson et al. 2008; A Uzawa et al. 2013). My work 
suggests that HMGB1 may also serve as a ‘flag’ of disease activity, which we have 
shown takes place distal to the active lesions and involves CNS-resident cells.  
Given that its expression and/or release can trigger a cascade of variable 
outcomes, in this final body of work we wished to take these observations forward 
using an in-vitro model to explore possible sequelae following HMGB1 stimulation 
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alongside other mediators. In addition, we focussed our attention on a novel 
family of CNS-enriched molecules associated with cell survival and function, some 
of which are linked to HMGB1, in an effort to hone in on more specific events 
linked to HMGB1 biology. These are the LRRIg molecules- AMIGO-1, -2 and -3 and 
LINGO-1. As discussed in Chapter 1, General introduction, AMIGO-1 and -2 have 
been shown to have important roles in neurite fasciculation, neuronal signalling 
and survival (Zhao et al. 2011; Kuja-Panula et al. 2003; Ono et al. 2003b; Peltola et 
al. 2011; Rabenau et al. 2004; Ono et al. 2009b), whilst AMIGO-3 and LINGO-1 both 
appear to bind to the NgR1, potentiating neurodegenerative pathways via RhoA 
activation (Mi et al. 2004; Ahmed et al. 2013). 
As the most striking changes in HMGB1 expression described in chapters 3 and 4 
were observed in OGD- a critically important cell in MS biology- we used the 
immortalised MO3.13 OGD-like cell line (McLaurin et al. 1995) in the first part of 
this chapter. This enabled us to model expression patterns of HMGB1 in response 
to pro-inflammatory and anti-inflammatory stimuli in this cell type, to simulate 
aspects of the micro-environment in the MS brain.  We also explored the 
association between HMGB1 and the LRRIg molecules in this setting, in addition 
to examining whether other pro/anti-inflammatory cues influenced LRRIg 
expression. In the latter part of the chapter, we examined novel expression 
patterns of the AMIGO family of molecules using both autopsy and actively 
demyelinating, human biopsy tissue.  
In summary, the purpose of this chapter of work was to examine potential 
downstream effectors of HMGB1 function and was primarily concerned with 
hypothesis generation 
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6.2  Hypotheses 
1. HMGB1 influences expression of LINGO-1 and the AMIGO family of 
proteins. 
2. AMIGO-1 and AMIGO-2 expression is reduced in a pro-inflammatory 
environment whereas AMIGO-3 and LINGO-1 expression is increased 
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6.3  Aims 
1. To examine factors influencing the expression of HMGB1 in an in-vitro 
model using the immortalised MO3.13 OGD cell-line  
2. To compare the impact of HMGB1 stimulation vs. other pro- and anti-
inflammatory mediators on expression of LRRIg molecules in MO3.13 cells 
3. To perform a novel investigation of LRRIg molecule expression patterns in 
human brain tissue, comparing non-inflamed control (non-MS) vs. MS 
patients 
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 6.4  Methods 
6.4.1 MO3.13 cell culture 
The immortalised human-human hybrid cell line expressing phenotypic 
characteristics of primary oligodendrocytes was used in this chapter of work 
(McLaurin et al. 1995) and has been discussed in Chapter 2, General Methods. In 
brief, cells were cultured in high glucose formulation of DMEM supplemented with 
10% Fetal Bovine Serum Gold, with added Pen/Strep (1X). Cells were maintained 
in 75cm2 tissue-culture flasks (Greiner Bio-One, Frickenhausen,Germany) at 370C 
(humidified) with 5% CO2 and passaged at 70% confluency. Approximately 5x105 
cells were added to each well in 6-well plates and left for 24h to allow adherence. 
Media was then replaced with low-serum DMEM, (0.5% serum) and left for a 
further 24h. Serum reduction was employed as it has been reported that this led 
to the expression of the mature oligodendrocyte marker (GST-π) in this cell line 
(Haq et al. 2003).  
6.4.2 Cell culture treatments  
A variety of pro-/anti-inflammatory treatments were used to stimulate the 
MO3.13 OGD-like cell line. HMGB1 was used for the first time and further 
background detailing its use in other cell types is given below. All cell culture 
treatments were stimulated for 24h and used at a standard concentration of 
10ng/ml cytokine in low-serum DMEM (0.5%) apart from bvHMGB1 where we 
used a range of doses. 
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Baculoviral (bv) HMGB1 
HMGB1 was identified as a potent proinflammatory mediator when applied 
exogenously (Wang 1999), but the original recombinant protein used in these 
studies was bacterially-derived from E.Coli. Further work compared this form of 
the protein to that derived following expression of the protein in a baculoviral 
system, producing a more pure form of the peptide (Parkkinen et al. 1993; 
Rouhiainen et al. 2007). They demonstrated that whilst the purified peptide 
isolated from eukaryotic cells can itself still elicit TNFα and nitric oxide production 
from mononuclear cells, the proinflammatory activity is much reduced when 
compared to HMGB1 produced from bacterially-produced HMGB1. This difference 
between baculoviral and bacterially-derived HMGB1 was explained by the fact 
that the HMGB1 molecule is well-known to avidly complex with other molecules, 
particularly the bacterially-derived lipophilic polypeptides present in E.Coli.  
To consider the effects of HMGB1 itself as opposed to highly inflammatory 
contaminants; we chose to use bvHMGB1 in our treatments (Novus Biologicals: 
NBC1-18488). We performed dose response relationships as there is limited data 
concerning standard HMGB1 stimulation doses in cell culture conditions. 
6.4.3 RNA extraction and RT-PCR 
Cell supernatant was removed and RNA extracted from cultured cells using the 
RNEasy Mini Kit (Qiagen, Hilden, Germany) as described in the General Methods, 
Chapter 2. Concentration was then determined at OD260 using a NanoDrop ND-
2000 UV spectrophotometer (Thermofishes, Surrey, UK). 1μg of RNA was used for 
generation of cDNA using the High Capacity cDNA Archive kit (Applied 
Biosystems, Warrington, UK).  
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6.4.4 Real-time (RT) PCR 
As detailed previously, target and house-keeping (GAPDH) gene expression was 
determined using Applied Biosystem “assay on demand” primer-probes along 
with Lightcycler® 480 Probes Master reagents for the RT reaction mixture (Roche 
Diagnostics, Switzerland). Samples were added to the RT reaction mixture to a 
total volume of 5μl and loaded in duplicate in multiplex format (i.e. target and 
house-keeping gene in each well) into white 384-well plates. Ct values were 
generated by the LightCycler 480 machine (Roche Diagnostics, Switzerland), and 
∆CT values calculated with reference to GAPDH. As outlined previously, arbitrary 
units (AU) [AU = 1000 x (2- ∆Ct)] and fold-change (R/Q) [R/Q = 2-∆∆Ct) using 
treatment – control condition ∆Ct values to generate ∆∆Ct values, were then 
calculated. Genes and NCBI reference are shown in table 6.1.                                                                                                                                                                                                                         
 
Table 6.1. List of genes used for RT-PCR with corresponding NCBI and Applied 
Biosystems reference codes.  
6.4.5 Protein extraction and determination of concentration 
Cells were harvested, pelleted and cell culture supernatants removed. Pellets were 
then lysed using RIPA buffer (Sigma R0278) with added protease inhibitor 
GENE	 NCBI	REFERENCE	(HUMAN)	 AB	ASSAY	REF	
GAPDH	 NM_002046.3	 Hs02758991_g1	
HMGB1	 NM_002128.4	 Hs01590761_g1	
AMIGO-1	 NM_020703.2	 Hs00827030_g1	
AMIGO-2		 NM_001143668.1	 Hs00406170_g1	
AMIGO-3	 NM_198722.2	 Hs03055344_s1	
LINGO-1	 NM_032808.5	 Hs00262326_s1	
RAGE	 NM_001136.4	 Hs00542584_g1	
TLR-4	 NM_138554.3	 Hs00152939_m1	
	
 189 
 
cocktail (PIC) (Roche Diagnostics, Basel, Switzerland), centrifuged and the 
clarified protein supernatant collected as outlined in the General Methods, chapter 
2. Protein concentrations were then determined using the BioRadDC kit (Bio-Rad, 
Hemel Hempstead, UK).  
6.4.6 Immunoblotting  
 Immunoblotting was used to determine total protein expression of HMGB1 and 
the LRRIg molecules under differing cell culture conditions using Novex® 
NuPage® 4-12% Bis-Tris protein gels under reducing conditions (Invitrogen, 
Paisley, UK). Proteins were transferred to PVDF membranes using the Trans-
Blot® Turbo™ machine (Bio-Rad, Hemel Hempstead, UK).  
Primary antibodies were all polyclonal antibodies raised in rabbit, with anti- 
HMGB1, anti-AMIGO-1, anti-AMIGO-2, anti-AMIGO-3 from Abcam (Cambridge, 
UK) whilst anti-LINGO-1 antibody was from Upstate (Dundee, UK). All antibodies 
were used at a dilution of 1:500, except HMGB1 which was used at a dilution of 
1:1000. Secondary antibodies used for HMGB1 and LRRIg primary antibodies 
were against rabbit, at 1:5000. Membranes were stripped and re-probed for HRP-
conjugated β-actin 1:5000 (Genscript, New Jersey, USA). Bands were visualised 
using the ECL detection kit (GE Healthcare, Bucks, UK) and bands visualised using 
the ChemiDoc™ XRS system. Densitometry was calculated using the in-built 
software. 
6.4.7 Immunohistochemistry 
6.4.7.1 Patient demographics 
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As described in detail in chapter 4 tissue blocks were obtained from the UK MS 
Brain Bank. Specific patient characteristics are demonstrated in table 6.2. 
 
Table 6.2. Demographic data for patient used in LRRIg neuropathological 
study. PR= progressive relapsing; SP= secondary progressive; PP= primary progressive; 
NK= not known 
 
6.4.7.2 Immnunohistochemical(IHC) analysis  
IHC analysis was performed as described in Chapter 2, Materials and Methods, and 
was carried out using the Leica Bondmax automated stainer. Antibodies used 
were anti-MBP, -CD68, -CD3, -GFAP and –HMGB1 as described in table 2.1, and 
anti-AMIGO-1, -2 (10μg/ml) and–LINGO-1 (100 μg/ml) as described above. The 
AMIGO-3 antibody was raised in mouse following in-house design, with a peptide 
sequence taken from the extracellular signalling sequence as the immunogen, 
with monoclonal specificity. All antibodies were extensively optimised in order to 
achieve an acceptable balance between signal: noise. Sequential sections were 
AGE SEX
MS	
SUBTYPE	
DISEASE	
DURATION		(Y) PMI	(H) CAUSE	OF	DEATH
MS
42 F PP 6 11 BRONCHOPNEUMONIA
57 M PR 33 21 MULTIPLE	SCLEROSIS
50 M SP NK 24 BRONCHOPNEUMONIA
73 M PP 52 20
LEFT	VENTRICULAR	FAILURE,	
BRONCHOPNEUMONIA
39 F SP 21 18 BRONCHOPNEUMONIA
44 F SP 19 20 URINARY	TRACT	INFECTION;	SEPSIS
53 M SP 33 14 SEPTICAEMIA	DUE	TO	UTI
77 M SP 39 19
BRONCHOPNEUMONIA;	
MYOCARDIAL	INFARCTION
40 M SP 16 27 BRONCHOPNEUMONIA
CONTROL
82 M N/A N/A 21 NK
78 F N/A N/A 33 MYELOID	LEUKAEMIA
67 F N/A N/A 33
ACUTE	ARRHYTHMIA,	INTESTINAL	
OBSTRUCTION
71 F N/A N/A 24 ACUTE	BRONCHITIS
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used to delineate lesion borders and cellularity by staining with H&E, MBP and 
CD68 in order to verify presence of ‘active’ and ‘chronic active’ lesions in-house. 
This was also useful for ascertaining whether there was evidence of demyelination 
(GM/ WM) in the ‘normal-appearing white-matter’ tissue blocks in our hands, as 
well as in non-MS control tissue. Comparative IR staining intensity was not 
assessed between the different molecules, partly due to the differing 
concentrations of antibodies used, but was assessed within different tissue types.  
 
6.5  Statistical analysis 
Prism for Mac Version 5.0 (La Jolla, California, USA) was used to perform statistical 
analysis. For in-vitro work, both ∆Ct and fold-change values used for PCR work 
and densitometric protein band analysis were used in statistical tests. In-vitro 
data was normally distributed and comparisons between multiple treatments 
were analysed using one-way analysis of variance (ANOVA) with Tukey’s post-hoc 
multiple comparison test used to account for type 1 errors. Continuous data was 
expressed as mean and standard error of the mean (SEM). The threshold for 
statistical significance was set at p<0.05. 
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6.6  Results 
IN-VITRO DATA 
6.6.1 HMGB1 is expressed in the MO3.13 cell line, although its receptors 
TLR4 and RAGE are weakly detectable at baseline. 
At baseline, HMGB1 mRNA expression is evident, consistent with its ubiquitous 
expression in most cells (Yang et al. 2013). However, basal levels of its two key 
receptors, TLR4 and RAGE were barely detectable. 
 
Figure 6.1. Baseline mRNA expression of HMGB1 and its receptors in the 
oligodendroglial cell line, MO3.13. Total mRNA expression for each of the genes is 
presented as arbitrary units (AU). Data are expressed as mean ± SEM. n=3. 
 
6.6.2 Stimulation of MO3.13 cells with TGF-β1 increases HMGB1 mRNA 
expression but total protein levels are unchanged  
TGF-β1 significantly increased HMGB1 mRNA expression as compared to IFNγ or 
IL-1β (p=0.005 and P=0.016 respectively) as shown in figure 6.2A. However, this 
phenomenon was not observed at the total protein level using immunoblotting 
(figure 6.2B) as semi-quantitative densitometry did not show any significant 
difference between the control and the same range of mediators (figure 6.2C). 
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6.6.3 HMGB1 receptors, RAGE and TLR4 are significantly upregulated 
following HMGB1 stimulation of MO3.13 cells. 
MO3.13 cells demonstrate mRNA expression of the HMGB1 receptors, RAGE and 
TLR4, upon stimulation with bvHMGB1 (figure 6.3). Interestingly, TGF-β1 also 
significantly increased RAGE mRNA expression compared to the other mediators, 
similar to HMGB1. However, TLR4 demonstrated marked sensitivity to bvHMGB1 
stimulation, whilst treatment with the other mediators did not produce a 
significant change in expression compared to control. 
 
The effect on RAGE expression was maintained at total protein with HMGB1 
treatment compared to other treatments, but was lost with TGF-β1 stimulation. 
Classically pro-inflammatory stimuli appeared to reduce expression compared to 
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control (figure 6.4A). Assessment of TLR4 expression using western blotting was 
not possible due to poor antibody specificities. 
                 
Figure 6.4. Total protein expression of RAGE following exposure to multiple 
cytokines in oligodendroglial-like cells. (A) shows a representative western blot and 
semi-quantitative densitometric analyses demonstrating that expression of RAGE in 
MO3.13 cells is increased at the total protein level by HMGB1 stimulation, and this was 
weakly significant. All cytokine treatments were normalised to low serum control values.  
Data are expressed as mean ± SEM (n=3) 
 
 
6.6.4 Expression of LRRIg molecules is responsive to treatment with 
HMGB1 in MO3.13 cells 
 
6.6.4.1 AMIGO-1 expression is increased by high doses of HMGB1 at both 
mRNA and total protein level 
As shown in figure 6.5, HMGB1 stimulation of MO3.13 cells showed a dose-
dependent increase in AMIGO-1 mRNA expression, with a peak fold-change at 
100ng/ml. This same pattern was replicated at the protein level using western 
blotting analysis and interestingly, all other cytokines appeared to suppress 
AMIGO-1 expression at the tested doses as compared to control. 
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Figure 6.5. High-dose bvHMGB1 stimulation increases AMIGO-1 mRNA and total 
protein levels. (A) Dose-response curve demonstrating increased effect of bvHMGB1 on 
AMIGO-1 mRNA expression at 100ng/ml vs. 5 or 20ng/ml (n=3; p<0.05). (B) mRNA levels 
of AMIGO-1 following stimulation by a panel of cytokines (n=6). (C) total protein levels of 
AMIGO-1 following stimulation by a panel of cytokines, as assessed by western blotting. 
bvHMGB1 dose units = ng/ml. Asterisks denote significance of bvHMGB1 treatment vs 
cytokine treatment. *p<0.05 **p<0.005 ***p<0.0005 Statistical test used: ANOVA with 
Holm-Sidak post-hoc multiple comparison test. Data are expressed as mean±SEM (n=3-6). 
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6.6.4.2 AMIGO-2 mRNA expression is increased following HMGB1 
stimulation 
As shown in figure 6.6A, high levels of AMIGO-2 mRNA expression were evident at 
all doses of bvHMGB1 stimulation. Despite an apparent trend towards lower doses 
stimulating greater expression of AMIGO-2, there is variability in the data as 
shown by the error bars. When comparing total mRNA levels of AMIGO-2 
following stimulation by our panel of cytokines, expression was reduced 
compared to control in response both pro-and anti-inflammatory cytokine 
treatments, particularly IL-6 and TNFα, where the latter appeared to entirely 
supress expression. However, once again there appears to be an HMGB1-specific 
response, where expression is upregulated compared to all other treatments, and 
this is weakly significant as shown on in figure 6.6B. The HMGB1 dose used in this 
experiment was 100ng/ml, as this showed the least variability in dose-response.  
However, expression of total protein levels of AMIGO-2 using western blotting 
demonstrated that the situation was more complex. Multiple bands at differing 
molecular weights were observed, with a faint band at the expected MW of 55kDa. 
A more prominent band at approximately 30kDa was consistently evident, 
although the significance of this is unclear. 
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Figure 6.6. HMGB1 increases AMIGO-2 mRNA levels, but less obviously at the 
protein level. (A) Dose-response curve demonstrating effect of bvHMGB1 on AMIGO-2 
mRNA expression. (B) mRNA levels of AMIGO-2 following stimulation by a panel of 
cytokines. (C) total protein levels of HMGB1 following stimulation by a panel of cytokines, 
as assessed by western blotting (arrow: expected band at 55kDa). bvHMGB1 dose units = 
ng/ml. Asterisks denote significance of bvHMGB1 treatment vs cytokine 
treatment.**p<0.005 ***p<0.0005. Statistical test used: ANOVA with Holm-Sidak post-hoc 
multiple comparison test. Data are expressed as mean ± SEM (n=3-6). 
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6.6.4.3 AMIGO-3 expression is increased by low doses of bvHMGB1 
In contrast to AMIGO-1 data, AMIGO-3 mRNA expression levels were highest at 
lower doses of bvHMGB1 stimulation, as shown in figure 6.7A. Compared to the 
other cytokines used, the bvHMGB1-stimulated response produced a significantly 
greater effect on mRNA expression as demonstrated in figure 6.7B. 
 
Figure 6.7. bvHMGB1 treatment increases mRNA expression of AMIGO3. (A) Dose-
response curve demonstrating expression of AMIGO3 with increasing doses of 
bvHMGB1, (B) AMIGO3 expression is unchanged by either pro- or anti-inflammatory 
cytokine treatments. However, as noted with its two homologues, expression is 
upregulated following stimulation by bvHMGB1 compared to all other treatments. 
HMGB1 dose used: 5ng/ml. Asterisks denote significance of bvHMGB1 treatment vs 
cytokine treatment.***p=0.0001 ****p<0.0001Statistical test used: ANOVA with Holm-
Sidak post-hoc multiple comparison test. Data are expressed as mean ± SEM (n=3-6). 
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Unfortunately, it was not possible to perform western blotting to assess this effect 
at the protein level as a variety of antibodies tested failed to produce positive 
bands. 
6.6.4.4 LINGO-1 expression is increased by bvHMGB1 stimulation. 
bvHMGB1 consistently increased expression of LINGO-1 mRNA compared to 
control at all doses (figure 6.8A). It also stimulated almost 5-times greater fold-
change expression of LINGO-1 than the other cytokines used.  
                                                                            
Figure 6.8. bvHMGB1 treatment significantly increases mRNA expression of 
LINGO-1. (A) LINGO-1 mRNA expression is increased compared to control at all 
treatment doses of bvHMGB1 (B) LINGO1 expression is significantly increased following 
stimulation by bvHMGB1 compared to other treatments. HMGB1 dose used in (B): 
20ng/ml. Asterisks denote significance of bvHMGB1 treatment vs cytokine 
treatment.*p<0.05 **p<0.008Statistical test used: ANOVA with Holm-Sidak post-hoc 
multiple comparison test. Data are expressed as mean±SEM (n=3-6).  
 201 
 
Interestingly however, stimulation with IL-1β, IL-6 and TNFα also appeared to 
increase its expression approximately two-fold, with the difference between 
bvHMGB1-stimulated expression and these mediators being of correspondingly 
weaker significance (p<0.05) than between bvHMGB1 and IFNγ and TGFβ1 
(p<0.08).  
 
 
Figure 6.9.  Expression of LINGO-1 is increased in low-serum conditions and by 
bvHMGB1 and IL-1β stimulation. (A) demonstrates that low-dose bvHMGB1 
stimulation increased LINGO1 expression compared to higher doses, with IL-1β also 
consistently inducing expression compared to the other cytokines tested (B)LINGO-1 
expression is reduced in high-serum and induced when placed in low-serum conditions. 
(n=3). 
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When assessing total protein levels, expression of LINGO-1 was similar to control 
at lower doses of bvHMGB1 as shown in figure 6.9A, but appeared to be 
suppressed at higher doses. In addition, expression was consistently induced by 
IL-1β in particular, but was suppressed by both pro-inflammatory (TNFα, IL-6) 
and anti-inflammatory (TGF-β1) mediators. Interestingly, serum is known to 
contain TGF-β and the expression of LINGO-1 is similarly reduced in high-serum 
conditions as with TGF- β1 stimulation. This suggests a specific role for HMGB1 
and IL-1β in inducing expression of LINGO-1.  
I then decided to compare the expression pattern of LINGO-1 in high vs. low-
serum conditions to test whether global cellular stress precipitated by this change 
in treatment conditions produced differential LINGO-1 expression patterns. The 
results were striking, as LINGO-1 expression was barely detectable in high serum 
conditions and clearly induced in low-serum conditions, as shown in figure 6.9B. 
Possible reasons for this are discussed in section 6.7.  
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NEUROPATHOLOGICAL EXPRESSION OF LRRIg PROTEINS 
I performed a preliminary analysis of the expression pattern of these novel 
molecules in human brain. Using tissue from the UK MS Brain Bank as described 
in Chapter 4, expression patterns in non-MS control brain and in MS lesional and 
non-lesional tissue were assessed.  
6.6.5 Neuronal and stromal expression of AMIGO-1 and AMIGO-2 is robust 
in non-MS control brain tissue but markedly reduced in non-lesional 
MS brain tissue 
Immunohistochemical analysis of non-MS control brain tissue revealed the 
expression of AMIGO-1 and AMIGO-2 was most prominent in neurons within the 
grey matter (GM), where a characteristic, punctate staining pattern was evident 
(Figure 6.10A and 6.11A), reminiscent of the neuronal staining pattern observed 
in mice- Chapter 1, General introduction figure 1.8 (Peltola et al. 2011). In the MS 
tissue, both staining intensity and frequency of positively staining neurons were 
reduced. In the control white matter (WM), staining in OGD was discernible, 
though faint and in both GM and WM, stromal staining was prominent. However, 
in both NAWM and non-lesional regions of AL tissue blocks from MS patients, 
expression appeared to be reduced overall, with minimal staining, if any, in the 
white matter.  
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Figure 6.10 AMIGO-1 expression pattern in post-mortem human brain tissue. 
Expression demonstrated in both grey and white-matter as indicated in non-MS control 
(A, D), normal-appearing white matter (NAWM) (B,E) and non-lesional regions of active 
lesional (AL) tissue blocks (C,F). Inset in (A) and (C) illustrate IR in neurons (x63). Tissue 
blocks taken from inferior/ superior frontal gyri. Scale bar = 100m. 
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Figure 6.11. AMIGO-2 expression pattern in post-mortem human brain tissue. 
Expression demonstrated in both grey and white-matter as indicated in non-MS control 
(A, E), normal-appearing white matter (NAWM) (B,E) and non-lesional regions of active 
lesional (AL) tissue blocks (G,F). Inset in (A) and (C) illustrate IR in neurons (x63). Tissue 
blocks taken from inferior/ superior frontal gyri. Scale bar = 100m. 
 
6.6.6 AMIGO-3 expression is induced at low levels in active lesional MS 
tissue but is undetectable in non-MS control tissue. 
      In contrast to AMIGO-1 and -2, AMIGO-3 was not expressed in non-MS control 
tissue. Conversely, in AL tissue blocks, expression was evident in glial cells in the 
AL and in non-lesional WM, which morphologically appeared to be activated 
microglia (figure 6.12F; arrowhead). In the GM of AL tissue blocks, neuronal nuclei 
displayed evidence of faint IR, with weak staining also evident in the cytoplasm 
(figure 6.12C; arrow).  
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Figure 6.12. AMIGO-3 expression pattern in post-mortem human brain tissue. Non-
MS control (A, D), normal-appearing white matter (NAWM) (B,E) and non-lesional 
regions of active lesional (AL) tissue blocks (C,F). AMIGO-3 expression is undetectable in 
all tissue types, except faint IR in MS grey matter. However, the fine granularity and 
cresenteric appearance in neurons, (figure 6.12B; arrow), means we cannot exclude the 
possibility that this pattern of IR may represent lipofuscin staining. In MS white matter, 
AMIGO-3 positive cells with probably microglial morphology could be seen (arrowhead). 
Tissue blocks taken from inferior/ superior frontal gyri. Scale bar = 100m. 
 
6.6.7 LINGO-1 is robustly expressed in non-MS control patients, but is 
relatively reduced in MS patients in post-mortem tissue 
The most consistent difference between control and MS patients was in the 
neuronal expression pattern of LINGO-1 in the GM. This was characterised by an 
intensely immunoreactive, punctate appearance in neurons in the non-MS control 
cortex, evident over the neuronal soma and proximal dendrites, as seen in figure 
6.13D. The pattern was similar to the changes observed in AMIGO-1 and -2 
staining. Interestingly, this staining pattern was evident in the GM of NAWM tissue 
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blocks although there appeared to be fewer cells displaying it (figure 6.13E). In 
both demyelinated (data not shown) and non-lesional regions of the cortex, this 
characteristic pattern was clearly different as virtually all cells demonstrated a 
more homogenous staining pattern with fine granularity evident at higher power, 
as seen in 6.13F. In addition, increased IR along axons themselves was seen in the 
GM (inset).  
In the lesional white matter, as shown by the dotted line in figure 6.13C, LINGO-1 
staining was greatly reduced. This may reflect reduced expression within the 
stroma, but also may highlight reduction of axonal/ cellular expression, as the 
designated ‘AL’ tissue blocks were in fact late active or chronic actively 
demyelinating lesions.  
In non-lesional WM the degree of stromal staining was greater in non-MS control> 
MS NAWM> MS AL tissue blocks, as shown in figures 6.13G-I. However, it did not 
appear as if OGD themselves expressed LINGO-1 in the nucleus or cytoplasm 
(6.13G; inset) and instead, a punctate pattern throughout the stroma was seen. 
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Figure 6.13. LINGO- expression pattern in post-mortem human brain tissue. 
Expression demonstrated in both grey and white-matter as indicated in non-MS control 
(A, D, E), normal-appearing white matter (NAWM) (B,E,H) and non-lesional regions of 
active lesional (AL) tissue blocks (C, F, I). (A-C) Low magnification view. NB In figure 
6.14C, the dotted lines represent a lesional region of active/ chronic active demyelination. 
(D) All neuronal cells demonstrate punctate staining pattern; inset- located around 
neuronal soma and proximal dendrites. Arrow- OGD do not demonstrate IR. (E) Similar 
staining pattern in NAWM but fewer positive cells (F) Punctate staining pattern 
significantly reduced. Inset: staining pattern around soma more diffuse with clear axonal 
staining. Tissue blocks taken from inferior/ superior frontal gyri. Scale bar (A-C) = 1mm; (D-
I) = 100m; inset in (D) and (F) = 10m. 
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6.6.8 LRRIg expression pattern in early active lesional (EAL) tissue, from 
a biopsy sample in a patient with clinically isolated syndrome (CIS). 
The tissue characteristics of this biopsy sample have been addressed in detail in 
chapter 3. In figure 6.14A-D, the demonstration of florid inflammatory cell 
infiltrate with evidence of myelin fragmentation as opposed to demyelination per 
se (data not shown), illustrates the characterisation of this as an early 
inflammatory lesion as per ICDNS classification (www.icdns.org). In figure 6.15A, 
AMIGO-1 expression pattern is weak overall, although the finely spiculated 
appearance in lipophages may be attributable to myelin breakdown products, 
suggesting that AMIGO-1 may be expressed on the myelin sheath. In figure 6.15B, 
the background stromal staining pattern of AMIGO-2 is relatively increased, as is 
cell-specific staining in OGD and in macrophages. Interestingly it is relatively 
weaker in lipophages, suggesting that different types of macrophages/ microglia 
may express AMIGO-2.  
AMIGO-3 staining is undetectable in non-MS control autopsy tissue, and faintly 
evident in AL tissue blocks (figure 6.12). However, when comparing post-mortem 
and early active lesional biopsy tissue, expression was profoundly different. In 
spite of caveats relating to comparison between biopsy and autopsy tissue as 
discussed, the staining pattern in the early active lesional biopsy tissue was 
markedly increased using the in-house mouse monoclonal anti-AMIGO-3 
antibody. Once again isotype control antibody testing did not reveal evidence of 
non-specific IR. The predominant subcellular localisation was nuclear, and 
evident in macrophage, oligodendrocytes and–strikingly- neuronal nuclei. Anti-
AMIGO-3 IR overall was greater in the active lesional regions shown in figure 
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6.15C. In non-lesional white matter it demonstrates a punctate pattern adjacent 
to OGD (figure 6.16C; inset). The latter demonstrated clear IR around the 
chromatin structure within the nuclei of virtually all neuronal subtypes 
throughout the cortex and was particularly noticeable in large pyramidal nuclei. 
Despite the propensity of HMGB1 to translocate to the neuronal cytoplasm, its 
predominant staining pattern in non-lesional grey matter neurons was also 
nuclear as shown below in figure 6.19. LINGO-1 IR also shows increased stromal 
staining with a prominent, punctate pattern evident in lipophages- again 
suggesting myelin breakdown products. In addition, increased IR in OGD-like cells 
are also seen in this tissue type, which is further illustrated in figure 6.16, below. 
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Figure 6.14. Characterisation of early active lesional tissue, taken from a biopsy 
sample in a patient with clinically isolated syndrome (CIS). (A)-(D) demonstrate the 
basic staining pattern in this tissue block. (A) cytoarchitectural pattern as shown using 
H&E staining;inset- gemistoctic astrocytes with mitotic nuclei are evident (arrow), 
immediately adjacent to foamy macrophages (circle). (B) anti-CD3-positive cells 
demonstrating presence of lymphocytes in both a perivascular distribution and 
occasional cells migrating into the parenchyma. (C) numerous anti-CD68-positive cells 
are evident, predominantly lipophages morphologically (D) anti-GFAP-positivity is 
evident, demonstrating both gemistocytic astrocytes and the intense background glial 
fibrillary reaction in this lesion type. Scale bar = 100m. 
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Figure 6.15. LRRIg expression pattern in early active lesional tissue, taken from a 
biopsy sample in a patient with clinically isolated syndrome (CIS). (A)-(D) LRRIg 
expression pattern in this block. (A) shows minimal cell-specific or stromal AMIGO-1 IR, 
including in lipophages (inset; circle) although a punctate staining pattern is evident in 
the latter suggestive of myelin breakdown products. (B) AMIGO-2 IR is evident in the 
nuclei of cells including oligodendrocytes (arrow) but not in lipophages per se (circle). 
(C) AMIGO-3 IR appears to be predominantly nuclear, particularly in macrophages whilst 
IR is not evident in astrocytes (arrows) (D) LINGO-1 IR demonstrates a similar staining 
pattern to AMIGO-3 although pale, cytoplasmic IR can also be seen in astrocytes (arrow).  
Scale bar = 100m. 
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6.6.9 LRRIg expression pattern in non-lesional white matter, from an early 
active lesional tissue block 
As discussed in chapter 3 and 4, non-lesional regions were initially classified as 
being ≥7mm from the lesion border, with an intact myelin pattern and lack of 
significant inflammatory cell infiltrate or perivascular lymphocytic cuffing.  
In this context, once again AMIGO-1 IR was weak, with an occasional OGD-like cell 
displaying evidence of staining as seen in the inset in figure 6.16A. AMIGO-2 IR, 
however, clearly demonstrated OGD expression, as shown in figure 6.16B and 
stromal IR was also stronger than that observed in the autopsy material.  Once 
again, the AMIGO-3 staining pattern was markedly different in this tissue type, 
shown in figure 6.16C. Both OGD and macrophages appear to express AMIGO-3 
and staining was apparently upregulated in those OGD which demonstrated 
shrinkage in size and nuclear condensation- possibly highlighting pyknosis (inset; 
arrow). Anti-LINGO-1 IR in a punctate pattern along axons was evident in figure 
6.16D, but in addition, apparent cell-specific IR was also seen in OGD. This was in 
contrast to the findings in post-mortem tissue, where stromal and axonal IR was 
prominent but staining of the OGD cell body or processes were not clearly seen.  
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Figure 6.16. LRRIg expression pattern in non-lesional white matter adjacent to 
early active lesional tissue, taken from a biopsy sample in a patient with clinically 
isolated syndrome (CIS). (A) AMIGO-1 IR is low, similar to the pattern seen in figure 
6.15, above. Occasional punctate staining in OGD is evident (arrow). (B) AMIGO-2 IR is 
increased in non-lesional white matter, particularly in OGD as demonstrated lining up 
along the axon (arrow). A punctate staining pattern is clearly evident adjacent to these 
cells (inset). (C) AMIGO-3 IR is evident predominantly in macrophages, some of which 
demonstrate a rod-shaped appearance (arrowhead) and in OGD with variable IR. Those 
cells with condensed nuclei and which may represent apoptosing cells appear to stain 
more intensely. (D) LINGO-1 IR is evident in OGD and along the axon. Scale bar = 100m. 
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6.6.10 LRRIg expression pattern in non-lesional grey matter, from an 
early active lesional tissue block 
Figures 6.17A & -B demonstrate similar AMIGO-1 and AMIGO-2 IR patterns, in that 
neuronal expression is weak overall with a diffuse IR around the soma. Once again 
however, AMIGO-2 stromal staining was prominent. As seen in figure 6.17C, 
AMIGO-3 IR was again significantly different compared to autopsy tissue (figure 
6.12C), and this change was most striking in the non-lesional grey matter. Here, 
AMIGO-3 displays clear neuronal nuclear IR (inset), with occasional cytoplasmic 
expression in pyknotic neurons. In AMIGO-molecules, satellite cell (OGD) 
reactivity was not clearly discernible, though was evident in LINGO-1-positive 
cells (inset). 
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Figure 6.17 LRRIg expression pattern in non-lesional grey matter adjacent to early 
active lesional tissue, taken from a biopsy sample in a patient with clinically 
isolated syndrome (CIS). (A) AMIGO-1 IR is low although occasional punctate staining 
in neurons is evident. (B) AMIGO-2 demonstrates a similar IR staining pattern to (A) in 
non-lesional grey matter, where IR overall is weak, although the stromal IR is relatively 
greater than in AMIGO-1 (C) AMIGO-3 IR is clearly evident in neuronal nuclei, with 
occasional cytoplasmic staining seen in pyknotic neurons (not shown) (D) LINGO-1 IR is 
seen with a similar frequency and intensity of positively stained neurons to those in 
NAWM tissue blocks in the autopsy series, as shown in figure 6.13. Scale bar = 100m. 
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Finally, co-localisation studies are required to confirm cell-specific expression, 
with support from in-situ hybridisation and would need to be performed in future 
work. However, neuropathological assessment of cell types based on 
characteristic morphological appearances enables a preliminary assessment of 
this, and is summarised in Table 6.3, below. Control tissue was used although if 
certain expression patterns were increased/ decreased in this cell type in EAL 
tissue, this is indicated by arrows in superscript. 
 MACROPHAGE/ 
MICROGLIA 
ASTROCYTE OLIGODENDROCYTE NEURON 
AMIGO-
1 
± - ± +++↓ 
AMIGO-
2 
+↑ + +↑ +++↓ 
AMIGO-
3 
 ±↑ - -↑ -↑ 
LINGO-
1 
++↑ +↑ +↑ +++ 
Table 6.3. Summary of cell-specific expression of LRRIg proteins in early active 
lesional (EAL) biopsy tissue. Arrows denote the comparative staining intensity in early 
active lesional MS biopsy tissue. ↑=increased; ↓=decreased.. ± = weak; + = moderate; ++ = 
strong staining intensity. 
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6.7 Discussion 
In chapters 3 and 4, I demonstrated increased expression of HMGB1 in 
macrophages/microglia and OGD, and in chapter 5 reported that HMGB1 levels in 
the CSF were elevated in MS patients vs. controls, correlating with inflammatory 
cell count. It is plausible that it may therefore be released into the extracellular 
space and act as a pro-inflammatory mediator here. 
In this context, one of the aims of this chapter was to model aspects of the 
oligodendroglial response; both in terms of cues augmenting endogenous HMGB1 
expression in addition to the effects of exogenous HMGB1 stimulation on 
expression of putatively associated mediators such as the LRRIg molecules, in the 
MO3.13, OGD-like immortalised cell line.  
In addition, I also discuss neuropathological observations in both autopsy and 
biopsy tissue sampled in vivo. Clearly, comparing expression patterns between 
post-mortem and biopsy tissue is subject to a number of caveats, not least stability 
of the molecule relating to post-mortem interval and length of fixation time. 
Biopsy tissue is more likely to preserve antigen, due to quicker time to fixation, 
and relatively less time spent in formalin which may mask epitopes. Comparison 
with non-MS control biopsy tissue is thus most important and we are currently 
collecting material for exactly this purpose. As this was a preliminary study, these 
factors were not controlled for, and any observations reported below must be 
viewed in this context. In spite of this, the findings are novel and raise interesting 
scientific questions which are discussed below. 
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6.7.1 HMGB1 mRNA levels are increased by TGF-β1 stimulation but not by 
classically pro-inflammatory cytokines 
The rationale behind using different cytokine mediators to stimulate OGD-like 
cells is to recapitulate the pathological microenvironment of EAE or MS and 
examine subsequent responses in this setting. Thus, MO3.13 cells were treated 
using a range of cytokines simulating exposure from pro-inflammatory sources e.g 
Th1 (IFNγ), Th17 (IL-6) cells and macrophages (IL-1β, TNFα), vs. anti-
inflammatory stimulation using TGF-β1 (Qin et al. 2009; Rhodes et al. 2006a; 
Moransard et al. 2011). 
As shown in figure 6.1, HMGB1 is expressed at baseline in the MO3.13 cell line as 
would be expected by this near ubiquitous protein (Muller et al. 2004; Yao et al. 
2012), and as seen in the neuropathology work in chapters 3 and 4 in MS and non-
MS control OGD.  
Interestingly, our preliminary results show that TGF-β1 stimulation significantly 
increased HMGB1 mRNA expression compared to the other, classically pro-
inflammatory cytokines. This raises the possibility that endogenous expression of 
HMGB1 in this OGD-like cell is more sensitive to anti-inflammatory as opposed to 
pro-inflammatory stimuli.  
Recent work has highlighted the role of TGF-β released from the ‘alternative’ 
microglial phenotype (M2), and associated with anti-inflammatory function in the 
CNS (Pittet et al. 2013; Zhou et al. 2012). Induced M2 macrophages were also 
shown to produce anti-inflammatory cytokines such as IL-10 and TGF-β and their 
adoptive transfer into injured spinal cord stimulated local resulted in decreased 
spinal cord lesion volume, increased remyelination and preservation of neurons, 
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with significant functional improvement (Ma et al. 2014). As seen in chapter 4, 
there were increased numbers of CD68-positive cells in MS patients (lesional and 
non-lesional), vs. controls. M1/ M2 phenotypic characterisation was not 
performed, but recent work has demonstrated that M2 cells are present in non-
lesional MS brain tissue, and thus may be the source of exogenous TGF-β in these 
regions of MS brain tissue (J van Horssen et al. 2012; Singh et al. 2013).  
TGF-β signaling is principally mediated through receptor-activated Smad 
proteins. Olig1- an important transcription factor determining OGD linage (Xin et 
al. 2005)- is also a Smad 2/3 cofactor involved in TGF-β-induced cell motility in 
OGD and remyelination (Motizuki et al. 2013) (Kachar et al. 1986). Thus 
exogenous TGF-β may enhance OGD myelination and whether this is facilitated by 
HMGB1 needs to be determined in functional studies. 
6.7.2 HMGB1 stimulation upregulates expression of its receptors, TLR4 and 
RAGE, potentially creating an autocrine loop 
The work described above demonstrates HMGB1 and its receptors are expressed 
in the MO3.13 cells and therefore may also be expressed in OGD. The presence of 
exogenous HMGB1 increases expression of its receptors, likely contributing to a 
feed-forward loop whereby HMGB1-related responses in these OGD-like cells are 
propagated. Although the HMGB1 receptors, TLR4 and RAGE are expressed at 
very low levels at baseline, they appear to be highly sensitive to induction by 
exogenous bvHMGB1, as seen in figure 6.3. Oligodendrocytes are known to 
express TLR4, activating the MyD88 pathway and OPCs demonstrate JNK 
phosphorylation following direct ligation of TLR4, suggesting this signalling 
machinery is functionally active (Taylor et al. 2010). However, they are not 
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thought to secrete TNF or other pro-inflammatory cytokines via NFκB signaling as 
classically occurs in macrophages following TLR4 ligation for example (Yao et al. 
2010; Balabanov et al. 2007). In-vivo injection of LPS in mice demonstrated 
profound upregulation of NG2-positive cells, thought to be OPCs, up to a distance 
of 6500µm in the surrounding regions in response to this. LPS-related signalling 
is likely to take place via TLR4 and so it is tempting to speculate that HMGB1 in 
the extracellular space may stimulate a similar response in upregulating 
immature OGD.  Interestingly, this marked NG2+ upregulation started as early as 
2h post-injection and preceded the arrival of macrophages from the periphery 
(Rhodes et al. 2006b). The authors postulated that demyelinating lesions opened 
the BBB, allowing platelet-derived factors entry and NG2-cell proliferation, in 
order to promote regenerative responses. The mechanism of NG2-cell positivity 
‘spreading’ across the parenchyma was not specifically addressed but given my 
findings in the neuropathology work in non-lesional regions, this is particularly 
interesting. 
 In addition, TGF-β1 stimulation also significantly increased RAGE mRNA 
expression, although this was not observed with TLR4 expression. TGF-β1 
stimulation has been shown to increase RAGE expression in different cell types, 
including articular chondrocytes where it induces a phenotypic switch to 
encourage hypertrophy (Narcisi et al. 2012). In addition, the role of TGF-β and 
RAGE signalling in cell proliferation has also been examined with some reports 
suggesting that their promotion is related to STAT5 signalling (Brizzi et al. 2004). 
Thus, the increased mRNA levels of RAGE in oligodendroglial-like MO3.13 cells 
following stimulation by HMGB1 and TGF- β1 may represent an effort to promote 
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cell proliferation, although specific signalling machinery activated following their 
ligation needs to be identified. 
Further work has also demonstrated that the interaction between HMGB1 and 
TGF-β1 can have reparative function in general. In an alveolar cell injury model, 
wounded epithelial cell monolayers released HMGB1, which accelerated wound 
closure in the distal lung epithelium via the IL-1β-mediated activation of TGF-β1, 
and was postulated to be important in resolution of acute lung injury by 
promoting repair (Pittet et al. 2013). The authors further suggested that after 
injury, a controlled inflammatory response may have enhanced tissue repair and 
restoration of function, therefore a complete inhibition of this response by anti-
inflammatory agents may have an adverse effect on lung epithelial repair. They 
described that if this inflammatory response becomes uncontrolled and 
maladaptive because of the severity or frequency of repeated insults, it may 
become an important mechanism in the development of lung fibrosis, for example. 
These same principles could be applied to CNS pathology, and as discussed in 
chapter 1, it may be that exogenous HMGB1’s initial role is to stimulate 
regenerative processes, including in OGD cells.  
Western blotting analysis demonstrated that total protein levels of RAGE also 
increased following stimulation by HMGB1, but interestingly were downregulated 
by all other mediators. Some of these mediators may not be directly linked to 
RAGE expression, hence lack of protein expression in response to their 
stimulation.  
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In summary, our work supports the contention that OGD-like cells appear to have 
a more active role in innate immunity than previously thought, clearly responding 
to stimulation by bvHMGB1 in particular. 
6.7.3 AMIGO-1 expression is attenuated in a pro-inflammatory 
environment 
AMIGO-1 and -2 appear to be involved with neuroprotective responses (Chen et 
al. 2006; Zhao et al. 2014b; Laeremans et al. 2013) whereas AMIGO-3 and LINGO-
1 apparently augment neurodegenerative responses (Ahmed et al. 2013; Lee et al. 
2014; Rudick et al. 2008). Thus, we wished to investigate LRRIg expression 
profiles in the first instance, and their relation with exogenously applied HMGB1. 
We know that HMGB1 induces expression of AMIGO-1 in developing neurites and 
wanted to test whether a similar situation was evident in OGD-like cells. 
AMIGO-1 mRNA and protein levels are moderately increased by high doses of 
bvHMGB1 stimulation, but are unchanged compared to control by lower doses, as 
shown in figure 6.5. Expression at the total protein level is similarly evident at 
higher doses of bvHMGB1 stimulation but profoundly reduced by pro-
inflammatory cytokines in particular, and indeed by low-dose HMGB1. These 
changes suggest that AMIGO-1 expression is either unchanged or downregulated 
when exposed to pro-inflammatory mediators in this cell type, although caution 
needs to be exercised in extrapolating this to the in-vivo setting.  
The in-vitro findings thus inform the neuropathology work as AMIGO-1 
expression was weak in the generally proinflammatory environment of the white 
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matter lesion. In non-overtly lesional WM, AMIGO-1 staining is also weakly seen 
in OGD and microglia/ macrophages, but not obviously in astrocytes.  
However, this has implications in the context of MS where the tissue micro-
environment is likely abnormal in both lesional and non-lesional regions, as 
discussed at length in this thesis. The main literature relating to AMIGO-1 
highlights its apparent beneficial role in CNS function, with involvement in neurite 
growth/ survival in development (Kuja-Panula et al. 2003; Ono et al. 2003b; Zhao 
et al. 2014b; Chen et al. 2011). Thus, based on my work and the available 
literature, the possibility that reduction in AMIGO-1 levels in MS patients may 
result in loss of neuroprotective function warrants further exploration.  
6.7.4 Neuronal AMIGO-1 expression in non-MS controls is reminiscent of 
Kv2.1 channel pattern of expression  
In the post-mortem series, AMIGO-1 is robustly expressed in human brain tissue. 
It is predominantly expressed in neuronal and some perivascular cells in 
chronic/late active lesional tissue. Interestingly, the stromal background was 
significantly stronger in all non-MS control subjects, as was cell-specific staining 
in the GM. Expression patterns appear to be specific as both IgG controls and 
omission of the primary antibody demonstrate negative or weak staining only.  
The neuronal staining pattern demonstrated a characteristic, punctate 
appearance around the neuronal soma and proximal dendrites. This was 
reminiscent of the pattern of AMIGO-1 expression described by Zhao et al in 
animal studies where it co-localised with Kv2.1 in specific clusters at the plasma 
membrane. Further experiments also suggested binding of AMIGO-1 to Kv2.1 
(Chen et al. 2011; Zhao et al. 2014b) as well as functional dependence in vivo. They 
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were found to colocalise in mature but not early developing brain, suggesting that 
established function of AMIGO-1 in extension of developing neurites may not be 
its only role in mature brain. These findings led the authors to propose that 
AMIGO1 be regarded as an auxiliary subunit of the Kv2.1 channel and likely plays 
a role in central neuronal signalling. 
Given this, the reduction in expression of AMIGO-1 in MS patients in our work is 
intriguing. Work by Jukkola et al demonstrated somatodendritic Kv2.1 channels 
significantly decrease with increasing severity of EAE (Jukkola et al. 2012). If 
AMIGO-1 was found to co-localise with Kv2.1 in humans as in zebrafish and mice, 
the findings in EAE corroborate our findings of apparent decreased expression 
AMIGO-1 in our MS patients. It is worth noting that AMIGO-1 expression was 
consistently observed in large pyramidal neurons in particular, which is 
consistent with the known expression pattern of Kv2.1 (Murakoshi & Trimmer 
1999). We did not perform neuronal subpopulation analysis but it would be 
informative to perform a more detailed study examining this. Interestingly, in the 
early active lesion taken from a biopsy specimen in a patient with clinically-
isolated syndrome, the staining pattern was similarly reduced, suggesting that this 
downregulation in AMIGO-1 expression may actually occur early in the disease 
course. This would also be consistent with the Kv2.1 pattern of expression in EAE, 
however, where expression was found to be reduced at peak relapse in a 
relapsing-remitting EAE model, but normalised in the remission phase (Jukkola et 
al. 2012).  
Voltage-gated K+ channels (Kv channels) are a broad family of K+- selective ion 
channels that are critically important in the regulation of excitability in numerous 
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cells throughout the body. Kv2.1 channels form prominent clusters in 
somatodendritic regions of cortical/ hippocampal pyramidal neurons and spinal 
cord motor neurons (O’Connell et al. 2010; Misonou et al. 2004). It has a high 
threshold for activation and primarily regulates excitability during high-
frequency firing in pyramidal neurons in response to excitatory stimuli (e.g., 
glutamate and increased cytoplasmic Ca2+) and cell stress. In this situation, it can 
alter punctate clustering into a more diffuse pattern over the neuronal soma 
(figure 6.18.)  although whether this is driving pathology or represents a 
compensatory mechanism remains unclear.  
            
Figure 6.18. Kv2.1 expression changes from a clustered to a diffuse localisation 
upon stimulation with glutamate. Cultured neurons were incubated with 10 M 
glutamate for 10 min at 37 °C. The cells were then fixed and stained for Kv2.1 (green) and 
MAP-2 (red). Scale bar, 10 m.  Adapted from (Misonou et al. 2004) 
MS has been considered as a type of ‘channelopathy’, due to the dysregulation of 
many different ion channels in the disease (Schattling et al. 2014). Dalfampridine 
is a broad potassium channel inhibitor and is currently used as a symptomatic 
treatment in MS to enhance walking ability with modest success, primarily 
through enhanced conduction through demyelinated lesions (Jensen et al. 2014). 
However, use in routine clinical practice is limited by small gains in function and 
the development of adverse side-effects including-interestingly, trigeminal 
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neuralgia (Birnbaum & Iverson 2014).  It is possible that the latter may result 
following inhibition of ion channels such as Kv2.1, which would normally serve to 
damp down neuronal hyperactivity.  
Intracellular accumulation of sodium via channel dysfunction has also been 
extensively studied (Craner et al. 2004), but clinical trials employing sodium 
channel blockers have not been universally successful yet (Hayton et al. 2012). 
However, deeper understanding of the role of ion channels in MS pathology is an 
important aspect of future neuroprotective strategies and more recent studies 
have demonstrated early success with this, examining the role of acid-sensing ion 
channels (ASICs) (Arun et al. 2013).  Their potential interaction with AMIGO-1 has 
not been studied before and would be of interest. 
6.7.5 AMIGO-2 expression is suppressed by pro-inflammatory cytokines in vitro 
but expression is increased in active lesional MS tissue 
Whilst AMIGO-2 is implicated in pathological processes such as tumour biology 
(Rabenau et al. 2004), in the CNS it appears to promote cellular survival (Ono et 
al. 2003a). AMIGO-2 mRNA levels were suppressed by pro-inflammatory cytokine 
stimulation such as IL-6 and TNF-α in particular (figure 6.8). However, at the total 
protein level, AMIGO-2 is not expressed at the expected 55kDa weight, and instead 
multiple faint bands at differing molecular weights are observed. This may 
represent lack of antibody specificity, but a lower MW product is consistently 
observed at 30kDa.  Further work using stimulated fibroblasts have also shown 
that its expression is induced by TGF-β stimulation, but instead of multiple bands 
evident as in my work, 2 bands at 50kDa and 30kDa are consistently observed. 
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These independent findings possible cleavage of the molecule upon stimulation 
with TGF-β and warrant further exploration.  
Neuropathological analysis of non-MS control tissue demonstrates robust AMIGO-
2 staining, with a punctate staining pattern in the soma and proximal dendrites of 
neurons as seen with AMIGO-1. Although DAB reactivity is not stoichiometric as 
discussed, staining is particularly intense in control GM. As shown in figure 6.11 
however, there is a reduction in staining intensity in MS brain tissue compared to 
non-MS control. Reduced neuronal staining persists in both post-mortem and 
biopsy tissue taken from the patient presenting with CIS.  
In contrast, AMIGO-2 expression throughout the biopsy tissue is generally 
upregulated, particularly in OGD. Thus, although AMIGO-2 expression in neurons 
appeared to be reduced, the ready expression in OGD in this tissue suggests that 
it is induced in a pro-inflammatory microenvironment. Given the observation in-
vitro that pro-inflammatory mediators suppress AMIGO-2 mRNA expression, this 
is unexpected and may relate to the unusual immunoblotting pattern evident in 
figure 6.6C. The antibody is specific to a 15 a.a peptide sequence near the c-
terminal residues of the protein, therefore may represent a cleaved peptide from 
the cytoplasmic region, as alluded to earlier. Thus, whilst mRNA expression may 
be downregulated by pro-inflammatory mediators, this cytoplasmic region may 
be involved in pathophysiological processes. This is speculative and requires 
further investigation, which is underway. 
The other important observation is that AMIGO-2 IR appeared to be both nuclear 
and membrane-bound. This distribution was similarly described by Ono et al in 
their original description of AMIGO2 or alivin-1 (Ono et al. 2003b), identifying its 
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crucial role  in the depolarisation-dependent survival of cerebellar neurons. Cues 
for upregulation included Ca2+ signalling and expression was markedly reduced 
prior to apoptosis-related cell death, highlighting its importance in cell survival. 
Its nuclear and membrane-bound subcellular localisation was explained by other 
similar examples whereby signal-transducing receptors meant to be located at the 
plasma membrane are in fact located in the nucleus, such as EGFR and FGF 
receptors (Marti et al. 2001; Maher 1996). Curiously, they display transactivator 
activity and may function as transcription factors (Brosenitsch & Katz 2001). 
There is no evidence yet that AMIGO-2 may perform this function but its 
subcellular localisation warrants further evaluation of this.  
In addition, they do not present images or directly refer to the characteristic 
punctate clustering around the soma and proximal dendrites that we observed in 
the human tissue, although they do describe AMIGO-2 expression in this exact 
location in neurons.  
Thus, as with AMIGO-1 which displayed a similar pattern described above, its 
function may be related to cell survival against environmental stressors. Loss of 
expression may indicate impending cell death as described by Ono et al. However, 
it is also possible that the molecule is cleaved and this has pathogenic effects in 
non-neuronal cells, hence its upregulation in early active lesions. In-situ 
hybridisation would thus be particularly revealing in this context and forms the 
basis of future work. 
 
6.7.6 AMIGO-3 expression is increased in an active inflammatory environment 
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The in-vitro work demonstrated that upregulation of AMIGO-3 was sensitive to all 
doses of bvHMGB1 stimulation, but particularly at lower doses, as seen in figure 
6.9A. This suggests that OGD cells might upregulate AMIGO-3 in the presence of 
small amounts of extracellular HMGB1. The significance of this is unknown, but 
the importance of AMIGO-3 acting at the NgR/p75 receptor complex on axonal 
surfaces to activate RhoA signalling and potentiate neurodegenerative processes 
has been reported (Ahmed et al. 2013). It is tempting to speculate that 
extracellular HMGB1- presumably oxidised and hence pro-inflammatory- 
released by activated M1 phenotype macrophages/ microglia may potentiate 
neurodegenerative processes via this pathway, providing a potential mechanistic 
link between inflammatory and neurodegenerative processes. It is also worth 
noting that although levels of HMGB1 were significantly higher in the CSF of MS 
patients vs. controls in chapter 5, absolute levels detectable by the assay were low. 
Despite the fact that local HMGB1 levels in the parenchyma would be higher than 
those detectable in the CSF, the correlation with inflammatory cell numbers 
suggests that these relatively low levels would be more in keeping with 
inflammatory cell secretion vs necrotic release. The latter are seen in cases of 
trauma or bacterial infection for example, where CSF concentrations reach 
microgram levels. Thus, sensitivity to low levels of exogenous HMGB1 is an 
important finding and may well have pathological significance as described above.  
Interestingly, other pro-inflammatory mediators appeared to have no effect on 
AMIGO-3 expression, suggesting an HMGB1-specific response. Further work is 
required to examine this in greater detail but it is an entirely novel and exciting 
avenue to further explore.  
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AMIGO-3 staining is undetectable in non-MS control autopsy tissue, and faintly 
evident in AL tissue blocks (figure 6.12). However, expression was markedly 
increased in biopsy tissue, in both early active lesions and in surrounding non-
lesional grey and white-matter. Once again, a range of control conditions failed to 
reveal evidence of non-specific IR. Increased expression in active lesional regions 
may be linked to its function at the NgR complex on the axonal membrane to 
activate RhoA signalling in the presence of myelin proteins (Ahmed et al. 2013). 
However, anti-AMIGO-3 IR is also seen in the non-lesional white matter in a 
punctate pattern adjacent to OGD (figure 6.16C; inset), which may also be relevant 
in this context, despite the lack of overt demyelination. Certainly, myelin proteins 
present in the outer surface of the myelin sheath and adjacent to the axonal 
surface, such as MAG, act at this receptor complex suggesting that these changes 
may occur early in the pathology. 
The predominant subcellular localisation was nuclear; in macrophages, OGD and– 
most-strikingly- neuronal nuclei. The latter demonstrated clear anti-AMIGO-3 IR 
around the chromatin structure within virtually all neuronal nuclei. The apparent 
similarity with the HMGB1 neuronal staining pattern in this active lesional tissue 
(figure 3.4G; inset) is of further interest as HMGB1 is known to act as a facilitator 
of transcription due to its ability to alter chromatin structure (Müller et al. 2004). 
Whether AMIGO-3 also demonstrates this function and whether it is beneficial or 
detrimental to the cell is unclear at present.  
Unlike the AMIGO-1 and -2 rabbit polyclonal antibodies which were commercially 
produced, the AMIGO-3 antibody was a mouse monoclonal antibody, produced 
following our design of the peptide sequence used for mouse immunisation (MD, 
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personal communication). The AMIGO-1 and -2 antibodies used short peptide 
sequences from the cytoplasmic regions as immunogens, whereas the AMIGO-3 
antibody included the signal sequence in the extracellular domain, suggesting that 
its nuclear presence reflects the whole molecule being present here, or else 
possibly cleavage of this domain.  
6.7.7 The relationship between HMGB1 and LINGO-1 may reflect direct 
interaction between inflammatory and degenerative processes  
A similar pattern to that observed with AMIGO-3 was noted in LINGO-1 analyses, 
as this was also sensitive to upregulation of mRNA levels by HMGB1 at all doses 
used. In addition, proinflammatory cytokines upregulated mRNA expression of 
LINGO-1, but this response was significantly less when compared to bvHMGB1 as 
seen in figure 6.8. Using Western blotting, low dose bvHMGB1 appeared to 
stimulate LINGO-1 expression, with 20ng/ml consistently producing increased 
levels at both the mRNA and protein levels, whilst IL-1β also reliably induced 
LINGO-1 expression. Factors influencing expression of LINGO-1 itself have not 
been explored in great detail however, and the observation that both exogenous 
HMGB1 and IL-1β appear to increase total protein levels of LINGO-1 is relatively 
novel. Activated, pro-inflammatory microglia/ macrophages are well- known to 
release both of these molecules, and so may in fact serve as another link between 
inflammatory and degenerative processes in MS. 
The standard protocol for management of MO3.13 cells requires low serum 
conditions, but I compared expression of LINGO-1 in both high and low-serum 
conditions. The results were remarkably consistent, in that LINGO-1 total protein 
expression was consistently induced in a low-serum setting, with virtually none 
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detectable in high serum conditions. Whilst this finding requires further 
investigation, it provides interesting insight into this molecule. It suggests that 
global cellular stress, as represented by lower serum conditions, also stimulates 
the expression of LINGO-1. At the same time however, the specific purpose of 
serum depletion is to encourage MO3.13 cell differentiation toward a more 
mature OGD phenotype, and that cellular differentiation itself is a bioenergetically 
demanding process, placing the cell under metabolic stress. Serum depletion 
classically induces cells to withdraw from the proliferative cell cycle and enter the 
quiescent G0/G1 phase, facilitating differentiation (Van Rechem et al. 2010; 
Pirkmajer & Chibalin 2011). Thus, this observation likely reflects the fact that 
mature OGD are known to express LINGO-1 (Mi et al. 2005; Mi et al. 2007), 
although the possibility that it represents sensitivity to more global cellular 
stressors cannot be excluded and could be further explored.  
It has also been shown that LINGO-1 is not directly implicated in specific, adaptive 
neuroimmune aspects of MOG-induced EAE, but rather reflects CNS-specific 
processes. For example, the induction phase of EAE in LINGO-1 knock-out (KO) 
mice showed no difference when compared to wild-type mice (Mi et al. 2007). In 
addition, T-cell function was similar between the two groups, as shown by 
cytokine profile produced by encephalitogenic T-cells of LINGO-1 KO rodents and 
by the ability of the latter cells to induce EAE following adoptive transfer. 
However, the reverse of this i.e. adoptive transfer of encephalitogenic T-cells from 
wild-type rodents into LINGO-1 KO’s attenuated the signs and symptoms of EAE. 
Thus, LINGO-1 blockade either using Lingo-1 KO’s or by direct antagonism using 
a specific IgG antagonist produced CNS-specific benefits; with improved 
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functional outcomes of lower EAE scores in addition to physiological parameters 
such as diffusion tensor imaging (DTI), where fibre tract integrity was superior in 
LINGO-1 KO’s vs. wild-types. In addition, both myelin staining using toluidine-blue 
and electron microscopy confirmed the presence of enhanced remyelination. 
The relationship between HMGB1 and LINGO-1 in particular is novel and has not 
been explored previously. The sensitivity of both AMIGO-3 and LINGO-1 to 
exogenous HMGB1 is of particular interest when considering our CSF work, 
whereby levels were higher in MS patients vs. controls but otherwise low in 
absolute terms, as discussed above with respect to AMIGO-3 sensitivity to 
exogenous HMGB1. Thus, extracellular HMGB1 may behave in a classically pro-
inflammatory manner, and so upregulation of down-stream molecule expression 
such as LINGO-1 and AMIGO-3 especially may be an indicator of potentially 
damaging, pro-inflammatory processes classically associated with MS. Thus, this 
in-vitro work identifies an important potential link between pro-inflammatory 
processes occurring in MS and ensuing degenerative signalling pathways which 
may be activated as a result. 
6.7.8 LINGO-1 expression may be upregulated in OGD in early active lesional tissue 
but not in non-MS control or chronic MS brain tissue 
In non-MS control tissue, neuronal expression in the grey matter was clearly 
evident, with a similarly punctate staining pattern around the neuronal soma and 
proximal dendrites observed with AMIGO-1 and -2 IR. It is expressed in a similar 
pattern in the grey matter of ‘NAWM’ tissue blocks, although subjectively it 
appeared that fewer cells demonstrated this pattern. The staining intensity in non-
lesional grey matter of AL blocks was reduced and the majority of neurons 
 235 
 
demonstrated a more homogenous cytoplasmic pattern of expression, frequently 
highlighting axonal expression as shown in figure 6.15D. This suggests that 
chronic lesion activity may exhaust LINGO-1 expression, as most of the lesions 
were late or chronic active lesions in the autopsy series. In addition, the more 
diffuse expression pattern observed over the neuronal soma suggests that LINGO-
1 may also redistribute its characteristically punctate clusters of protein along the 
cell surface, as discussed earlier with respect to AMIGO-1. The normal association 
of LINGO-1 with ion channel physiology has not been described before, and 
certainly not reported in human brain. 
It also consistently appears that LINGO-1 expression was increased in the white 
matter of non-MS control subjects, although- importantly- this was predominantly 
within the stroma or along axons and was not directly expressed in the OGD cell 
body. In contrast, WM expression was generally reduced in MS patients from the 
autopsy series, as shown in the low power views in figure 6.13A-C. However, IR 
was clearly evident in OGD cell bodies as well as astrocytes in both lesional and 
non-lesional white matter in the early active lesional biopsy tissue, as well as the 
punctate staining throughout the stroma as seen in the post-mortem tissue. In 
addition, we observed a markedly spiculated appearance of foamy macrophages, 
suggesting that LINGO-1 was staining positively for myelin breakdown products, 
possibly derived from myelin stripped from axons. Thus, we can speculate that 
LINGO-1 is expressed along the myelin sheath in human brain, ready to interact 
with the NgR at the axonal surface, as has been shown in animal work (Mi et al. 
2005; Mi et al. 2004). In-situ hybridisation studies would be of great interest here 
in particular, as it may be that lipophages themselves don’t express LINGO-1, and 
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instead reflects uptake of cellular debris from damaged cells.  Recent work has 
shown that foamy macrophages are anti-inflammatory in their behaviour (Boven 
et al. 2006) and it is possible that these macrophages are attempting to curb 
degenerative activity involving LINGO-1 and RhoA signalling, and this acts as a cue 
for subsequent phagocytosis. These changes suggest that LINGO-1 is clearly 
upregulated in the early stages of MS, both in and around active lesions. 
LINGO-1 expression has been examined in human brain before, and some aspects 
of our findings in human brain are consistent this work (Satoh et al. 2007). Theirs 
was a smaller series of 5 MS patients but with 10 non-MS control patients, 
although they do not present IHC evidence of the staining pattern in the latter 
group of patients. They found prominent staining in astrocytes and macrophages, 
in addition to neurons, but questioned the data from Mi et al (Mi et al. 2005), as 
they did not find LINGO-1 expression in OGD. In addition, their western blotting 
data suggests that total protein expression is generally downregulated in MS 
tissue, compared to non-MS neurological control tissue. However, the tissue used 
for analysis by this group was chronic active lesional tissue, and I have similarly 
shown that there is a general down-regulation of LINGO-1 expression in this 
setting. In contrast, my findings in the early active lesional biopsy tissue reveal 
that LINGO-1 likely has an important role in the acute stages of lesion formation, 
and found clear evidence of OGD staining as described above.  
Interestingly, the expression pattern in neurons was also slightly different in our 
study compared to the work by this group. Although we rarely observed the 
characteristic, punctate staining pattern seen in non-MS control tissue in MS 
brains, we observed relatively weak staining with diffuse IR over the soma and 
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into the axon. The work by Satoh et al also demonstrated smooth cytoplasmic 
staining around a particular subgroup of pontine neurons. We used exactly the 
same antibody as used in this study, and so different antibody specificities are not 
attributable to differences. They do not state where in the pons these neurons are 
located but those forming part of the locus coeruleus, in the posterior area of the 
rostral pons, comprise the nucleus pigmentosus pontis i.e. ‘heavily pigmented 
nucleus of the pons’. Although we did not have samples from a similar area, we 
have seen in our own work that in basal ganglia regions, pigmented neurons have 
this exact appearance, regardless of antibody specificity. For this reason, we did 
not include these areas for own analysis. Thus, it is possible that melanin 
pigmentation may have contributed to the strongly IR, cytoplasmic staining 
pattern rather than specific IR per se.  On the other hand, this smooth appearance 
may reflect similar changes to those observed by ourselves, albeit at a greater 
intensity. This would presumably be due to the same process as described earlier, 
from a punctate staining pattern to a more diffuse one. For the rest of the analyses, 
they presented tissue taken from frontal lobe regions, and it would have been of 
interest to compare their LINGO-1 staining in these regions with our expression 
pattern, particularly in their non-MS control subjects, as we analysed tissue 
predominantly located in these regions also. 
In summary, it is likely that LINGO-1 has an important role early in MS-related 
pathology and so any analysis of human material would need to take this into 
account. Our in-vitro work suggests that exogenous HMGB1 increased expression 
of LINGO-1 both at the mRNA and total protein level in OGD-like MO3.13 cells. The 
higher levels of HMGB1 observed in the CSF of MS patients as described in chapter 
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5, may reflect its secretion by immune cells and thus propagate LINGO-1 mediated 
neurodegenerative processes within active lesional regions. It is thus possible that 
this represents a link between neuroinflammatory and  degenerative processes in 
MS.  
6.8 Limitations 
In vitro work: Immortalised cell lines can be obtained relatively easily for use in 
multiple experiments, giving an idea of how the equivalent cell might behave in-
vivo. However, potential drawbacks include their transformed nature as they are 
in the proliferative cell cycle stage, and this can skew results. To minimise 
potential confounders, we ensured that they were passaged when no more than 
70% confluent, all experiments were performed at low passage numbers and used 
identical culturing conditions including when repeating experiments for ‘n’ 
numbers. We also performed experiments at n≥3, in order to reduce the chance of 
random observations. However, results can only be interpreted within this model; 
using a primary cell line would recapitulate responses closer to the in vivo 
environment, although animal models and human tissue analysis (see below) 
would give a greater understanding of the disease specific biology. 
Ex vivo (neuropathology) work: General limitations when using both biopsy 
and autopsy material have been discussed in chapters 3 and 4. In this chapter of 
work, no attempt was made to semi-quantitate observed IR, and thus was a purely 
descriptive study. This introduces obvious bias but due to the novel nature of the 
examination of these molecules in human brain tissue, the main purpose was 
simply to observe findings that would inform a more detailed study going forward. 
The same principle holds for the fact that relatively few patients were examined 
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in both control and MS subjects, and findings would need replication in a larger 
study.  
In-situ hybridisation studies would be of interest in order to confirm the presence 
of mRNA expression of the molecules. Co-localisation studies, preferably using 
fluorescent-IHC would also be particularly helpful in identifying which cell types 
express the relevant molecules with greater certainty. 
6.9 Summary  
HMGB1 and its receptors are expressed in the MO3.13 OGD-like cell line, and 
potentially demonstrate autocrine behaviour to propagate sensitivity to 
exogenous HMGB1. HMGB1 also appears to directly upregulate mRNA and/ or 
protein expression of all LRRIg molecules, compared to a range of other pro- and 
anti-inflammatory mediators in this cell line, which is a novel finding and supports 
our original hypotheses.  
I have also examined AMIGO molecule expression for the first time in human brain 
tissue. AMIGO-1 and AMIGO-2 expression demonstrated similar patterns, with 
characteristically punctate clusters of expressed protein, situated around the 
neuronal soma and in the proximal dendrites. This pattern has been seen before 
in association with AMIGO-1, with Kv2.1 ion channel expression in neurons. I 
found that IR was reduced in neurons in MS brain tissue, as also seen with Kv2.1 
expression in EAE (Jukkola et al. 2012), raising the intriguing possibility that 
AMIGO molecule expression in MS highlights neuronal stress, resulting from 
either Wallerian degeneration as a result of distal demyelination or local neuronal 
metabolic stress. Thus, augmenting AMIGO-1 activity in particular may have 
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therapeutic implications as part of a neuroprotective strategy but further work is 
required to take forward our preliminary findings.  
AMIGO-3 expression was virtually undetectable in the post-mortem tissue but 
demonstrated striking changes in the early active lesional biopsy tissue, 
particularly in neurons, as did LINGO-1 expression. Thus AMIGO-3 and LINGO-1 
are clearly upregulated in an acutely inflamed microenvironment. In addition, the 
in-vitro work demonstrated that both AMIGO-3 and LINGO-1 appear to be 
particularly sensitive to low-dose HMGB1 stimulation; a finding which is 
potentially relevant when considering the relatively low levels of HMGB1 detected 
in the CSF of MS patients, albeit significantly higher when compared to control 
subjects. Given their known interaction at the NgR and potentiation of 
neurodegenerative processes, this phenomenon may highlight a novel link 
between inflammatory and neurodegenerative processes. In addition, the 
expression profile in non-lesional regions suggests that this process can occur 
more widely in MS brain tissue. The results thus support the suggestion that 
blockade of LINGO-1 may be beneficial in MS (Pepinsky et al. 2014) but we would 
also add that inhibiting the activity of AMIGO-3 is another potential 
neuroprotective, therapeutic strategy which warrants further investigation. 
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7  
General Discussion  
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The need to understand the basis of disease progression in MS remains unmet. 
Disease modifying therapies have significantly changed how MS is managed, due 
to the relative suppression of relapses on treatment. However, the evidence that 
progression of disability is halted by these treatments is inconclusive, despite this 
aspect of the disease generating profound morbidity and socio-economic burden. 
Evidence derived from biomarkers such as MRI and CSF analysis have suggested 
that disease processes driving MS are ongoing, in between relapses that affect 
clinically eloquent regions. This is reflected neuropathologically, as isolated 
inflammatory lesions are not the only manifestation of MS-related pathology. 
Thus, this PhD project investigated MS-related disease processes distal to classical 
inflammatory lesions in the neuropathological study and changes occurring 
predominantly in non-relapsing MS patients in the CSF study. The potential 
implications of these findings are considered in the series of questions, below. 
7.1   Does exogenous HMGB1 activate degenerative pathways in MS? 
The novel finding arising from this project is that HMGB1 expression was 
increased throughout the brain tissue of MS patients, vs non-MS controls, as seen 
in Chapters 3 and 4. CD68-positive, HMGB1-positive macrophages were clearly 
evident in early and late-active MS lesions as well as in non-lesional regions in 
both autopsy tissue from patients with progressive MS and in biopsy tissue taken 
in-vivo from a patient with a clinically isolated syndrome (CIS). In addition, as seen 
in Chapter 5, CSF HMGB1 levels were increased in MS patients at an early stage of 
disease vs. non-inflammatory control patients. However, absolute levels are much 
lower compared to those seen in the setting of CNS trauma and cellular necrosis 
for example, raising the possibility that secreted HMGB1 from either immune cells 
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or from the parenchyma itself may be contributing. The best-characterised role of 
HMGB1 is its pro-inflammatory effects upon release from activated macrophages 
as discussed in detail in Chapter 1, General Introduction (Wang et al., 1999), 
therefore its presence in the extracellular space may result in deleterious 
consequences. 
In Chapter 6, exogenous HMGB1 stimulation in-vitro upregulated expression of its 
receptors in OGD-like cells (MO3.13 cell line), potentially propagating chronic 
inflammation and damage to OGD. As discussed below, expression of the LRRIg 
molecules, AMIGO-3 and LINGO-1 is also significantly increased by bvHMGB1 
compared to other pro-inflammatory mediators. These molecules have both been 
reported to propagate neurodegenerative processes by signalling through the 
p75/NTR/ NgR complex (Mi et al. 2004; Ahmed et al. 2013). It is therefore 
tempting to suggest that exogenous HMGB1 may influence degenerative processes 
via AMIGO-3 and LINGO-1-associated RhoA signalling. Their expression in non-
lesional regions early-on in CIS brain tissue, also suggests that pathological 
processes are taking place globally in MS brain tissue, and thus treatments 
targeting these may have a greater impact on disability.  
Anti-LINGO1 trials are already underway as a novel MS therapy. It has recently 
been reported that 1st line disease-modifying agents are cost-effective and may 
slow progression of disease as assessed at 6y-follow up using robust statistical 
models (Palace et al. 2015). However, caution when interpreting this data should 
be used in certain instances. For example, censoring of patients when they 
switched to a non-scheme drug would probably select out the patients with more 
severe disease, potentially reducing disability progression estimates over time. 
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The importance of accurate assessment of treatment impact upon disability 
outcomes across the board are highlighted by this, and neuroprotective drugs 
such as anti-LINGO agents are attempting to address this. Phase I trials using anti-
LINGO-1 agents demonstrated an equivalent incidence of side-effects compared 
to placebo, with no adverse events (Tran et al. 2014). More recently, a phase II 
trial examining the effects of high-dose anti-LINGO1 infusion on optic neuritis 
outcomes (the ‘RENEW’ trial; NCT01721161) demonstrated superiority over 
placebo as it was associated with a 34% recovery of optic nerve latency vs. 
placebo, but not with secondary outcomes such as change in the thickness of 
retinal layers or with improved visual function itself 
(http://www.biogenidec.com/research_product_ pipeline.aspx?ID=5778). Whilst 
the improvements are modest in the primary outcome over 24 weeks, with no 
benefit in secondary outcomes, it is a landmark trial due to its novelty. It marks a 
departure from traditional immunomodulatory therapeutic approaches which 
have dominated the scene in MS over the past 25 years. The ‘SYNERGY’ trial using 
varying anti-LINGO-1 doses is ongoing, recruiting patients with both RRMS and 
SPMS and is due to complete in 2016. This will be a more detailed examination of 
outcome measures and its findings will be of significant interest. However, the 
modest benefits as seen in RENEW suggest that anti-LINGO-1 therapy is likely the 
first in a long line of future neuroprotective therapies. Our findings of increased 
AMIGO-3 expression in the context of an actively inflamed MS lesion from a biopsy 
specimen suggests that it has role at the earliest stage of disease. This, along with 
previously published data (Ahmed et al. 2013), suggests that AMIGO-3 antagonism 
may also demonstrate therapeutic potential and warrants further exploration.  
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  7.2  Does endogenous HMGB1 act as a protective agent in MS? 
We postulated earlier that exogenous HMGB1 may contribute to 
neurodegeneration via the LRRIg molecules. However, it is possible that 
endogenous HMGB1 expression in CNS cells reflects different cellular processes 
and further consideration of this forms the basis of future work.  
Upregulation of genes involved in ischaemic pre-conditioning, in normal-
appearing white matter (NAWM) have been demonstrated, suggesting that the 
background brain parenchyma in MS is under stress and that OGD themselves 
express multiple members of the STAT6 signalling pathway. This suggests an anti-
inflammatory, potentially protective phenotype in these cells. Protective 
responses in OGD have also been suggested in other studies, where their secretion 
of damage-related molecules, such as αB-crystallin have been shown to trigger an 
immunoregulatory response in surrounding macrophage/ microglial cells (Amor 
et al. 2010; Jack van Horssen et al. 2012; Van Noort et al. 2010; Singh et al. 2013; 
Van der Valk & Amor 2009; van Noort et al. 2010; Zeis et al. 2008; Graumann et al. 
2003; Ingram et al. 2014; Bsibsi et al. 2013b; Barnett et al. 2009). In the nucleus, 
HMGB1 acts as a master-regulator of small heat-shock protein expression, of 
which αB-crystallin/ HSPB5, is an example. Thus, HMGB1 may be linked to the 
processes described above, in driving protective responses in OGD via αB-
crystallin/ HSPB5 expression upon the appropriate cues. 
As discussed in section 1.4 of the General Introduction, redox modification 
relating to intensity of cellular stress, generally dictates the subsequent function 
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of HMGB1. Despite the apparently precarious balance between protective and 
destructive pathways in non-lesional MS brain tissue (Zeis et al. 2008), the degree 
of tissue stress is likely to be moderate in these regions. In this context, HMGB1 
may be secreted from its normal position in the nucleus into the cytosol, in a 
reduced form (figure 1.6). It is unknown whether this redox configuration of 
HMGB1 induces an immunoregulatory profile in surrounding microglia/ 
macrophages akin to αB-crystallin, and would be of great interest to further 
explore. However, reduced HMGB1 is known to augment autophagic pathways, 
and we know that it has multi-functional roles in this process (figure 1.5), both in 
the cytoplasm and extracellularly. It was not possible to reliably discern 
cytoplasmic translocation using brightfield microscopy in this study as OGD have 
scant cytoplasm evident in their cell bodies. Despite this, occasional cells were 
seen which may have demonstrated this in the brain tissue (Section 4.5.2; figure 
4.2), and in preliminary in-vitro fluorescence-ICC experiments using stimulated 
MO3.13 cells (data not shown). HMGB1 also has an important role in autophagy 
within the nucleus itself, and so even if the increased OGD expression of HMGB1 
in MS patients vs. controls reflects nuclear vs. cytoplasmic subcellular localisation, 
this may reflect autophagic processes in any case. Thus, one mechanism of OGD 
protection may be related to potentiation of autophagic pathways in MS brain 
tissue. Given the critically important role of HMGB1 in mediating autophagy, this 
may be relevant to the findings presented in this thesis.                                                                                                                                 
Autophagy pathways in MS have not been explored in detail before, although 
autophagic activity in T-cells has been reported, contributing to chronicity of 
infection (Pua et al. 2007). Basal levels of autophagy are low in non-diseased brain 
tissue using the GFP-LC3 autopahgy mouse model (Mizushima et al. 2004) but as 
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discussed in chapter one, section 1.4.5.5, its upregulation in other neurological 
diseases is increasingly recognised (Frake et al. 2015). Interestingly, it has also 
recently been reported that mTOR/p70S6K signalling can distinguish between 
routine, maintenance-level autophagy from autophagic cell death during 
influenza-A infection (Datan, E et al. 2015). LC3 is critically important for 
transport and maturation of the autophagosome. A recent study found that its 
expression was significantly upregulated in surviving OGD in Nasu-Hakola disease 
(NHD)- a rare autosomal recessive disorder characterized by sclerosing 
leukoencephalopathy, using IHC in human brain (Satoh et al. 2014). In contrast, 
expression was not detected in OGD in the lesional rim of chronic demyelinating 
lesions in MS patients, although was evident in Iba-1-positive microglia/ 
macrophages. As I have demonstrated in this work, expression of HMGB1 was 
lower in similar chronic lesional/ peri-lesional areas and we can speculate that 
this is related to exhaustion of autophagic pathways. Accordingly, analysis of LC3-
II expression in our acutely demyelinating biopsy tissue specimen would be of 
great interest in taking this forward. 
In vivo studies utilising the Long–Evans shaker (les) rat model with severe CNS 
dysmyelination and subsequent demyelination during development have also 
revealed autophagic changes specifically affecting OGD (Kwiecien et al. 1998). 
Oligodendrocytes from les rats have been shown to accumulate cytoplasmic 
vesicles and electron microscopic studies have characterised these as early and 
late autophagosomes, along with an increase in autophagy markers using IHC and 
Western blotting (Smith et al. 2013). Interestingly, upregulating autophagy 
promoted membrane extensions in les oligodendrocytes in vitro. In vivo, 
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intermittent fasting promoted autophagy and increased the proportion of 
myelinated axons as well as myelin sheath thickness in both les and control rats. 
Thus this work identified an important role for autophagy in promoting the 
survival and function of oligodendrocytes, which may be relevant in MS. 
The potential importance of autophagy is readily apparent in neurodegenerative 
diseases, where helping clearance of intracellular protein aggregates may improve 
cellular function. Both in vitro and in vivo work using mouse models has 
demonstrated that upregulation of autophagy results in clearance of a wide range 
of aggregate-prone molecules, particularly smaller, soluble aggregates (Chen et al. 
2012; Winslow et al. 2010). Statins are thought to augment autophagic processes 
amongst other roles (Ghavami et al. 2012), and have recently been shown to 
ameliorate whole-brain atrophy measures and some disability outcomes in 
patients with progressive MS- a clinical cohort who have traditionally been 
refractory to disease modulation. This seminal study demands more pre-clinical 
work be done to investigate the mechanisms behind these observations, but we 
can speculate that potentiation of autophagy may be one aspect of this apparently 
neuroprotective effect. More recently, the specific peptide sequence of the 
functionally-relevant domain of the pro-autophagic molecule beclin-1 has been 
identified. This peptide has been modified to enhance cellular penetration and 
directly augment autophagic clearance of intracellular aggregates, with relevance 
to diseases such as Huntington’s (Shoji-Kawata et al. 2013).                                                                                                                                                      
We can thus speculate that one aspect of increased HMGB1 expression in 
oligodendrocytes found in this study may be reflecting autophagic processes in 
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MS vs. non-MS control brain tissue. Whilst MS is by no means a classical 
neurodegenerative disease with known intranuclear inclusion proteins, it would 
be of interest to further explore its potential role here in more detail, given the 
importance of HMGB1 in autophagy. Certainly, if further evidence is presented 
which suggests that autophagy is relevant to the pathogenesis, this would 
represent an entirely novel therapeutic avenue of MS research.  
Further work demonstrated that autophagic clearance of protein aggregates were 
identified in OGD precursors (NG2 cells) in Alzheimer’s disease mouse models (W. 
Li et al. 2013). NG2 cells have established roles in neuroprotection and immune 
modulation, particularly in the setting of myelinogenesis but also in neuronal 
survival (for review, see: Boda & Buffo 2014). Intense anti-amphoterin /HMGB1 
immunoreactivity (IR) in OGD of relatively immature phenotype were seen in the 
developing rodent (M. M. Daston & Ratner 1994). Morphologically, they were 
reminiscent of NG2 cells, although not specifically tested for, and adult rodents 
showed much weaker IR in comparison. My work in human tissue found that OGD 
were weakly HMGB1-positive in some non-MS control subjects, but IR was 
profoundly increased in MS brain tissue in comparison. This also raises the 
possibility that subpopulations of OGD may demonstrate immature cell 
characteristics in MS patients as discussed earlier. We know that OGD precursor 
cells (OPCs) are numerous, certainly in peri-lesional regions of MS brain (G 
Wolswijk 1998; Chang et al. 2000a). The presence of myelin proteins is 
traditionally thought to create an inhibitory environment and to halt 
differentiation into mature OGD (Mi et al. 2007). However, a potential explanation 
for the widespread increase in anti-HMGB1 IR in MS patients might be that the 
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brain has an endogenous strategy for dealing with cellular stress; by employing 
widespread changes within OGD themselves. One mechanism may be via re-
expression of developmental pathways (John et al. 2002; Chang et al. 2000b) and/ 
or by increasing cellular proliferation rate (Pua et al. 2007). HMGB1 is known to 
have an important role in proliferation, and its deletion by the use of RNAi 
lentiviral vectors has been shown to significantly decrease cell proliferation (Song 
et al. 2012). In addition, deletion of HMGB1 rendered cells vulnerable to apoptosis 
induced by oxaliplatin and mediated by the caspase-3 pathway. Whether this 
occurs in OGD is purely speculative, and relatively little experimental evidence 
exists at present to support or refute the notion.  
A final explanation for increased anti-HMGB1-IR is that HMGB1 may be sensing 
direct infection within the CNS by bacterial or viral pathogens. We know that 
HMGB1 is a promiscuous sensor of many different pathogens, viruses in particular 
(Yanai et al.2009), and it is possible that OGD are either infected themselves or 
else are responding to signals released by other cells e.g. macrophages/microglia. 
This hypothesis is purely speculative, and direct assay of infective antigens using 
novel sequencing techniques could be performed to further investigate this. 
  7.3  Is AMIGO-1 involved in regulating neuronal excitability in MS brain tissue?  
This family of molecules have multiple CNS-specific roles including cell adhesion, 
fasciculation and myelination. I have demonstrated that their expression is 
upregulated by HMGB1 in the MO3.13, OGD-like cell-line, particularly in the case 
of AMIGO-3 and LINGO-1. The latter two molecules have both been reported to 
propagate neurodegenerative processes by signalling through the p75/NTR/ NgR 
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complex (Mi et al. 2004; Ahmed et al. 2013), with potential pathological relevance 
as described above. However, the changes in expression of AMIGO-1 in particular 
highlight potential mechanisms of cellular stress in MS brain tissue compared to 
control. Whilst expressed robustly in neurons of non-MS control patients in a 
classically punctate pattern, I found that this was significantly reduced in both 
post-mortem and biopsy MS tissue. The expression of AMIGO-1 has been 
intimately linked to the expression and function of the potassium channel kv2.1 
(Peltola et al. 2011). The redistribution of ion channels may be influenced by 
demyelinating insult due to the metabolic changes resulting in the cell, or else 
reflect intrinsic neuronal dysfunction. The changes in AMIGO-1 expression pattern 
may be reflecting similar pathology, although dedicated co-localisation studies 
examining Kv2.1 with AMIGO-1 would thus be informative. 
 7.4  Conclusion 
The purpose of this project was to further explore novel markers of disease in MS. 
Generalised pathology in MS brain tissue is increasingly recognised to occur at 
early stages of disease, but the molecular mechanisms underlying these changes 
are not completely understood. HMGB1 is a well-characterised molecule, known 
to act as a link between sterile damage and innate immune mechanisms. My 
analysis of HMGB1 expression patterns in human subjects with and without MS, 
in non-lesional regions of tissue in neuropathological work, and in non-relapsing 
patients with respect to the CSF study, demonstrated novel findings. The 
significantly increased expression of HMGB1 in non-lesional regions in the 
neuropathological work lends support to the concept of MS as a generalised CNS 
disorder, rather than a disease characterised by development of focal, 
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inflammatory lesions alone. As these changes were noted early-on in the disease 
course in chapter 3, this suggests that these widespread pathological changes do 
not necessarily occur exclusively in progressive MS patients. Despite the majority 
of MS patients being in remission rather than relapse, higher HMGB1 CSF 
concentrations were found in MS patients vs. controls, further suggesting that the 
disease process is ongoing in between relapses, as supported by the FLC and NfL 
data also.  
The finding that exogenous HMGB1 stimulation significantly upregulates AMIGO-
3 and LINGO-1 expression in OGD-like cells suggests that it may influence 
neurodegenerative processes, thus acting as a potential link between 
neurodegenerative and inflammatory pathways. However, endogenously 
expressed HMGB1 is likely to be in a different redox state to oxidised, pro-
inflammatory, extracellular HMGB1. In this setting, it may augment 
neuroprotective pathways, possibly by participating in autophagic processes 
within OGD. We remain hopeful that neuroprotective therapeutic approaches may 
yield greater benefit for patients with progressive MS than those currently 
available. 
7.5  Future perspectives 
7.5.1  Further HMGB1 expression analysis in MS brain tissue 
Whilst I have presented a comprehensive assessment of HMGB1 expression in MS 
and non-MS control patients, and between different sub-types of tissue, further 
work in this area would help to confirm these findings. Using snap-frozen non-MS 
control and MS human brain tissue, further studies include: 
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(i) Determination of HMGB1 mRNA expression in different cell types using in-
situ hybridisation analysis 
(ii) Confirmation of cell types expressing HMGB1 with co-localisation studies 
using IHC-Fl. Cell markers would include olig2/ Nogo-A for OGD, CD68 for 
macrophages/ microglia, CD3 for pan T- lymphocytes, CD20 for (immature) 
B-cells, NeuN for neurons, GFAP for astrocytes and NG2 for OPC. 
(iii) Compare HMGB1 staining pattern in a range of non-MS and non-neurological 
control subjects using biopsy material 
(iv) Western-blotting (WB) analysis to assess total expression of HMGB1 in MS 
vs non- MS brain tissue. Pre-screening of each block with MBP/ oil-red O to assess 
extent of demyelination in all tissue blocks would be essential. Performing sub-
cellular localisation studies would be useful; for example, a lower nuclear: 
cytoplasmic anti-HMGB1 expression ratio in MS vs control tissue would suggest 
cytoplasmic translocation and the associated implications with pathology in MS 
tissue. In addition, examination of post-translational modifications of HMGB1 
such as acetylation status in the non-MS vs MS control subjects would also be of 
great interest, although assessment of redox status would ultimately be most 
informative. 
7.5.2 HMGB1, autophagy and MS  
A novel area of research relates to the potential role of autophagy in MS, and how 
HMGB1 may be implicated, given its established role in this cellular process. 
Neuropathological tissue analysis of LC3, for example, would be of interest in the 
biopsy tissue in particular. To address this in-vitro, MO3.13 cells and primary OGD 
cultures could be used to investigate:  
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(i) basal levels of autophagy e.g. measuring LC3B or LC3 I:LC3II ratios 
(ii) whether these levels change if HMGB1 is knocked-down e.g. using RNAi 
lentiviral vectors (HMGB1-/-) or if it is stably over-expressed.  
(iii) the effect of these changes on cellular viability; for example using a triplex 
assay to measure cell viability, cytotoxicity and apoptosis in the same 
sample.  
This experimental set-up can then be used to investigate the effects of cellular 
stress e.g. following hypoxia/ starvation on autophagy markers and cell viability 
in wild-type or HMGB1-/- OGD. Once this model is established, selected pro-
autophagic drugs could be screened to determine whether autophagy is 
augmented in OGD, whether they affect cell viability and how any changes 
compare to manipulations in HMGB1 expression.  
Further in-vivo studies could be designed on the basis of data arising from the 
above experiments.  
7.5.3 LRRIg molecules and MS 
This is also a novel area and there are a number of potential avenues of research 
arising from this project. The following suggestions explore research questions 
arising from the project directly and indirectly: 
(i) Confirmation of cell types expressing each of the LRRIg molecules with co-
localisation studies using IHC-Fl, as outlined in 7.5.1(i) 
(ii) Determination of LRRIg mRNA expression in different cell types using in-situ 
hybridisation analysis 
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(iii) Compare LRRIg staining pattern in a range of non-MS and non-neurological 
control subjects using biopsy material, in particular AMIGO-3 
(iv) Co-localisation studies of AMIGO-1 and Kv2.1 in human brain tissue using 
in-situ hybridisation and IHC-Fl  
(v) In-vitro work using primary neuronal cell cultures, for example: 
a. To perform sub-cellular localisation studies to examine levels of AMIGO-3 
expression under different experimental conditions to further investigate 
the nuclear localisation of AMIGO-3 seen in the NAGM in the biopsy tissue 
work 
b. Investigate whether AMIGO-3 knock-down e.g. using RNAi lentivial vectors 
alters cell viability using the triplex assay as described above 
(vi) In-vivo work using the EAE rodent model of MS to investigate whether 
AMIGO-3 antagonism ameliorates clinical outcomes 
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Figure A2. HMGB1-positive staining is specific when compared to the staining pattern 
using negative controls. Negative controls were performed by (A) using affinity-purified 
rabbit polyclonal IgG isotype control (B) using preimmune serum from the rabbit 
immunised with the specific HMGB1 peptide sequence, at a dilution of 1:400. The 
staining is markedly reduced in the negative control data as compared to the positive 
anti-HMGB1 staining pattern as shown in (C) for comparison. Scale bar = 100µm 
Figure A1. Patient MS1. T2-weighted Axial FLAIR MRI - taken from presenting scan 
performed at referring hospital, demonstrating multifocal parenchymal changes in the 
right occipital lobe extending into the corpus callosum, as well as a juxtacortical lesion 
in the right frontal lobe. MRI- magnetic resonance imaging 
